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A B S T R A C T
Background
Accumulating evidence suggests an association between prenatal exposure to antiepileptic drugs (AEDs) and increased risk of both
physical anomalies and neurodevelopmental impairment. Neurodevelopmental impairment is characterised by either a specific deficit or
a constellation of deficits across cognitive, motor and social skills and can be transient or continuous into adulthood. It is of paramount
importance that these potential risks are identified, minimised and communicated clearly to women with epilepsy.
Objectives
To assess the effects of prenatal exposure to commonly prescribed AEDs on neurodevelopmental outcomes in the child and to assess
the methodological quality of the evidence.
Search methods
We searched the Cochrane Epilepsy Group Specialized Register (May 2014), Cochrane Central Register of Controlled Trials (CEN-
TRAL) in The Cochrane Library (2014, Issue 4), MEDLINE (via Ovid) (1946 to May 2014), EMBASE (May 2014), Pharmline (May
2014) and Reprotox (May 2014). No language restrictions were imposed. Conference abstracts from the last five years were reviewed
along with reference lists from the included studies.
Selection criteria
Prospective cohort controlled studies, cohort studies set within pregnancy registers and randomised controlled trials were selected for
inclusion. Participants were women with epilepsy taking AED treatment; the two control groups were women without epilepsy and
women with epilepsy who were not taking AEDs during pregnancy.
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Data collection and analysis
Three authors (RB, JWand JG) independently selected studies for inclusion.Data extraction and risk of bias assessments were completed
by five authors (RB, JW, AS, NA, AJM). The primary outcome was global cognitive functioning. Secondary outcomes included deficits
in specific cognitive domains or prevalence of neurodevelopmental disorders. Due to substantial variation in study design and outcome
reporting only limited data synthesis was possible.
Main results
Twenty-two prospective cohort studies were included and six registry based studies. Study quality varied. More recent studies tended
to be larger and to report individual AED outcomes from blinded assessments, which indicate improved methodological quality.The
developmental quotient (DQ) was lower in children exposed to carbamazepine (CBZ) (n = 50) than in children born to women without
epilepsy (n = 79); mean difference (MD) of -5.58 (95% confidence interval (CI) -10.83 to -0.34, P = 0.04). The DQ of children
exposed to CBZ (n = 163) was also lower compared to children of women with untreated epilepsy (n = 58) (MD -7.22, 95% CI -
12.76 to - 1.67, P = 0.01). Further analysis using a random-effects model indicated that these results were due to variability within the
studies and that there was no significant association with CBZ. The intelligence quotient (IQ) of older children exposed to CBZ (n
= 150) was not lower than that of children born to women without epilepsy (n = 552) (MD -0.03, 95% CI -3.08 to 3.01, P = 0.98).
Similarly, children exposed to CBZ (n = 163) were not poorer in terms of IQ in comparison to the children of women with untreated
epilepsy (n = 87) (MD 1.84, 95% CI -2.13 to 5.80, P = 0.36). The DQ in children exposed to sodium valproate (VPA) (n = 123) was
lower than the DQ in children of women with untreated epilepsy (n = 58) (MD -8.72, 95% -14.31 to -3.14, P = 0.002). The IQ of
children exposed to VPA (n = 76) was lower than for children born to women without epilepsy (n = 552) (MD -8.94, 95% CI -11.96
to -5.92, P < 0.00001). Children exposed to VPA (n = 89) also had lower IQ than children born to women with untreated epilepsy (n
= 87) (MD -8.17, 95% CI -12.80 to -3.55, P = 0.0005).
In terms of drug comparisons, in younger children there was no significant difference in the DQ of children exposed to CBZ (n =
210) versus VPA (n=160) (MD 4.16, 95% CI -0.21 to 8.54, P = 0.06). However, the IQ of children exposed to VPA (n = 112) was
significantly lower than for those exposed to CBZ (n = 191) (MD 8.69, 95% CI 5.51 to 11.87, P < 0.00001). The IQ of children
exposed to CBZ (n = 78) versus lamotrigine (LTG) (n = 84) was not significantly different (MD -1.62, 95% CI -5.44 to 2.21, P =
0.41). There was no significant difference in the DQ of children exposed to CBZ (n = 172) versus phenytoin (PHT) (n = 87) (MD
3.02, 95% CI -2.41 to 8.46, P = 0.28). The IQ abilities of children exposed to CBZ (n = 75) were not different from the abilities of
children exposed to PHT (n = 45) (MD -3.30, 95% CI -7.91 to 1.30, P = 0.16). IQ was significantly lower for children exposed to
VPA (n = 74) versus LTG (n = 84) (MD -10.80, 95% CI -14.42 to -7.17, P < 0.00001). DQ was higher in children exposed to PHT
(n = 80) versus VPA (n = 108) (MD 7.04, 95% CI 0.44 to 13.65, P = 0.04). Similarly IQ was higher in children exposed to PHT (n
= 45) versus VPA (n = 61) (MD 9.25, 95% CI 4.78 to 13.72, P < 0.0001). A dose effect for VPA was reported in six studies, with
higher doses (800 to 1000 mg daily or above) associated with a poorer cognitive outcome in the child. We identified no convincing
evidence of a dose effect for CBZ, PHT or LTG. Studies not included in the meta-analysis were reported narratively, the majority of
which supported the findings of the meta-analyses.
Authors’ conclusions
The most important finding is the reduction in IQ in the VPA exposed group, which are sufficient to affect education and occupational
outcomes in later life. However, for some women VPA is the most effective drug at controlling seizures. Informed treatment decisions
require detailed counselling about these risks at treatment initiation and at pre-conceptual counselling. We have insufficient data about
newer AEDs, some of which are commonly prescribed, and further research is required. Most women with epilepsy should continue
their medication during pregnancy as uncontrolled seizures also carries a maternal risk.
P L A I N L A N G U A G E S U M M A R Y
Treatment for epilepsy in pregnant women and the development of the child
Background
For most women who have epilepsy it is important for their health that they continue their medication during pregnancy. Over the
last 25 years research has shown that children exposed to these medications in the womb can be at a higher risk of having a birth defect
or poorer level of development.
Research question
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This review aimed to understand whether exposure to antiepileptic drugs (AEDs) during pregnancy is linked to poorer levels of ability
for skills such as IQ, language and memory (neurodevelopment).
Characteristics of the studies
The review included 28 studies. Participants were women with epilepsy taking commonly used AEDs who were compared to either
women without epilepsy or women who had epilepsy but who were not treated with AEDs. Comparisons were also made between
children exposed to different AEDs in the womb. The evidence presented in this review was up to date to May 2014.
Results
- The evidence for younger children exposed to carbamazepine (CBZ) in the womb was conflicting, however this was likely to be due
to differences in the way that these studies were carried out. In older children those exposed to CBZ were not poorer in their IQ than
children who were not exposed. No link was found between the dose of CBZ and child ability.
- Both younger and older children exposed in the womb to sodium valproate (VPA) showed poorer cognitive development in comparison
to children not exposed and children exposed to other AEDs. A link between dose of VPA and child ability was found in six studies;
with higher doses of the drug linked to a lower IQ ability in the child. The level of this difference was likely to increase the risk of
poorer educational levels.
- Children exposed to CBZ in the womb did not differ in their skills from children exposed to lamotrigine (LTG), however very few
studies investigated this. There were also no differences between children exposed to phenytoin (PHT) in the womb and those exposed
to CBZ or those exposed to LTG.
- There were very limited data on newer medications such as LTG, levetiracetam or topiramate.
Quality of the studies
The quality of how studies were designed varied. The more recently completed studies tended to have higher quality ratings, which
suggests more reliable evidence.
Conclusions
This review found that children exposed to VPA in the womb were at an increased risk of poorer neurodevelopment scores both in
infancy and when school aged. The majority of evidence indicates that exposure in the womb to CBZ is not associated with poorer
neurodevelopment. Data were not available for all AEDs that are in use or for all aspects of child neurodevelopment. This means
decision making for women and their doctors is difficult. Further research is needed so that women and their doctors canmake decisions
based on research evidence about which medication is right for them in their childbearing years.
B A C K G R O U N D
Description of the condition
Epilepsy is a common disorder affecting up to 1% of the popula-
tion (Hauser 1990). Approximately one third of people receiving
antiepileptic drugs (AEDs) are women of reproductive age (Yerby
1994), and approximately 1 in 250 pregnancies are exposed to
AEDs (Lindhout 1992). There is a growing body of evidence re-
porting an association between prenatal exposure to AEDs and
negative physical and neurodevelopmental outcomes in the child
(Bromley 2013; NEAD Study; Tomson 2011). However, the la-
tency between widespread use of an AED in women of child-
bearing age and knowledge of any teratological risk or safety con-
cerns leads to uncertainty about the best course of action for both
women and their treating physicians.
Description of the intervention
AEDs are the most common treatment for epilepsy and treatment
continuation during pregnancy is a necessity for most women with
epilepsy. AEDs readily cross the placenta from themother into the
foetus (Bossi 1982) and are documented to pose different levels
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of teratogenic risk (Tomson 2011), which are dependent on the
agent, its dose, timing of exposure and the genetic influences of
both the mother and the foetus (Brent 2004).
How the intervention might work
Exposure to AEDs during foetal development is noted to be asso-
ciated with altered neuronal development in animal models. Re-
ported alterations include disruption of neuronal birth, migra-
tions and altered programmed cell death (Bittigau 2003;Miyazaki
2005). These are hypothesised to underpin the reported neu-
rodevelopmental alterations noted in human infants and children
(Bittigau 2003).
Early case reports have documented learning disabilities and dif-
ficulties, and low IQ or educational difficulties in children with
major or minor congential malformations attributed to maternal
AED use (Ardinger 1988; Chevallier 1989; Clayton-Smith 1995;
Hanson 1976; Winter 1987). A number of studies completed
during the 1980s and 1990s aimed to investigate whether cogni-
tive difficulties were associated with maternal use of AEDs during
pregnancy but conflicting results were obtained due, at least in
part, to methodological differences (FINNISH Study; Hill 1982;
Huth 1982; Steinhausen 1994). Recent prospective studies report
a significant association between prenatal exposure to sodium val-
proate and poorer cognitive functioning, often defined as intel-
lectual quotient (IQ) or developmental quotient (DQ) (Bromley
2010; Cummings 2011; Meador 2009; Nadebaum 2011). The
risks associated with other AEDs remain unclear with conflict-
ing results reported for carbamazepine (CBZ) (Cummings 2011;
Gaily 2004; Meador 2011) and little evidence in relation to expo-
sure in utero to lamotrigine (LTG) (NEAD Study), levetiracetam
(LEV) (Shallcross 2011) or topiramate (TPM).
In addition to adverse neurodevelopmental outcomes in relation
to cognitive abilities, a link between maternal use of AEDs dur-
ing pregnancy and an increased prevalence of neurodevelopmen-
tal disorders such as autistic spectrum disorders has been reported
(Bromley 2009; Christianson 1994; Christensen 2013; Moore
2000; Rasalam 2005; Williams 1997).
Why it is important to do this review
To continue AED treatment during pregnancy requires a risk-
benefit decision to be taken. On one side there is the risk prenatal
exposure to AEDs poses to the physical and neurodevelopment
of the child and the lifelong implications associated with such
damage to the early developing brain (Dean 2002). On the other
side of this decision is the health and wellbeing of the mother who
requires treatment for epilepsy. Careful consideration is required
with regard to maximising treatment whilst limiting the risks to
the foetus.
Although a teratogenic role for certain AEDs is supported by a
number of studies, results conflict with regard to the degree of risk,
making it difficult to counsel women regarding their choice of
treatment during pregnancy. Assessing neurodevelopmental out-
comes is complex, long and expensive due to the numbers of pa-
tients required and the time required for follow up; resulting in
a number of different methodologies being employed. There is,
therefore, a clear need for a systematic review of the existing data
to aid decision-making. Although randomised controlled trials
(RCTs) would be considered to provide the most reliable evidence
about the effects of AEDs taken during pregnancy, RCTs are con-
sidered unethical in this area and even if undertaken would pose
considerable difficulties in terms of design, recruitment and in-
terpretation. In view of this we have decided to proceed with a
systematic review of all available evidence including registry based
data, prospective cohort studies and RCTs (if available).
Evidence from this review can aid the decisions clinicians and
women with epilepsy are required to make about the treatment of
epilepsy in the childbearing years. The final review replaces a pre-
viously published Cochrane review entitled ’Common antiepilep-
tic drugs in pregnancy in women with epilepsy’ (Adab 2004).
O B J E C T I V E S
To assess the effects of prenatal exposure to commonly prescribed
AEDs on neurodevelopmental outcomes in the child and to assess
the methodological quality of the evidence.
This review examined neurodevelopmental outcomes following
exposure toAEDs during pregnancy compared to unexposed preg-
nancies in women representative of the general population or un-
exposed pregnancies in women with epilepsy. Comparisons were
also made between specific monotherapy AED exposures.
M E T H O D S
Criteria for considering studies for this review
Types of studies
The following types of study were considered.
1. Randomised controlled trials (RCTs). These are studies
which included women with epilepsy requiring treatment who
were randomised to a particular AED prior to conception or to a
control group. The intervention group were women with
epilepsy taking an AED of interest as monotherapy.
2. Prospective observational cohort studies. These included
consecutive participants from single- or multi-centre
4Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
participating sites, where information regarding the pregnancy
and history were collected prior to knowledge of the outcome.
The intervention group were women with epilepsy taking an
AED of interest as monotherapy.
3. Registry studies. Registry studies involve the ascertainment
of data from a wide region, country or number of countries and
recruitment is often based on self referral or clinician referral
leading to non-sequential case ascertainment. Both independent
and industry sponsored registry data were considered for
inclusion. These included data from pregnant women
ascertained retrospectively from prospective malformation
registers. The intervention group were women with epilepsy
taking an AED of interest as monotherapy.
Types of participants
The following participants were eligible for the treatment group:
• pregnant women with epilepsy taking a single AED of
interest.
Participants eligible for the control groups were:
• pregnant women with epilepsy taking an AED; or
• pregnant women with epilepsy taking no AED; or
• pregnant women who did not have epilepsy.
Studies reporting AED use solely in pregnant women with other
conditions (for example mood disorders, pain etc) were excluded.
Types of interventions
Intervention group
Womenwith epilepsy receivingAED treatments including but not
limited to:
phenobarbitone, phenytoin (PHT), carbamazepine (CBZ), oxcar-
bazepine, sodium valproate (VPA), lamotrigine (LTG), topiramate
(TPM), gabapentin, vigabatrin, tiagabine, zonisamide, levetirac-
etam (LEV), ethosuximide, clobazam, clonazepam, zonisamide,
pregabalin, lacosamide, retigabine, rufinamide, and sulthiame.
Comparisons of different AEDs were explored.
Control groups
Women with a diagnosis of epilepsy who were not taking AEDs
and women without epilepsy and who were not taking medication
for a chronic condition during pregnancy.
Women with epilepsy taking monotherapy treatment were em-
ployed as a ’comparator’ group in analyses to enable AED treat-
ment comparisons.
Types of outcome measures
Primary outcomes
Global cognitive functioning or ability
Global cognitive functioning or ability refers to a summary score of
key cognitive processes such as reasoning, processing speed, men-
tal flexibility and knowledge (Baron 2004). The most frequently-
reported measure of global cognitive functioning is the intelli-
gence quotient (IQ). Typically in younger children global ability
assessments additionally include assessment of motor and social
skills, due to their importance at this age, producing an outcome
reported as the development quotient (DQ). Two dominant DQ
assessments (the GriffithMental Development Scales and the Bay-
ley Scales of Infant and Toddler Development) differ in their ap-
proach to assessing overall cognitive ability. The Griffiths Mental
Development Scales include child motor ability along with other
cognitive skills to create the overall reportedDQ score. In contrast,
the Bayley Scales of Infant and Toddler Development explore mo-
tor ability separately and therefore data from these two measures
could not be combined in a meta-analysis. Global cognitive ability
in school aged children is typically assessed as IQ.
As well as a continuous variable, the primary outcome will be
investigated and reported as the prevalence of children who fell
below the average range. Typically, standardised measures of IQ
and DQ have a mean of 100 and a standard deviation of 15,
meaning that scores under 85 would be below the average range.
Secondary outcomes
Neurodevelopmental disorders
The proportion of children who experience the following neu-
rodevelopmental disorders:
• autistic spectrum disorders;
• attention deficit-hyperactivity disorder (ADHD);
• dyspraxia.
The above disorders were chosen as they are important neurode-
velopmental disorders and have been associated with prenatal ex-
posure to AEDs (Adab 2004). These diagnoses were author-de-
fined but consistent with the Diagnostic and Statistical Manual of
Mental (DSM-IV) criteria for these conditions.
Cognitive domains
The differences between specific cognitive domain scores includ-
ing:
• attention;
• executive function;
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• language;
• memory;
• visuospatial.
In addition to a global cognitive ability score, neuropsychological
assessment often examines more defined or specific cognitive skills
which might contribute to lowered levels of global cognitive func-
tioning. For example, themajority of IQ tests will report Verbal IQ
(VIQ) (also known as Verbal Comprehension) and Performance
IQ (PIQ) (also known as Non-Verbal IQ). Attention, language
and memory abilities are core cognitive skills that influence other
cognitive functions and understanding the functioning of these
systems following prenatal exposure is key.
Search methods for identification of studies
Electronic searches
We searched the following databases:
1. Cochrane Epilepsy Review Group Specialized Register
using the search terms pregnancy, pregnant, prenatal, teratogen,
teratogenic, fetal, fetus, birth maternal and in utero (29 May
2014);
2. Cochrane Central Register of Controlled trials
(CENTRAL) in The Cochrane Library (2014, Issue 4) using the
search strategy set out in Appendix 1;
3. MEDLINE (Ovid) using the search strategy set out in
Appendix 2 (from 1946 to 29/05/2014);
4. EMBASE (29 May 2014) using the search strategy set out
in Appendix 3;
5. Pharmline (30 May 2014); and
6. Reprotox (30 May 2014).
The MEDLINE search strategy was adapted to meet the require-
ments of the EMBASE, Pharmline and Reprotox databases.
No language restrictions were employed in the searches.
Searching other resources
Conference abstracts were reviewed for the last seven years
(2007 to 2014) from Neurology meetings, including the In-
ternational League Against Epilepsy meetings (International
EpilepsyCongress, EuropeanCongress onEpileptology, Asian and
Oceanian Epilepsy Congress, and Latin American Congress on
Epilepsy) and Teratology meetings (The Teratology Society and
European Teratology Society). The Epilepsia Journal supplements
from the past seven years (2007 to 2014) were searched for confer-
ence proceedings. Where possible, abstracts were linked to pub-
lished data sets. Authors of abstracts which were not yet published
were contacted for further information. When further informa-
tion was unavailable the abstracts were listed in Characteristics of
studies awaiting classification.
Reference lists of original research and review articles were cross-
matched to the studies generated from the electronic searches.
Reference lists of recent review articles were searched, and lead and
corresponding authors in the area were contacted for any relevant
unpublished material.
Data collection and analysis
Selection of studies
Three authors (RB, JW, JG) reviewed the titles and abstracts of
articles highlighted by the searches and removed studies that ob-
viously did not meet the inclusion criteria. Full-text reports were
used by two authors (RB, JP) to determine eligibility. Disagree-
ments were discussed and if not resolved the opinion of a third
author (JG) was sought and all other authors were consulted if
necessary. Multiple reports from single studies are common in this
field and reports were linked where possible.
Data extraction and management
Five authors (RB, JW, NA, AS, AJM) undertook data extraction
from the included studies by splitting the number of studies into
equal parts. Data extraction was cross-checked. Data were ex-
tracted using pre-standardised electronic data extraction forms.
This was initially piloted by members of the review team and
amendments were made where necessary (see Appendix 4 for the
data extraction form).
Assessment of risk of bias in included studies
Five authors (RB, JW, NA, AS, AJM) assessed risk of bias in the
included studies by splitting the number of studies equally. Risk
of bias assessments were cross-checked. Due to the observational
design of some of the studies, we decided to utilise a version of the
extended Cochrane Collaboration tool for assessing risk of bias,
developed by the Cochrane Non-Randomised Studies Methods
Group. The tool examines selection bias (sequence generation, al-
location concealment), performance bias (blinding), attrition bias
(incomplete outcome data, blinding), detection bias (blinding,
other potential threats to validity), reporting bias (selective out-
come reporting), and the influence of confounding variables. The
domains of blinding, incomplete outcome data, selective outcome
reporting, confounding variables and other bias were rated on a
five-point scale, ranging from low in bias to high risk of bias, ac-
cording to the risk on the outcome (See Appendix 5; Appendix 6
for extended risk of bias tools). The parameters of this scale were
determined by the review authors (see Table 1 for the scale param-
eters).
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Measures of treatment effect
The primary outcome of global cognitive ability (DQ and IQ) and
secondary outcomes relating to cognitive domains were measured
on a continuous scale and the measure of treatment effect was the
mean difference (MD). Secondary outcomes relating to the pres-
ence of a neurodevelopmental disorder or an IQ below a specified
range were categorical data and the measure of treatment effect
was the risk ratio (RR). As data were sparse, with some studies
reporting zero events in one or both groups, the risk difference
(RD) was also calculated.
Unit of analysis issues
Repeated observationswere common. This was dealt with through
the analysis of separate time points, which limited the likelihood
of more than one observation from a single cohort. As children age
the complexity of their cognitive functioning improves, requiring
different assessment techniques and considerations. The abilities
of children under the age of three are typically assessed using a
developmental scale where the outcome is reported as a DQ. For
school aged children of five years plus, the typical assessment of
global cognitive ability would take the form of an intelligence
assessment which is reported as the IQ. However, assessments of
DQcan extendup to eight years of agewith IQmeasures extending
down to two years of age and authors varied in their selection of
DQ or IQ to assess pre-school aged children.
Another unit of analysis issue in this review was the inclusion in
studies of multiple children born to one mother. Studies varied
in their inclusion of siblings, however data without the siblings
included were rarely reported in full in the original papers and
therefore at the review level it was not possible to address this issue.
Dealing with missing data
Missing data were sought through contact with the study authors.
Reasons for missing data were sought to determine if they were
missing at random, or not, but analyses were undertaken using the
available data.
Assessment of heterogeneity
Clinical heterogeneity was assessed by examining the differences
in study characteristics in order to inform decisions regarding the
combination of study data. An a priori hypothesis of sources of
clinical heterogeneity would be: type of population (regional, na-
tional or international, single- or multi-centre); loss to follow up;
maternal factors including age, duration of AED treatment, IQ,
lifestyle factors, monotherapy or polytherapy, socioeconomic sta-
tus, type of epilepsy, use of other medications and years of edu-
cation. Child factors included: age of assessment, gestational age
at birth, gender, seizure exposure, time of follow up and outcome
measurement. Where applicable, we also assessed statistical het-
erogeneity by examining the I2 statistic and the Chi2 test. In the
event heterogeneity was significant, both fixed-effect and random-
effects model analyses were presented enabling examination of the
differences.
Assessment of reporting biases
Outcome reporting bias was investigated using the ORBIT tool
categories (Kirkham 2010). All protocols were requested from
study authors to enable comparison of the outcomes of interest.
Only four protocols were provided.
Publication bias was examined by identifying unpublished data,
by carrying out a comprehensive search of multiple sources and re-
questing any unpublished data from authors. We looked for small-
study effects to establish the likelihood of publication bias. Funnel
plots were intended to be examined in the event an appropriate
number of studies could be combined, however this was unachiev-
able. The Cochrane Collaboration recommends a minimum of
10 studies to be combined when examining funnel plots (Higgins
2011).
Data synthesis
For each comparison with data available for at least two stud-
ies, we performed a meta-analysis to provide overall estimates of
treatment effect. A fixed-effect model was utilised for the primary
data analyses, with exploration of potential explanations for het-
erogeneity. Secondary analyses, adopting a random-effects model
to incorporate the assumption that the different studies were es-
timating different yet related treatment effects, was undertaken.
Sources of variability between the studies were also investigated.
For continuous outcomes the pooled MD was calculated with the
95% CI. For categorical outcomes the pooled RR was calculated
with the 95% CI. As data were sparse for many studies a further
analysis was undertaken to calculate the RD and 95% CI. As the
method of synthesis that is used can impact on the estimate of
pooled treatment effect for sparse data, sensitivity analysis was un-
dertaken to explore the robustness of the results with different as-
sumptions regarding the method of analysis. These analyses were
not pre-planned in the protocol as it was not clear at the plan-
ning stage that data would be so sparse. Several included studies
provided data which were deemed appropriate to be incorporated
into a meta-analysis. Studies were not included in a meta-analy-
sis if there was only one study contributing to a comparison, the
measure used was not a standardised measure (that is a test with
published standard norms) or the assessment used to measure the
outcome was fundamentally different to others (that is overall data
from Griffiths Mental Development Scales assessment and data
from assessments conducted with the Bayley Scales of Infant and
Toddler Development). These studies were discussed narratively
within the results and discussion sections.We also expected to find
differences in the definitions of neurodevelopmental disorders as
these were author defined. These differences were examined at the
analysis stage to ensure the appropriate combination of data.
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Comparisons included:
1. specific monotherapy group versus controls on global
cognitive functioning;
2. specific monotherapy group versus controls on
neurodevelopmental disorders;
3. specific monotherapy group versus controls on specific
cognitive domains;
4. specific monotherapy group versus specific monotherapy
group on all above outcomes.
Each comparison was stratified by control group, study design and
measurement characteristics to ensure appropriate combination of
study data.
Subgroup analysis and investigation of heterogeneity
Heterogeneity across studies was explored by visual inspection of
forest plots, interpretation of the I2 statistic and the P value for
the test of heterogeneity. If there was evidence of heterogeneity,
subgroup analysis was carried out to explore the potential causes of
heterogeneity using the factors listed previously. These subgroup
analyses were stratified by drug, study design and type of control
group. Random-effects model analyses were carried out in addi-
tion to fixed-effect model analyses to incorporate any unexplained
heterogeneity in the calculation of the pooled effect.
Sensitivity analysis
Sensitivity analyses were carried out to explore the effects of the
method of analysis for categorical data and to explore the effect of
fixed-effect and random-effectsmodels (see previous descriptions).
See Table 2 for the results of the sensitivity analysis.
In cases where the number of events was 0 or 1, sensitivity analysis
was performedusing three alternative statisticalmethods including
odds ratio (Mantel-Haenszel (M-H) method and Peto method)
and risk difference (M-H method). This was carried out for four
comparisons only and the results are displayed in Table 2. The
significance of the overall effect estimates was only altered in one
comparison where the level of significance changed from non-
significant to significant.
R E S U L T S
Description of studies
Results of the search
The search identified 10,769 records from the databases outlined
in Electronic searches and 55 records were found through hand-
searching. Following the removal of duplicates, 10,233 records re-
mained; these were screened for inclusion in the review. Of these,
10,157 records were excluded due to irrelevance, leaving 83 full
texts to be assessed for eligibility. Twenty-six were excluded (see
Figure 1 and Characteristics of excluded studies for reasons for ex-
clusion). A total of 28 studies were included in the review, from 59
reports; 10 of these were included in the meta-analyses. We iden-
tified one unpublished study (Jackson 2013) and were provided
with a draft publication and study data which we have included in
the review and meta-analysis. Unpublished data pertaining to the
studies of Bromley 2010; Cummings 2011/2013 and Shallcross
2011 were provided. The 18 studies remaining were discussed in
narrative form due to an inability to combine themwith other data
because of different methodological aspects or failure to report
all required outcome data (that is number of included children,
means along with standard deviations (SD), CIs or standard errors
(SE).
8Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Included studies
From a total of 57 full texts, 28 independent studies were in-
cluded in this review. No RCTs were found, 22 included studies
were prospective cohort studies (Arulmozhi 2006; Bromley 2010;
Bromley 2013; D’Souza 1991; FINNISH Study; GERMAN
Study; Hanson 1976; Hill 1974; Hirano 2004; Jackson 2013;
Leavitt 1992; NEADStudy; Ornoy 1996; Regesta 1996; Rihtman
2012; Rihtman 2013; Rovet 1995; Shallcross 2011; Sobczyz 1977;
Thomas 2008; Veiby 2013; Wide 2002) and six were registry
studies (Cummings 2011/2013; Eriksson 2005; Gaily 2004; Jones
1989; Nadebaum 2011; Thomas 2007). See Table 3 for a com-
parison of all study designs and methods. See Characteristics of
included studies for details about each included study.
There were 29 linked papers, these full texts were related to an
included study as they presented information on the same cohort
of children.
Excluded studies
Twenty-six studies were excluded from the review (Annegers 1974;
Antiga 2010; Dean 2002; Dessens 2000; Forsberg 2011; Holmes
2000; Holmes 2005; Jakubowska 1981; Kelly 1984; Kozhokaru
2010; Latis 1982; Lekwuwa 1995; Majewski 1981; Meador
2010; Moore 2000; Mortensen 1996; Mortensen 2003; Oyen
2007; Parisi 2003; Perinola 1992; Rasalam 2005; Sereno-Colo
1984; Steinhausen 1982; Vanoverloop 1992; Vert 1982; Yamatogi
1993). Several of these papers were not written in the English lan-
guage and therefore were sent for translation and data extraction
in order to determine the study design and methodology used.
Twenty of the excluded studies employed a retrospective design or
they were classed as a record linkage study or case series, not for
inclusion within this review. Three studies did not examine the
neurodevelopmental outcomes of interest to this review (Lekwuwa
1995; Meador 2010; Yamatogi 1993), two studies had no control
group data (Perinola 1992; Vert 1982) and one study examined
outcomes in a non-epilepsy population (Mortensen 1996).
Risk of bias in included studies
All domains of bias were rated on a scale of 1 to 5. The description
of the scale parameters for each domain is presented in Table 1.
Allocation
For the domains of sequence generation and allocation conceal-
ment all included studies were rated as high risk of bias. Whether
carried out prospectively or as a registry study the included stud-
ies did not employ rigorous methods (that is randomisation to
treatment) as the research questions were not conducive to the
design features of these types of study design. However, the non-
randomised risk of bias tool used in this review required the assess-
ment of these two domains on a level playing field in comparison
to RCTs. See Figure 2 for a summary of risk of bias judgements.
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Blinding
Overall, 17 studies were rated as 2 as the outcome assessors were
blinded to the exposure status of the individuals (Bromley 2010;
Cummings 2011/2013;D’Souza 1991; Eriksson 2005; FINNISH
Study; Gaily 2004; GERMAN Study; Hill 1974; Jackson 2013;
Leavitt 1992; Nadebaum 2011; NEAD Study; Ornoy 1996;
Rihtman 2013;Rovet 1995;Thomas 2008;Wide 2002) and there-
fore the risk of bias was low in these studies. Five of the studies were
rated as unclear due to the lack of details regarding methods of
blinding (Arulmozhi 2006; Hanson 1976; Hirano 2004; Regesta
1996; Rihtman 2012).The remainder of the studies were rated as
4 or 5 meaning that few or no methods were used to blind the
outcome assessors or other study team members leaving open the
possibility that the outcomes were likely to be affected by knowl-
edge of the outcome or treatment (Bromley 2013; Jones 1989;
Shallcross 2011; Sobczyz 1977; Thomas 2007; Veiby 2013).
Incomplete outcome data
Only three studies (Hirano 2004; Rihtman 2012); Rihtman 2013
were rated as 1 (low bias) as there were no missing data. The ma-
jority of studies (Arulmozhi 2006; Bromley 2010; Bromley 2013;
Cummings 2011/2013;D’Souza 1991; Eriksson 2005; FINNISH
Study; Gaily 2004; Hanson 1976; Leavitt 1992; Nadebaum 2011;
NEAD Study; Ornoy 1996; Regesta 1996; Rovet 1995; Shallcross
2011; Thomas 2008)were rated 2 as there was only a small amount
of missing data from the reports and this was balanced across the
groups or appropriate reasons were reported. Three studies (Hill
1974; Thomas 2007; Wide 2002) were rated as 3 suggesting a
possible implication on the outcomes due to a larger amount of
missing data. Two studies (Jackson 2013; Jones 1989) were rated
as 4 as there was a large amount of missing data which was imbal-
anced across the groups suggesting the outcomes were likely to be
affected. Two studies (GERMAN Study; Veiby 2013) were rated
5 suggesting a high risk of bias due to the lack of information pro-
vided about a large amount of missing data. One study (Sobczyz
1977) was rated unclear due to the lack of detail regarding missing
data.
Selective reporting
Selective outcome reportingwas rated on a 1 to5 scale, one demon-
strating low risk of bias and five demonstrating high risk of bias.
The majority of studies (GERMAN Study; Hanson 1976; Hirano
2004; Jackson 2013; Nadebaum 2011; Ornoy 1996; Regesta
1996; Rihtman 2012; Rihtman 2013; Rovet 1995; Shallcross
2011; Sobczyz 1977; Thomas 2007; Thomas 2008; Veiby 2013;
Wide 2002) were rated 2 as there was no evidence of selective out-
come reporting within the publications; however this could not
be tested against the protocols for the studies as they were not pro-
vided. Three studies were rated 3 as the risk of bias was unclear due
to a small amount of non-reporting (Arulmozhi 2006; D’Souza
1991; FINNISH Study). Four studies were rated 4 due to selective
reporting (Cummings 2011/2013; Hill 1974; Jones 1989; Leavitt
1992).
Study protocols were requested from authors who had contact
details available. Only five responses were received with protocols
being provided (Bromley 2010; Bromley 2013; Eriksson 2005;
Gaily 2004; NEAD Study). The protocol for GERMAN Study
was unavailable. No other responses were received.
For the four studies where the protocol was made available a rating
of 1 for low risk of bias was allocated as there was no evidence of
selective outcome reporting following protocol review.
Other potential sources of bias
Any other biases were examined and this domain was rated on a
scale of 1 to 5. The main other sources of bias that were identified
included data for different AEDs being combined and the use
of inappropriate measures for year of recruitment or for age of
children at assessment. Taking all studies into account, nine were
rated as low risk of bias (Bromley 2010; Bromley 2013;Nadebaum
2011; NEAD Study; Rovet 1995; Shallcross 2011; Thomas 2007;
Thomas 2008; Wide 2002), nine were unclear (Arulmozhi 2006;
Cummings 2011/2013; Gaily 2004; GERMAN Study; Jackson
2013; Leavitt 1992; Ornoy 1996; Regesta 1996; Veiby 2013) and
10 were rated as at high risk of bias (D’Souza 1991; Eriksson 2005;
FINNISH Study; Hanson 1976; Hill 1974; Hirano 2004; Jones
1989; Rihtman 2012; Rihtman 2013; Sobczyz 1977). See the risk
of bias tables for the individual studies in the Characteristics of
included studies.
Confounding variables
A pre-specified list of confounding variables was compiled prior
to carrying out the review as described in Assessment of risk of
bias in included studies. Overall, six studies were rated as at low
risk of bias and scored either a 1 or 2 (Bromley 2010; Bromley
2013; Cummings 2011/2013; Nadebaum 2011; NEAD Study;
Shallcross 2011) as they examined relevant variables and used an
appropriate method of analysis to deal with them. Eleven stud-
ies were rated 3 (unclear risk of bias) as they showed evidence of
investigating some important confounders but not all that were
relevant to the area (Arulmozhi 2006; D’Souza 1991; Gaily 2004;
GERMAN Study; Hanson 1976; Hirano 2004; Regesta 1996;
Rovet 1995; Thomas 2007; Veiby 2013;Wide 2002). Eleven stud-
ies were rated as high risk of bias and scored either a 4 or a 5
(Eriksson 2005; FINNISH Study; Hill 1974; Jackson 2013; Jones
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1989; Leavitt 1992; Ornoy 1996; Rihtman 2012; Rihtman 2013;
Sobczyz 1977; Thomas 2008). These studies either did not ex-
amine the influence of key confounding variables or they did not
employ appropriate methods to account for them, or included
women taking AEDs for other indications.
Effects of interventions
Neurodevelopmental outcomes of children exposed
to carbamazepine (CBZ) in comparison to control
children
Eight studies investigated the cognitive abilities of children ex-
posed to CBZ in comparison to a control group where the out-
come was measured as DQ with four studies reporting child IQ.
Developmental quotient (DQ)
CBZ versus controls (women without epilepsy)
Pooled results from three studies (GERMAN Study; Ornoy 1996;
Rovet 1995) using the Bayley Scales of Infant Development re-
ported a significant MD of -5.58 (95% CI -10.83 to -0.34, P =
0.04, I2 = 60%) with the children exposed to CBZ (n = 50) ex-
hibiting poorer earlier performance than control children (n = 79).
Due to high heterogeneity a random-effects model analysis was
undertaken and gave an MD of -4.35 (95% CI -14.04 to 5.34,
P = 0.38), which changed the overall estimate to non-significant
(Analysis 1.2).
Leavitt 1992 reported that the group means on the Bayley Scale
of Infant and Toddler Development were not significantly differ-
ent for children exposed to CBZ (mean 122, SD not reported,
P = 0.571) in comparison to general population control children
(mean 119, SD not reported); however, the specific number of
children exposed to CBZ monotherapy was not reported in the
paper and this study could not contribute to the meta-analysis.
Two studies were identified to have investigated the neurodevel-
opment of children exposed to CBZ in comparison to control
children using the Griffith Mental Development Scales (Bromley
2010; Wide 2002). Bromley 2010 found that the overall DQ of
children exposed to CBZ (n = 48) did not differ significantly from
control children (n = 230) (CBZ mean 98, 95% CI 94.0 to 102.5
versus control mean 100, 95% CI 98.9 to 102.1, P = 0.342).
Consistently, Wide 2002 also failed to find a significant difference
between the DQ of the children exposed to CBZ either at nine
months of age (n = 35) and control children (n = 81) (CBZ mean
(unstandardised) 350, range 324 to 435 versus control mean (un-
standardised) 335, range 307 to 396, P = 0.4). Similarly, reassess-
ment at four years of age also found that the children exposed to
CBZ (n = 35) were not significantly different in comparison to
control children (n = 66) (CBZ mean (unstandardised) 641, 95%
CI unclear, P value not reported versus control mean (unstandard-
ised) 641, 95% CI unclear, P value not reported). Meta-analysis
was not possible as data were not provided in one of the publica-
tions (Wide 2002) in a format that allowed calculation of mean
difference (Analysis 1.1). Finally, Ornoy 1996 found a significant
difference in the abilities of children exposed to CBZ (n = 19)
(mean 99.4, SD 21) in comparison to controls (n = 12) (mean
113, SD 15, P < 0.05) when measured using the McCarthy Scales
of Children’s Abilities.
CBZ versus controls (women with epilepsy not taking AEDs)
The pooled results from two studies (Jackson 2013; Thomas 2008)
measuring neurodevelopment with the Bayley Scales of Infant and
Toddler Development and comparing children exposed to CBZ
(n = 163) to the offspring of women with untreated epilepsy (n =
58), found a significant MD of -7.22 (95% CI -12.76 to -1.67,
P = 0.01, I2 = 56%) indicating poorer developmental abilities for
children exposed to CBZ. Due to high heterogeneity a random-
effects model analysis was undertaken and gave an MD of -5.60
(95% CI -15.40 to 4.20, P = 0.26) changing the result to non-
significant (Analysis 2.2).
Intellectual quotient (IQ)
CBZ versus controls (women without epilepsy)
The pooled MD comparing IQ levels of 150 CBZ exposed chil-
dren to 552 control children across three studies (Bromley 2010;
Gaily 2004; Thomas 2007) was not statistically significant (MD
-0.03, 95% CI -3.08 to 3.01, P = 0.98, I2 = 0%) (Analysis 1.3).
CBZ versus controls (women with epilepsy not taking AEDs)
Four studies, two prospective (Bromley 2010; Thomas 2007) and
two register studies (Eriksson 2005; Gaily 2004), were pooled
in a meta-analysis. The MD for 163 CBZ exposed children in
comparison to 87 control children was non-significant (MD 1.84,
95% CI -2.13 to 5.80, P = 0.36, I2 = 0%) (Analysis 2.3).
Autistic spectrum disorder
Three studies investigated whether children exposed to CBZ were
at greater risk of being diagnosed with an autistic spectrum disor-
der. Two studies (Bromley 2010; Eriksson 2005), using a prospec-
tive and register methodology respectively, identified and inves-
tigated rates of autistic spectrum disorder in children exposed to
CBZ in comparison to a control group. Bromley 2013 found that
in comparison to general population control children there was
no increased risk of autistic spectrum disorder (2% versus 1.8%,
P value not reported). In the small study by Eriksson 2005 no
cases were identified for either the control group (n = 13) or the
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CBZ exposure group (n = 13) (P value not reported), probably
due to small group size. Unpublished data provided in relation to
the Cummings 2011/2013 study reported a 6% prevalence within
the group exposed to CBZ but control data were not available.
Meta-analysis would not have been reliable due to the difference
in methods used to collect the data across these three studies.
Parental reporting regarding infants at the age of 18 months did
not find the children exposed to CBZ (n = 41) to be at an increased
risk on an autism checklist (CBZ 8.8% versus control 10.0%, OR
1.1, 95% CI 0.3 to 3.6, P > 0.05) or on a questionnaire of autistic
traits (CBZ 2.9% versus control 0.5%, OR 3.3, 95% CI 0.5 to
24.8, P > 0.05) in comparison to children born to women without
epilepsy (n = 225) (Veiby 2013). In this study, at 36 months,
parents were asked to re-rate their child in terms of autistic traits
and the CBZ exposed children (n = 31) again were not found to
differ significantly from control children (n = 154) (CBZ 3.4%
versus 0.7%, OR 2.5, 95% 0.3 to 19.1, P > 0.05).
Specific cognitive abilities
The pooled estimates for VIQ resulted in an MD of -1.81 (95%
CI -4.94 to 1.33, P = 0.26, I2 = 74%), from 136 CBZ exposed
children compared to 351 general population controls (Bromley
2010; Gaily 2004). Due to the high statistical heterogeneity a
random-effects model analysis was undertaken and produced an
MD of -1.84 (95% CI -8.01 to 4.34, P = 0.56) resulting in no
change to the level of significance (Analysis 1.5).
The pooled estimates for PIQ (MD 1.27, 95% CI -1.55 to 4.09,
P = 0.38, I2 = 0%), calculated from 136 CBZ children compared
to 351 general population controls from two studies (Bromley
2010; Gaily 2004), were not statistically significant (Analysis 1.6).
Consistently, non-significant MDs were also found for children
exposed to CBZ (n = 149) in comparison to no medication con-
trols (n = 83) for VIQ (MD 0.13, 95% CI -3.98, 4.23, P = 0.95,
I2 = 0%) and PIQ (MD 3.65, 95% CI -0.60 to 7.90, P = 0.09,
I2 = 0%) based on three studies (Bromley 2010; Eriksson 2005;
Gaily 2004) (Analysis 2.6; Analysis 2.7).
In children aged between seven and 85 months of age, the reg-
istry study by Rovet 1995 reported that the language development
of children exposed to CBZ (n = 28) did not differ significantly
from matched controls (n = 28) for either language comprehen-
sion or language expression (mean scores unavailable from the pa-
per). Bromley 2010, also measured early language development
and failed to find a significant difference between the abilities of
children exposed to CBZ (n = 48) under two years of age and
control children (both standard (n = 230) and no-medication (n
= 27)). No significant difference was found between the children
exposed to CBZ or general population controls (CBZ mean 103,
95% CI 98 to 108 versus control mean 105, 95% CI 103 to 106,
P = 0.684) or to children born to women with untreated epilepsy
(mean 109, 95% CI 105 to 114, P = 0.307). In an older aged
cohort, the language abilities of 14 CBZ (mean 74.9, SD 21, P
= 0.87) exposed children did not differ from controls (mean not
reported) in the registry study of Thomas 2007 when assessed at
school age. Meta-analysis was a not carried out due to the variation
in language measures used and the different language outcomes
targeted.
In terms ofmotor abilities, Thomas 2008 found comparablemotor
development between children exposed to CBZ (n = 101) (mean
95, 95% CI 90 to 100, P value not reported) and no-medication
control children (n = 32) (mean 94.7, 95% CI 85 to 105). This
was consistent with the findings of Ornoy 1996 (CBZ (n = 20)
mean 97.5, SD 18 versus controls (n = 34) mean 101, SD 12, P >
0.05), Bromley 2010 (CBZ (n = 48) mean 94, 95% CI 89 to 99
versus controls (n = 230) mean 98, 95% CI 97 to 100, P = 0.059)
and also the small study by Arulmozhi 2006 (CBZ (n = 7) mean
101, SD 4 versus controls (n = 30) mean 102, SD 4.7, P value not
reported).
CBZ versus controls: prevalence of below average
performance
For CBZ there were too few studies with similar methodolo-
gies to allow for meta-analysis in comparison to control children.
Cummings 2011/2013 reported a significantly increased preva-
lence of performance 1 SD below the normative mean based on 49
CBZ exposed children in comparison to 44 controls (10% versus
4.5% respectively,OR 7.7, 95%CI 1.4 to 43.1, P < 0.01), assessed
with either the GrifftihsMental Development Scales or the Bayley
Scales of Infant and Toddler Development. With the prevalence
of children performing at a level 2 SDs below the mean only the
data by Cummings 2011/2013 reported this, and noted that 2%
of children exposed to CBZ and only 1% of control children fell
below 2 SDs from the mean; a difference which was not signifi-
cant.
In the study by Veiby 2013 parents completed the Ages and Stages
Questionniare for their child at 6, 18 and 36 months of age. No
significant level of difference in the prevalence of performance
2 SD from the mean was reported for the children exposed to
CBZ (n = 48) in comparison to children born to women without
epilepsy (n = 276) for gross motor development (CBZ 12.8% ver-
sus control 12.0%, OR 1.3, 95% CI 0.5 to 3.0, P > 0.05), fine
motor development (CBZ 10.9% versus control 6.9%, OR 2.3,
95% CI 0.9 to 6.0, P > 0.05) or early social development (CBZ
12.8% versus control 13.4%, OR 1.4, 95% CI 0.6 to 3.3, P >
0.05). At 18 months of age the children exposed to CBZ (n =
41) scored significantly at risk for their fine motor development
(CBZ 10.0% versus control 5.1%, OR 3.3, 95% CI 1.1 to 9.2,
P < 0.05) and their personal and social skill development (CBZ
12.2% versus control 3.7%, OR 3.2, 95%CI 1.3 to 8.3, P < 0.05)
but not for gross motor skills (CBZ 0% versus control 3.2%, OR
calculation not possible) in comparison to the control children (n
= 221). Reassessment again at 36 months of age failed to find any
significant differences between the children exposed to CBZ (n =
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31) and control children (n = 154) for gross motor skills (CBZ
6.5% versus control 6.0%, OR 2.3, 95% CI 0.5 to 9.9, P > 0.05),
fine motor skills (CBZ 3.3% versus control 5.6%, OR 1.0, 95%
CI 0.1 to 7.5, P > 0.05), communication skills (CBZ 0% ver-
sus control 1.3%, OR could not be calculated), or sentence skills
(CBZ 6.5% versus control 3.9%, OR 1.2, 95% CI 0.3 to 5.1, P
> 0.05) (Veiby 2013). Consistently, Bromley 2010 using the Grif-
fiths Mental Development Scales found no significant difference
in the prevalence of below average performance for children ex-
posed to CBZ (n = 48, 16%) in comparison to general population
control children (n = 230, 8%) or children born to women with
an untreated epilepsy (n = 27, 7%) in children aged two years. It
was likely that these conflicting results were due tomethodological
differences.
Dose of CBZ
No relationship between dose of CBZ and neurodevelopmental
outcome was reported in five (Bromley 2010; Gaily 2004; Jackson
2013; Ornoy 1996; Rovet 1995) of the six identified studies that
had investigated this issue. The sixth study (NEAD Study) failed
to find an association between CBZ dose and general cognitive
ability (DQ and IQ); however, the study reported a relationship
between CBZ dose and verbal abilities when the cohort were three
years of age. It was of note, however, that this association was not
replicated in this cohort when they were six years of age (NEAD
Study).
Neurodevelopmental outcomes of children exposed
to lamotrigine (LTG) in comparison to control
children
Despite its widespread use in women of childbearing age, only
three identified studies (Bromley 2010; Cummings 2011/2013;
Rihtman 2013) investigated the cognitive abilities of children ex-
posed to LTG in comparison to a control group. Due to differ-
ences in methodologies and data reporting meta-analysis was not
possible.
Developmental quotient (DQ)
LTG versus controls (women without epilepsy)
Using the Griffiths Mental Development Scales, Bromley 2010
investigated the cognitive abilities of children exposed to LTG (n
= 34) (mean 99, 95% CI 94 to 103, P = 0.21) in comparison to
control children (n = 230) (mean 100, 95% CI 99 to 102); no
significant differences were found.
LTG versus controls (women with epilepsy not taking AEDs)
In the study by Bromley 2010, the mean DQ for children exposed
to LTG (n = 34) (mean 99, 95% CI 94 to 103, P = 0.470) was not
significantly different from that of children born to women with
untreated epilepsy (n = 27) (mean 104, 95% CI 101 to 108).
Intellectual quotient (IQ)
LTG versus controls (women without epilepsy)
Consistent with the assessment at the earlier age, Bromley 2010
failed to find a significant difference between the children exposed
to LTG (n = 29) (mean 103, SD 11, P = 0.22) in comparison to
control children of women without epilepsy (n = 210) (mean 107,
SD 12) in their prospective cohort at six years.
Rihtman 2013 compared 41 LTG exposed children to 52 control
children. These data could not be combined with that of Bromley
2010 due to the inclusion of children born to women with psychi-
atric indications who were exposed to LTG (10%). Rihtman 2013
found a non-significant difference between the children exposed
to LTG and control children (LTGmean 105.56, SD 12.49 versus
control mean 108.71, SD 10.20, P > 0.05).
LTG versus controls (women with epilepsy not taking AEDs)
Only a single identified study investigated this comparison.
Bromley 2010 found comparable mean IQs for children exposed
to LTG (n = 29) (mean 103, SD 11, P value not reported) and
children born to women with untreated epilepsy (n = 25) (mean
104, SD 13).
Autistic spectrum disorder
The rate of diagnosis of autistic spectrum disorder in children ex-
posed to LTG was only reported in one published study (Bromley
2013). In comparison to a rate of 1.8% in the general population
controls (n = 210) the prevalence of 3.3% for the LTG group (n =
30) was not significantly higher in children at six years of age. In
unpublished data (linked to Cummings 2011/2013) a 0% preva-
lence of autistic spectrum disorder in 35 LTG exposed children
was reported; no control data were available however.
Investigation of autistic symptomatology was undertaken in one
study. Veiby 2013 found that, based on parental ratings, children
aged 18 months were not at increased risk based on an autism
checklist (LTG 15.6% versus controls 10.0%, OR 1.8, 95% CI
0.9 to 3.8, P > 0.05) or on a questionnaire regarding autistic
traits (LTG 3.1% versus 0.5%, OR 1.5, 95% CI 0.2 to 11.0, P
> 0.05). At 36 months, however, parental ratings indicated an
increased risk in the LTG group (n = 44) of autistic traits (LTG
9.3% versus control 3.4%, OR 5.0, 95% CI 1.7 to 14.4, P < 0.05)
in comparison to controls (n = 154) (Veiby 2013).
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Specific cognitive abilities
The VIQ (mean 99, SD 13, P = 0.23) and PIQ (mean 103, SD
12, P = 0.34) of children exposed to LTG (n = 29) did not differ
significantly in comparison to general population controls (n =
210) (VIQmean 103, SD 12; PIQmean 106, SD 13) or untreated
epilepsy controls (n = 29) (VIQ mean 99, SD 12, P value not
reported; PIQ mean 104, SD 14, P value not reported) in the one
identified study to investigate such abilities in school aged children
(Bromley 2010). From the same cohort but at a younger age time
point (under two years of age) children exposed to LTG were also
not found to significantly differ from control children for their
early development across language (LTG mean 104, 95% CI 98
to 100 versus control mean 105, 95% CI 103 to 106, P = 0.476),
motor (LTGmean 100, 95%CI 94 to 105 versus controlmean 98,
95%CI, 97 to 100, P = 0.733), social (LTGmean 100, 95%CI 95
to 106 versus control mean 97, 95% CI 95 to 98, P = 0.379) and
non-verbal skills (LTGmean 97, 95% CI 91 to 103 versus control
mean 102, 95%CI 100 to 104, P=0.104). The younger aged LTG
exposed children were found to be significantly poorer in their
hand and eye co-ordination (LTGmean 90, 95% CI 84 to 97, P =
0.104) in comparison to general population controls (mean 101,
95% CI 98 to 103); however this difference disappeared when
confounders (that is maternal IQ and socioeconomic status) were
adjusted for (Bromley 2010). Rihtman 2013 reported poorer fine
motor skills for children exposed to LTG (n = 42) in comparison
to control children (n = 52) (LTG mean 30.57, SD 22.90 versus
control mean 43.08, SD 21.17, P < 0.05) as well as poorer gross
motor skills (LTG mean 34.78, SD 24.47 versus control mean
49.92, SD 28.29). Visual perception abilities were also noted to
be poorer in the Rihtman 2013 study for the children exposed to
LTG (n = 42) in comparison to control children (n = 51) (LTG
mean 42.76, SD 31.85 versus control mean 60.46, SD 28.68, P
< 0.05) as were motor co-ordination abilities (LTG mean 31.18,
SD 28.62 versus control mean 51.53, SD 25.26, P < 0.05) but
not their visual-motor integration abilities (LTG mean 53.86, SD
25.24 versus control mean 63.90, SD 23.78, P < 0.05).
LTG versus controls: prevalence of below average
performance
Two studies compared the prevalence of child DQ performance 1
SDbelow themean, but meta-analysis was not possible. The study
by Cummings 2011/2013 found that 2.9% of children exposed
to LTG (n = 35) and 4.5% of control children fell 1 SD below the
mean, a difference that was not significant. Consistently, Bromley
2010 also found comparable levels of below average performance
in 34LTG exposed children (15%) and 230 control children (8%).
At 6 months of age Veiby 2013 did not find children exposed to
LTG (n = 71) to be at an increased risk of 2 SDs below the mean
on parental completed measures of gross motor skills (LTG 15.7
versus controls 12%, OR 1.5, 95% CI 0.8 to 2.9, P > 0.05), fine
motor skills (LTG 10.1 versus control 6.9, OR 1.8, 95% CI 0.8
to 3.9, P > 0.05) or early social development (LTG 12.7% versus
control 13.4%, OR 1.2, 95% CI 0.6 to 2.5, P > 0.05). At 18
months, parents provided further ratings of their child’s develop-
ment and reported no significant levels of difference between the
children exposed to LTG (n = 65) and control children (n = 221)
for gross motor skills (LTG 7.8% versus control 3.2%, OR 1.7,
95% CI 0.6 to 5.1, P > 0.05), fine motor skills (LTG 3.1% versus
control 5.1%, OR 0.9, 95% CI 0.2 to 3.7, P > 0.05) or personal
and social skills (LTG 3.1% versus control 3.7%, OR 0.6, 95%
CI 0.2 to 2.7, P > 0.05). Reassessment of this group at 36 months
found that, based on parent ratings, children exposed to LTG were
at an increased risk of poorer sentence skills (LTG 14.3% versus
control 3.9%, OR 2.8, 95% CI 1.2 to 6.9, P < 0.05) but not gross
motor skills (LTG 9.8% versus control 3.3%, OR 2.4, 95% CI
0.8 to 7.0, P > 0.05), fine motor skills (LTG 7.7% versus control
5.6%, OR 2.1, 95% CI 0.7 to 7.0, P > 0.05) or communication
skills (LTG 7.1% versus controls 1.3%, OR 2.0, 95% CI 0.6 to
6.7, P > 0.05).
Dose of LTG
No relationship between dose and child DQ or IQ was found
(Bromley 2010; NEAD Study); this was not investigated in the
study by Cummings 2011/2013. Rihtman 2013 found a relation-
ship between dose of LTG on fine motor ability and non-verbal
IQ but not for the other cognitive measures.
Neurodevelopmental outcomes of children exposed
to levetiracetam (LEV) in comparison to control
children
Only one study was identified by the searches to have investi-
gated the neurodevelopment of children exposed to LEV in utero
(Shallcross 2011).
Developmental quotient (DQ)
LEV versus controls (women without epilepsy)
One study investigated the neurodevelopment of children exposed
to LEV in comparison to children born towomenwithout epilepsy
(Shallcross 2011) who were under two years of age. Data collected
using theGriffithsMentalDevelopment Scales found that children
exposed to LEV (n = 51) (mean 99.9, 95%CI 97 to 103, P = 0.62)
did not differ significantly in comparison to general population
control children (n = 97) (mean 98.8, 95% CI 96 to 102).
LEV versus controls (women with epilepsy not taking AEDs)
Nocomparisons comparing theDQof children exposed to LEV to
children born to women with untreated epilepsy were identified.
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Intellectual quotient (IQ)
No studies measured this aspect of neurodevelopment in compar-
ison to either control type.
Autistic spectrum disorder
No studies were identified.
Specific cognitive abilities
In the study by Shallcross 2011, children exposed to LEV (n = 51)
did not differ from control children on tasks of language (LEV
mean 100.5, 95% CI 97 to 104 versus control mean 101.2. 95%
CI 98 to 104, P=0.79), hand and eye coordination (LEV mean
101.8, 95% CI 97 to 106 versus control mean 97.4, 95% CI 94
to 101, P = 0.14), non-verbal reasoning (LEV mean 101.7, 95%
CI 98 to 105 versus control mean 101.4, 95% CI 98 to 105, P =
0.92) or social development (LEV mean 98.0, 95% CI 94 to 102
versus control mean 98, 95% CI 95 to 101, P = 0.99).
In a later paper linked to the Shallcross 2011 paper, the research
group reported on global cognitive ability of 53 LEV exposed
children at between three and four years of age in comparison to
children born to women without epilepsy (n = 131); 32% of this
LEV group had been assessed under the age of two years and were
reported in the Shallcross 2011 publication. Consistent with the
outcome at the younger age assessments the children exposed to
LEV did not differ in their performance on tasks of motor devel-
opment (LEV mean 110.4, SD17.2 versus control mean 110.9,
SD 20.1, P=0.9), social development (LEV mean 116.5, SD 19.1
versus control mean 119.9, SD 16.3, P = 0.1), hand and eye co-
ordination tasks (LEV mean 104.8, SD 13.9 versus control mean
103.3, SD 15.6, P = 0.8), non-verbal skills (LEV mean 109.9, SD
15.4 versus control mean 110.5, SD 16.3, P = 0.6) and practical
developmental skills (LEV mean 113.4, SD 16.6 versus control
mean 113.9, SD 17.0, P = 0.5). The authors also completed the
Reynell Scales of Infant and Toddler Development to assess lan-
guage development in the pre-school aged LEV exposed children
in comparison to the control children. No significant differences
were found in terms of language comprehension (LEVmean 49.6,
SD 10.3 versus control mean 52.2, SD 9.6, P = 0.2); for language
expression skills the children exposed to LEV scored significantly
higher than the control children (LEVmean 52.0, SD 13.4 versus
control mean 46.6, SD 10.2, P = 0.01).
Dose of LEV
In the study by Shallcross 2011 a linear relationship between daily
dose of LEV and the Griffiths Mental Development score was
noted to be significant, but it was a weak relationship (r = 0.25).
Neurodevelopmental outcomes of children exposed
to phenytoin (PHT) in comparison to control children
Despite its many years of use only five studies investigated the
cognitive abilities of children exposed to PHT in isolation from
other AEDs. Variance across methodologies limited our ability to
perform meta-analysis.
Developmental quotient
PHT versus controls (women without epilepsy)
The pooled MD estimate from 20 children exposed to PHT in
comparison to 44 controls (GERMAN Study; Rovet 1995) was
not statistically significant (MD -0.12, 95% CI -7.54 to 7.30, P
= 0.98, I2 = 55%) using the Bayley Scales of Infant and Toddler
Development (Analysis 5.1). Leavitt 1992 reported that the mean
scores on the Bayley Scales of Infant and Toddler Development
were not significantly different for children exposed to PHT in
comparison to general population control children (PHT mean
113, SD not reported versus control mean 119, SD not reported,
P = 0.173); however, the specific number of PHT monotherapy
exposed children was not reported in the paper. Wide 2002 noted
no significant difference at nine months of age for 21 children
exposed to PHT (mean 635, 95% CI unclear versus control mean
641, 95% CI unclear, P value not reported) in terms of global
neurodevelopment on the Griffiths Mental Development Scales.
This finding was consistent with later follow up of this cohort
at four years (PHT n = 15 mean (unstandarised) 635, 95% CI
unclear, P value not reported).
PHT versus controls (women with epilepsy not taking AEDs)
Thomas 2008 failed to find a significant difference between chil-
dren exposed to PHT (n = 29) (PHT mean 90.3, 95% CI 77
to 103, P value not reported) and controls (n = 32) (mean 92.3,
95% CI 81 to 103) when children were assessed with an adapted
version of the Bayley Scales of Infant and Toddler Development.
Intellectual quotient (IQ)
Two studies investigated the IQ abilities of children exposed
to PHT in comparison to control children (FINNISH Study;
Thomas 2007), however neither compared PHT monotherapy
outcomes to controls in isolation and therefore the data could not
be reported for PHT.
Autistic spectrum disorder
No studies were identified.
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Specific cognitive abilities
Rovet 1995 demonstrated significantly poorer language abilities
in children exposed to PHT compared to controls as measured by
the Reynell Language Scales across both comprehension and ex-
pressive language (means not reported). Arulmozhi 2006, reported
delayed sitting abilities in 18 infants exposed to PHT when com-
pared to 30 control children (means not reported). Wide 2002
also found delayed motor development in 15 PHT exposed chil-
dren aged between four and five years of age (PHT mean 98, 95%
CI unclear versus control mean 106, 95% CI unclear). Finally, a
non-significant OR for PHT (n=12) (OR 1.37, 95% CI 0.38 to
5.0, P value not reported) in comparison to controls was noted for
specific cognitive dysfunction in the early FINNISH Study.
Dose of PHT
The studies of Rovet 1995 and NEAD Study investigated but
failed to demonstrate a dose effect with PHT.
Neurodevelopmental outcomes of children exposed
to phenobarbital (PB) in comparison to control
children
Despite its historical use the majority of investigations into chil-
dren exposed to PB reported outcomes as part of a single AED
exposed group rather than as a group in its own right. Therefore,
limited data was available on PB exposure and child neurodevel-
opmental outcomes.
Developmental quotient
PB versus controls (women without epilepsy)
Leavitt 1992 reported that the mean Bayley scores were not sig-
nificantly different for children exposed to PB (mean 115, SD not
reported, P = 0.372) compared to general population control chil-
dren (mean 119, SD not reported); however the specific number
of women with PB monotherapy was not reported in the paper.
PB versus controls (women with epilepsy not taking AEDs)
Thomas 2008 failed to find a significant difference between chil-
dren exposed to PB (n = 41) (mean 90.3, 95%CI 94 to 97, P value
not reported) and control children (n = 32) (mean 92.3, 95% CI
81 to 103).
Intellectual quotient (IQ)
PB versus controls (women without epilepsy)
Thomas 2007 collected IQ data in children exposed to PB (n=14)
mean 86.2, SD 11, P value not reported) however they did not
make a direct statistical comparison to control children (n= 201)
(mean 93, SD 14.4).
Autistic spectrum disorder
No studies were identified.
Specific cognitive abilities
Thomas 2007 reported on the language abilities of 14 children
exposed to PB (mean 70.6, SD 9, P = 0.146) however they did
not make a direct comparison to control children, whose overall
language mean was not reported.
Dose of PB
No studies reported on dose of PB and child DQ or IQ.
Neurodevelopmental outcomes of children exposed
to primidone (PRM) in comparison to control children
Few studies reported on exposure to primidone in isolation from
other treatments and only one included study assessed cogni-
tive outcomes in children exposed to monotherapy primidone
(GERMAN Study).
Developmental quotient (DQ)
Only one study investigated DQ in PRM exposed infants in com-
parison to controls. The GERMAN Study reported a non-signif-
icant difference between 15 PRM exposed infants (mean 105.7,
SD 13, P value not reported) and 15 matched controls (mean
110.1, SD 10).
Intellectual quotient (IQ)
PRM versus controls (women without epilepsy)
In theGERMANStudy, 15 cases exposed toPRM(mean92.6, SD
2, P = 0.033) did not differ from control children representative
of the general population (mean 105.4, SD 11).
Autistic spectrum Disorder
No studies were identified.
Specific cognitive abilities
No studies were identified.
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Dose of PRM
Nostudies investigated dose of PRMand child neurodevelopment.
Neurodevelopmental outcomes of children exposed
to topiramate (TPM) in comparison to control
children
Only a single article was identified which assessed the neurodevel-
opment of children exposed to topiramate (Rihtman 2012).
Developmental quotient (DQ)
No studies were identified.
Intellectual quotient (IQ)
TPM versus controls (women without epilepsy)
The article by Rihtman 2012 included just nine TPM exposed
children of which only sixwere offsprings ofmothers with epilepsy.
Global cognitive ability was assessed using the Stanford-Binet fifth
edition and the authors reported a significant difference between
the nine TPM exposed children and 18 control children in terms
of global cognitive ability (TPM mean 96.33, SD 10.37 versus
control mean 111.39, SD 12.20, P = 0.005).
Autistic spectrum disorder
No studies were identified.
Specific cognitive abilities
In the article by Rihtman 2012 a large number of specific cognitive
abilities were assessed. The children exposed to TPM (n = 9) were
found todiffer significantly fromcontrol children (n=18) on a task
of visual perception (TPM mean 92.00, SD 13.73 versus control
mean 110.41, SD 15.88, P = 0.010), tasks of motor control (TPM
mean 78.56, SD 17.36 versus control mean 101.47, 16.82, P =
0.005), general co-ordination (TPMmean 20.71, SD 4.15 versus
control mean 23.57, SD 2.47, P = 0.035), finemotor performance
(TPM mean 6.78, SD 1.86 versus control mean 9.00, SD 2.14,
P = 0.016) and also on gross motor performance (TPM mean
7.78, SD 2.44 versus 10.72, SD 3.49, P = 0.043). No significant
differences were found on tasks of visual motor integration (TPM
mean 95.56, SD 9.79 versus control mean 106.83, SD 16.94, P =
0.067), control during motor movement (TPM 20.14, SD 5.27
versus control mean 22.28, SD 3.56, P = 0.380) or on fine motor
perceptual abilities (TPM mean 22.86, SD 2.79 versus control
mean 23.86, SD 1.96, P = 0.300).
Neurodevelopmental outcomes of children exposed
to sodium valproate (VPA) in comparison to control
children
Ten studies investigated the cognitive abilities of children exposed
to VPA in comparison to a control group (Bromley 2010; Bromley
2013; Cummings 2011/2013; Gaily 2004; GERMAN Study;
Jackson 2013; Rihtman 2013; Shallcross 2011; Thomas 2007;
Thomas 2008).
Developmental quotient (DQ)
VPA versus controls (women without epilepsy)
Three studiesmade comparisons between children exposed toVPA
and children born to women who did not have epilepsy (Bromley
2010;Cummings 2011/2013;GERMANStudy). TheGERMAN
Study measured neurodevelopment with the Bayley Scales of In-
fant and Toddler Development and found a significant difference
between nine VPA exposed (mean 103.5, SD 11, P = 0.01) and
nine matched control children (mean 116.8, SD 11). In a larger
sample, Bromley 2010 demonstrated a significant difference be-
tween the VPA exposed (n = 42) (mean 92, 95% CI 87 to 96, P
< 0.001) and control children (n = 230) (mean 100, 95% CI 99
to 102) for early development measured by the Griffiths Mental
Development Scales.
VPA versus controls (women with epilepsy not taking AEDs)
The pooled results from two studies measuring neurodevelopment
with the Bayley Scales of Infant and Toddler Neurodevelopment
(Jackson 2013; Thomas 2008) found VPA exposed children (n =
123) to have a significantly lower development in comparison to
children born to mothers with epilepsy not taking AEDs (n = 58)
with aMD of -8.72 (95% CI -14.31 to -3.31, P = 0.002, I2 = 0%)
(Analysis 4.2).
Using the Griffiths Mental Development Scales, children exposed
to VPA (mean 92, 95%CI 87 to 96, P value not reported) had sig-
nificantly poorer DQ than children born to women with epilepsy
untreated (mean 104, 95% CI 101 to 108) (Bromley 2010).
Shallcross 2011, demonstrated significantly poorer neurodevelop-
ment in a VPA (n = 44) (mean 82.2, SE 2.5, P < 0.001) group
recruited from the UK Epilepsy and Pregnancy Register in com-
parison to control children (n = 97) (mean 99.0, SE 1.4). How-
ever, this control group overlapped with that of Bromley 2010 and
therefore was not included in the meta-analysis.
Intellectual quotient (IQ)
VPA versus controls (women without epilepsy)
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The pooled estimate from three studies, one prospective study
(Bromley 2010) and two register studies (Gaily 2004; Thomas
2007), found a significant MD of -8.94 (-11.96 to -5.92, P <
0.00001, I2 = 88%) finding VPA exposed children (n = 76) to
have poorer levels of neurodevelopment in comparison to control
children (n = 552) (Analysis 3.3). Variance was high between the
studies included in this meta-analysis (I2 = 88%) and visual in-
spection of the plot indicated that this was due to the small study
of Thomas 2007 where the results, based on only 12 cases, were
in the opposite direction to those of the other included studies,
reporting a higher mean for the small VPA group in comparison
to the controls. A random-effects model analysis was undertaken
and gave an MD of -5.28 (95% CI -15.54 to 4.97, P = 0.31),
which altered the significance of the results. However, the forest
plot clearly indicated that the Thomas 2007 study was in contra-
diction to the other four studies and therefore a sensitivity analysis
without this study showed a significant MD of -11.42 (-14.68 to
8.15, P < 0.00001), altering the I2 statistic to 2% and indicating
little variance between the other studies.
Rihtman 2013 also compared VPA exposed children to control
children using the Standford Binet, fifth Edition, however 21%
were not born to women with epilepsy and therefore this data
could not be combined in a meta-analysis. It was of note that the
mean dose of VPAwas low (546.3mgdaily), probably reflecting its
use for a non-epilepsy indication in this paper. In the comparison
of the 30 VPA exposed children to 52 control children Rihtman
2013 reported no significant differences in terms of global IQ
(VPA mean 103.93, SD 10.00 versus control mean 108.71, SD
10.20, P > 0.05).
VPA versus controls (women with epilepsy not taking AEDs)
Four studies contributed to the pooled estimates for child IQ in
those exposed to VPA compared to the offspring of women with
untreated epilepsy (Bromley 2010; Eriksson 2005; Gaily 2004;
Thomas 2007). Meta-analysis found a significant MD of -8.17
(95% CI -12.80 to -3.55, P = 0.0005, I2 = 27%) with VPA (n
= 89) exposed children having a lower IQ than controls (n = 87)
(Analysis 4.3).
Autistic spectrum disorder
Three studies reported on the prevalence of autistic spectrum di-
agnosis in groups of children exposed to VPA (Bromley 2013;
Cummings 2011/2013; Eriksson 2005). In the largest study, the
prevalence of autistic spectrum diagnosis was 8% in the VPA ex-
posed group compared to 1.8% in the general population controls
(n = 210) (Bromley 2013) in six year olds. Cummings 2011/2013
noted a 12% prevalence of autistic spectrum disorder in the group
exposed to VPA. Finally, Eriksson 2005 reported two cases from
15 (15.4%) who had autistic and regressive behavioural features
suggestive of low intelligence in children aged 6 to 13 years. Meta-
analysis was not possible due to the variance in the way these data
were collected. Veiby 2013 analysed parental reports of autistic
symptomology at 18 and 36months of age. At 18months the chil-
dren exposed to VPA (n = 25) were not reported to be at a signifi-
cantly higher risk based on an autism checklist (VPA 8.3% versus
10.0%, OR 1.0, 95% CI 0.2 to 4.5, P > 0.05) or on a measure of
autistic traits (VPA 0% versus 0.5%, OR could not be calculated)
in comparison to control children (n = 221). Consistently, at 36
months parents did not report the children exposed to VPA (n =
19) to be at an increased risk of autistic traits (VPA 5.6% versus
0.7%, OR 3.7, 95% CI 0.5 to 28.4, P > 0.05) in comparison to
control children (n = 154).
Specific cognitive abilities
The VIQ abilities of VPA exposed children (n = 64) were signifi-
cantly poorer than general population control children (n = 351)
in the pooled estimates from two studies (Bromley 2010; Gaily
2004) with aMDof -11.39 (95%CI -14.68 to -8.10, P < 0.00001,
I2 = 0%) (Analysis 3.6). Consistently, in comparison to no treat-
ment controls (n = 83) the VIQ was demonstrated to be signif-
icantly lower for children exposed to VPA (n = 77) (MD -8.81
95% CI -13.32 to -4.30, P = 0.0001, I2 = 0%) (Analysis 4.6). For
PIQ, children exposed to VPA (n = 64) had significantly poorer
abilities (MD -10.48, 95% CI -13.94 to -7.02, P < 0.00001, I2
= 68%) compared to general population controls (n = 392) based
on the pooled estimates from these two studies (Bromley 2010;
Gaily 2004) (Analysis 3.7). This was consistent with the pooled
estimates for PIQ for children exposed to VPA (n = 77) in com-
parison to no treatment controls (n = 83) (MD -7.20, 95% CI
-12.44 to -1.96, P = 0.007, I2 = 12%) based on three studies
(Bromley 2010; Eriksson 2005; Gaily 2004) (Analysis 4.7). Due
to high heterogeneity a random-effects model analysis was per-
formed for women on VPA versus women without epilepsy for the
PIQ results and gave a significant MD of -12.11 (95% CI -19.66
to -4.55, P = 0.002), which did not alter the significance of the
overall estimate. The data from Rihtman 2013 were not included
in the meta-analysis (due to inclusion of psychiatric indications)
but the VIQ and PIQ were assessed and reported and were not
in agreement with the meta-analysis results. In the Rihtman 2013
study no significant difference was reported for VIQ (VPA mean
101.38, SD 11.73 versus 105.27, SD 11.76, P < 0.05) or PIQ
(VPAmean 106.59, SD 10.32 versus 112.06, SD 11.02, P < 0.05)
for the children exposed to VPA (n = 29) in comparison to chil-
dren born to women without epilepsy (n = 52).
To date few studies have consistently investigated specific cognitive
ability types in comparison to a control group or shared a control
group (in the case of Bromley 2010 and Shallcross 2011) and
therefore meta-analysis was not possible.
In terms of early gross motor development, Bromley 2010 found
that the children exposed to VPA were significantly poorer on
motor abilities than general population control children (VPA
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mean 91, 95% CI 86 to 96 versus control mean 98, 95% CI
97 to 100, P = 0.015). VPA exposed infants taking part in the
Kerala Pregnancy Register had high rates of motor delay (38%);
however no statistical comparison to the no medication control
group was reported (Thomas 2008). At the later assessment of
the Shallcross 2011 cohort, children exposed to VPA (n = 45)
performed significantly less well on tasks of motor development
(VPAmean 96.6, SD 22.1 versus control mean 110.9, SD 20.1, P
= 0.001). In school aged children, Rihtman 2013 reported poorer
gross motor function (VPA mean 31.30, SD 24.18 versus control
mean 49.92, SD 28.29, P < 0.05) and poorer motor control (VPA
mean 25.54, SD 26.54 versus control mean 51.53, SD 25.26, P <
0.05) in VPA exposed children (n = 29) in comparison to children
born to women without epilepsy (n = 30).
Early language development was assessed by a number of studies
in comparison to control children. Bromley 2010 found the lan-
guage skills of VPA exposed children to be poorer than control
children born to women without epilepsy (VPAmean 97, 95%CI
92 to 103 versus control mean 105, 95%CI 103 to 106, P=0.008)
and in comparison to children born to women with untreated
epilepsy (control mean 109, 95% CI 105 to 114, P value not
reported). Consistently, Shallcross 2011 used the same measure
and also found poorer language development in children exposed
to VPA (VPA 84.9, SE 2.7 versus control mean 101.3, SE 1.6,
P ≤ 0.001). When children in the Shallcross 2011 cohort were
assessed later at between three and four years of age, the children
exposed to VPA were still significantly poorer in terms of language
comprehension abilities (VPA mean 44.0, SD 16.1 versus control
mean 52.2, SD 9.6, P = 0.003) but did not differ from control
children on expressive language abilities (VPAmean 43.1, SD15.9
versus control mean 46.6, SD 10.2, P = 0.9), although we noted
that the language assessment measure was different at this reassess-
ment (Reynell Language Scales). Thomas 2007 investigated the
language development of children exposed to VPA in comparison
to control children; however, no direct statistical comparison was
reported between these groups. Finally, verbal dysfunction was
present in three of 15 cases (23%) in the small cohort of Eriksson
2005 in comparison to a single case in the control group (7.7%).
The social abilities of infants were assessed in two studies. Bromley
2010 found that young children exposed to VPA had poorer social
abilities (VPAmean 90, 95% CI 85 to 95 versus control mean 97,
95% CI 95 to 98, P = 0.003); with Shallcross 2011 also reporting
this association in children under the age of two years (VPA mean
87.9, SE 2.9 versus control mean 98.2, SE 1.6, P = 0.001). Re-
assessment of the Shallcross 2011 cohort at between three and four
years of age showed continuing poorer early social development
(VPA mean 108.4, SD 21.4 versus control mean 119.9, SD 16.3,
P = 0.002).
One study reported significantly poorer hand and eye co-ordina-
tion in children exposed to VPA (n = 42) (VPA mean 89, 95%
CI 84 to 95 versus control mean 101, 95% CI 98 to 103, P <
0.001) (Bromley 2010), which was consistent with the report of
increased fine motor difficulties reported by Rihtman 2013 in 30
VPA exposed children (VPA mean 24.57, SD 18.74 versus con-
trol mean 43.08, SD 21.17, P < 0.05). However, assessment of
the Shallcross 2011 cohort failed to find a significant difference
between VPA exposed children (n = 40) and control children (n =
96) for hand and eye co-ordination at the younger age assessment
(under two years of age) (VPA mean 95.4, SE 2.9 versus control
mean 97.6, SE 1.9, P = 1.00) or at the older age assessment (VPA
mean 102.1, SD 17.7 versus control mean 103.3, SD 15.6, P =
0.9).
Finally, two studies investigated non-verbal reasoning in children
under the age of two years using the Griffths Mental Develop-
ment Scales (Bromley 2010; Shallcross 2011), with both finding
a poorer level of performance for the children exposed to VPA
(Bromley 2010: VPA mean 92, 95% CI 87 to 97 versus control
mean 102, 95% CI 100 to 104, P < 0.001; Shallcross 2011: VPA
mean 93.5, SE 3.3 versus control mean 101.6 SE 1.8, P=0.040).
At the reassessment of the Shallcross 2011 cohort later in child-
hood, however, the non-verbal abilities of the children exposed to
VPA were comparable to the control children (VPA mean 111.4,
SD 23.1 versus control mean 110.5, SD 16.3, P = 0.6).
VPA versus controls: prevalence of below average
performance
For VPA in comparison to controls, although a number of stud-
ies reported the prevalence of DQ performance below the aver-
age range, meta-analysis was limited due to heterogeneity across
methodologies. Based on two studies the meta-analysis demon-
strated a significantly increased risk of below average performance
(RR 10.33, 95% CI 2.05-52.01, P = 0.005, I2 = 0%) (Bromley
2010, Eriksson 2005). The study by Cummings 2011/2013 also
reported a significant increase in the number of children with be-
low average performance (1 SD) among the 58 valproate exposed
children (39.6%) in comparison to 44 controls (4.5%) with a sig-
nificant OR of 26.1 (95%CI 4.9 to 139; P < 0.001). Consistently,
Bromley 2010 demonstrated a significantly increased risk of per-
formance 1 SD below the mean for children exposed to VPA (n
= 42, 29%) in comparison to general population controls (n =
230, 8%) and control children born to women with and untreated
epilepsy (n = 27, 7%). Using parent completed questionnaires to
rate child development at six months, Veiby 2013 reported no
significant difference between the children exposed to VPA (n =
27) and control children (n = 276) for the prevalence of below av-
erage performance on gross motor development (VPA 7.4% ver-
sus control 9.8%, OR 0.7, 95% CI 0.2 to 2.8, P > 0.05), fine
motor development (VPA 11.5% versus control 6.9%, OR 2.1,
95% CI 0.6 to 7.3, P > 0.05) or early social development (VPA
3.7% versus control, OR 0.3, 95% CI 0.1 to 2.4, P > 0.05). At 18
months, Veiby 2013 reported significant differences for the VPA
exposed children (n = 25) in comparison to control children (n
= 221) with regards to rates of impairment in gross motor skills
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(VPA 16% versus control 3.2%, OR 7.0, 95% CI 2.4 to 21.0,
P < 0.05) but not on measures of fine motor skills (VPA 4.0%
versus control 5.1%, OR 1.3, 95% CI 0.2 to 9.7, P > 0.05) or
personal or social skills (VPA 0% versus control 0.9%, OR could
not be calculated). Parents were asked to rate their child again at
36 months when the children exposed to VPA were rated to be
at risk of poor sentence skills (VPA 15.8% versus 3.9%, OR 3.4,
95% CI 1.0 to 12.0, P < 0.05) but not for difficulties with gross
motor development (VPA 10.5% versus 3.3%, OR 3.4, 95% CI
0.8 to 14.9, P > 0.05), fine motor development (VPA 5.6% ver-
sus control 5.6%, OR 1.7, 95% CI 1.7 0.2 to 13.1, P > 0.05) or
communication skills (VPA 10.5% versus 1.3%, OR 3.5, 95% CI
0.8 to 15.4, P > 0.05).
Dose of VPA
It was consistently reported that higher levels of VPA were asso-
ciated with poorer levels of global neurodevelopment (Bromley
2010;Gaily 2004; Jackson 2013;NEADStudy).Most commonly,
doses of 800 to 1000 mg daily were reportedly associated with in-
creasing levels of risk. It was of note that the mean dose of VPA in
the Rihtman 2013 study (mean dose 546.3 mg daily) was consid-
erably below this level and may have accounted for the differences
in findings between this study and the majority of other included
studies. In addition to a relationship between dose and global cog-
nitive abilities, the studies of Nadebaum 2011 and the NEAD
Study group also demonstrated a dose relationship between higher
VPA doses and poorer language skills. Thomas 2008 reported a
relationship between dose of VPA and infant motor ability. How-
ever, not all studies replicated this association between dose and
ability (Shallcross 2011).
AED versus AED comparisons across
neurodevelopmental outcomes
CBZ versus VPA
A total of nine studies investigated the abilities of children ex-
posed to CBZ and VPA (Bromley 2010; Cummings 2011/2013;
Eriksson 2005; Gaily 2004; GERMAN Study; Jackson 2013;
NEAD Study; Thomas 2008; Thomas 2007).
Developmental quotient (DQ)
Four studies were prospective and used the Bayley Scales of In-
fant and Toddler Development (GERMAN Study; Jackson 2013;
NEAD Study; Thomas 2008). The pooled estimates suggested a
higher mean score for CBZ (n = 210) compared to VPA (n = 160)
but this was not statistically significant (MD 4.16, 95% CI -0.21
to 8.54, P = 0.06, I2 = 5%) (Analysis 17.1). Only one identi-
fied study used the GriffithsMental Development Scales (Bromley
2010) and found a significantly poorer outcome for children ex-
posed to VPA (n = 42) (mean 92, 95% CI 87 to 96, P = 0.028)
in comparison to those exposed to CBZ (n = 48) (mean 98, 95%
CI 94 to 103).
Intellectual quotient (IQ)
Two prospective studies (Bromley 2010; NEAD Study) and three
registry studies (Eriksson 2005; Gaily 2004; Thomas 2007) as-
sessed IQ in children exposed to CBZ or VPA. The pooled esti-
mate found a higher mean score for children exposed to CBZ (n
= 191) in comparison to VPA exposed children (n = 112) (MD
8.69, 95% CI 5.51 to 11.87, P < 0.00001, I2 = 43%) (Analysis
17.2).
Autistic spectrum disorders
Three studies investigated the prevalence of autistic spectrum dis-
order in children exposed to either CBZ or VPA (Bromley 2013;
Cummings 2011/2013; Eriksson 2005). In one study the pres-
ence of autistic and regressive behavioural features were reported
for 2/13 (15.4%) of children exposed to VPA, with no such cases
in the CBZ exposed children (Eriksson 2005). Bromley 2013 re-
ported an increased prevalence of autistic spectrum disorders with
VPA (4/50, 8%) in comparison to CBZ (0/50, 0%). In this study
the diagnoses were made independent of the study team, through
routine clinical services. An unpublished data set was provided
(Cummings 2011/2013), which reported consistent data in the
two studies above (VPA 8/58, 13.7% and CBZ 3/49, 6.1%, P
value not available). Meta-analysis was not carried out due to vari-
ations in the methodologies of these studies.
Specific cognitive abilities
The meta-analysis of VIQ was based on three studies (Bromley
2010; Eriksson 2005; Gaily 2004) as the NEAD Study did not
report VIQ isolated from other language measures (Analysis 17.3).
A significant MD of 8.44 (95% CI 4.21 to 12.66, P < 0.00001, I2
= 0%) was found favouring theVIQ outcome for children exposed
to CBZ (n = 149) in comparison to those exposed to VPA (n =
77). Meta-analysis using the same studies but regarding the PIQ
abilities of children exposed to CBZ (n = 149) and VPA (n = 77)
also found a significant MD of 10.48 (95% CI 6.02 to 14.94, P
< 0.00001, I2 = 0%) with children exposed to CBZ performing
better (Analysis 17.4).
Due to heterogeneity in the investigation of specific cognitive abil-
ities a meta-analysis was not possible.
At three years of age, the NEAD Study reported the specific cog-
nitive abilities of children exposed to CBZ in comparison to chil-
dren exposed to VPA on a verbal and non-verbal index. The verbal
index included a naming vocabulary task, a verbal comprehension
task, an expressive communication task, an auditory comprehen-
sion task and a picture naming task. The children exposed to VPA
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(n = 43) were reported to have a significantly poorer verbal index
than the children exposed to CBZ (n = 59) (CBZmean 93.0, 95%
CI 88.6 to 97.3 versus VPA mean 83.9, 95% CI 78.8 to 89.0,
P value not reported). On the non-verbal index, no significant
difference was found between the CBZ exposed children and the
VPA exposed children (CBZ mean 99.6, 95% CI 95.0 to 104.2
versus VPA mean 98.5, 95% CI 93.1 to 103.8, P value not re-
ported). At six years of age, the NEAD Study noted significant
differences between the memory (CBZ (n = 61) mean 104, 95%
CI 100 to 108 versus VPA (n = 49) mean 92, 95% CI 87 to 98,
P = 0.0010) and language (CBZ mean 104, 95% CI 102 to 107
versus VPA mean 97, 95% CI 94 to 100, P = 0.005) abilities of
the children exposed to VPA, with non-significant differences for
CBZ exposed children in comparison to VPA exposed children
for non-verbal abilities (CBZ mean 104, 95% CI 102 to 107 ver-
sus VPA mean 101, 95% CI 98 to 104, P = 0.08) and executive
abilities (CBZ mean 105, 95% CI 103 to 108 versus VPA mean
101, 95% CI 98 to 104, P = 0.11).
Nadebaum2011, assessed global language development in 23VPA
exposed children in comparison to 34 children exposed to CBZ.
The number of children considered to have language delay varied
(30.4% VPA exposed children versus 17.6% in the CBZ exposed
children) but a significant difference was not found between the
group means.
CBZ versus VPA: prevalence of below average performance
A comparison of below average performance for children exposed
to VPA and children exposed to CBZ, from three studies using the
Bayley Scales of Infant and Toddler Development (DQ) (Jackson
2013; NEAD Study; Thomas 2008), found a non-significant RR
of 0.83 (95% CI 0.62 to 1.12, P = 0.22, I2 = 0%). This was based
on 152 VPA exposed children and 211 CBZ exposed children for
performance 1 SD below the mean (Analysis 17.5). The pooled
estimate for performance 2 SDs below the mean gave a non-sig-
nificant RR of 0.77 (95% CI 0.38 to 1.58, P = 0.47, I2 = 17%)
based on 81 VPA exposed children and 110 CBZ exposed children
(Jackson 2013; NEAD Study) (Analysis 17.6).
In older children whose abilities were measured by IQ the pooled
estimate from three studies (Bromley 2010; Eriksson 2005;NEAD
Study) provided a statistically significant RR of 0.40 (95%CI 0.19
to 0.83, P = 0.01, I2 = 0%) based on 91 CBZ exposed children and
87VPA exposed children for prevalence of performance 1 SD from
the mean, showing that VPA exposed children had a higher rate
of below average performance (Analysis 17.8). The more severe
level of IQ impairment (2 SDs from the mean) was reported by
four studies (Bromley 2010; Eriksson 2005; Gaily 2004; NEAD
Study) with a non-significant RR of 0.26 (95% CI 0.05 to 1.19,
P = 0.08, I2 = 0%) based on 177 CBZ exposed children and 100
VPA exposed children (Analysis 17.7).
CBZ versus LTG
Four studies investigated the abilities of both children exposed
to CBZ and to LTG (Bromley 2010; Cummings 2011/2013;
Nadebaum 2011).
Developmental quotient (DQ)
Two studies assessed the neurodevelopment of children exposed
to either CBZ or LTG using the Bayley Scales of Infant and
Toddler Development (Cummings 2011/2013; NEAD Study).
Cummings 2011/2013 reported child neurodevelopment scores
on the Bayley Scales of Infant and Toddler Development in con-
junction with scores collected on the Griffiths Mental Develop-
ment Scales and therefore meta-analysis was not possible. The
NEAD Study reported that the neurodevelopment of children ex-
posed to CBZ (n = 43, mean 94, SD 15) was not significantly
different from those exposed to LTG at two years of age (n = 57,
mean 97, SD 17, P value not reported).
Two studies measured infant neurodevelopment with the Griffiths
Mental Development Scales (Bromley 2010; Cummings 2011/
2013). Bromley 2010 noted no significant difference between the
children exposed to CBZ (n = 48, mean 98, 95% CI 94 to 103)
and those exposed to LTG (n = 34, mean 99, 95% CI 94 to 103),
however these data overlapped in part with the NEAD Study.
Intellectual quotient (IQ)
Two studies assessed the IQ of children exposed to CBZ and LTG
(Bromley 2010; NEAD Study). These studies overlapped in part
and meta-analysis was conducted utilising only the additional UK
children who had not been reported as part of the NEAD study.
Pooled estimates gave a non-significant MD of -1.62 (95% CI -
5.44 to 2.21, P = 0.41, I2 = 0%) when comparing 78 children
exposed to CBZ and 84 LTG exposed children from two studies
(Bromley 2010; NEAD Study) (Analysis 12.2).
Autistic spectrum disorders
No significant differences between the rates of autistic spectrum
disorder were reported in the study by Bromley 2013. No cases
(0%) were found in this study from 50 CBZ exposed children and
30 LTG exposed children at six years of age. Unpublished data
provided by Cummings 2011/2013 reported a 6.1% prevalence
(3/49) for CBZ in comparison to 0% prevalence for those exposed
to LTG (0/35).
Specific cognitive abilities
Only the NEAD Study assessed and reported on specific cognitive
abilities of children exposed to CBZ and children exposed to LTG.
A verbal index was created by the authors and included a naming
vocabulary task, a verbal comprehension task, an expressive com-
munication tasks, an auditory comprehension task and a picture
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naming task. At three years of age the children exposed to CBZ
(n = 59) did not differ significantly from the children exposed to
LTG (n = 70) on this verbal index (CBZ mean 93.0, 95% CI 88.6
to 97.3, P value not reported). A non-verbal index was also created
based on a block design task and a task of visual-motor integra-
tion. The children exposed to CBZ did not differ from the chil-
dren exposed to LTG on this non-verbal index (CBZ mean 99.6,
95% CI 95.0 to 104.2 versus LTG mean 106.3, 95% CI 101.7 to
110.9, P value not reported). At six years of age a comprehensive
assessment of a range of cognitive abilities was undertaken. No
differences were found between the CBZ exposed children (n =
61) and the LTG exposed children (n = 74) on tasks of memory
(CBZ (n = 61) mean 104, 95%CI 100 to 108 versus LTG (n = 74)
mean 106, 95% CI 102 to 110, P value not reported), language
(CBZmean 104, 95% CI 102 to 107 versus LTG mean 105, 95%
CI 102 to 107, P value not reported) and executive functioning
(CBZmean 105, 95% CI 103 to 108 versus LTG mean 107, 95%
CI 104 to 109, P value not reported).
Rates of language impairment were higher for children exposed
to CBZ (n = 34, 17.6%) but were not significantly different from
the rates in children exposed to LTG (n = 9, 0%); the numbers
were small and the difference was not statistically significant in the
study by Nadebaum 2011.
CBZ versus LTG: prevalence of below average performance
The pooled estimate for DQ performance 1 SD below the mean
demonstrated no significant difference in the frequency of perfor-
mance in this range for children exposed to CBZ (n = 76) in com-
parison to children exposed to LTG (n = 83) (RR 2.28, 0.63 to
8.22, P = 0.21, I2 = 0%) from two studies (Bromley 2010; NEAD
Study) (Analysis 12.3).
CBZ versus PHT
Developmental quotient (DQ)
Pooled results from four identified studies (GERMAN Study;
NEAD Study; Rovet 1995; Thomas 2008) using the Bayley Scales
of Infant and Toddler Development found a non-significant MD
of 3.02 (95% CI -2.41 to 8.46, P = 0.28, I2 = 0%) for 172
CBZ exposed children in comparison to 87 PHT exposed chil-
dren (Analysis 13.1). Wide 2002 compared the development of
35 children exposed to CBZ (mean 618, 95% CI unclear) to 15
children exposed to PHT (mean 635, 95% CI unclear) and failed
to find a significant difference for overall cognitive ability.
Intellectual quotient (IQ)
A non-significant MD was noted for CBZ (n = 75) in comparison
to PHT (n = 45), with an MD of -3.30 (95% CI -7.91 to 1.30,
P = 0.16, I2 = 0%), with data coming from two studies (NEAD
Study; Thomas 2007) (Analysis 13.2).
Autistic spectrum disorders
No studies reported rates of autistic spectrum disorder in these
two AED groups simultaneously.
Specific cognitive abilities
The NEAD Study assessed the verbal and non-verbal cognitive
abilities of children exposed to CBZ in comparison to those ex-
posed to PHT. A verbal index was created by the authors which
included a number of language tasks. At three years of age the tasks
included in this index were a naming vocabulary task, a verbal
comprehension task, an expressive communication tasks, an audi-
tory comprehension task and a picture naming task. The children
exposed to CBZ (n = 59) were not significantly different from
the children exposed to PHT (n = 39) on this verbal index (CBZ
mean 93.0, 95% CI 88.6 to 97.3 versus PHT mean 95.9, 95%
CI 91.0 to 100.8, P value not reported). A non-verbal index was
created and included a block design task and a task of visuomotor
integration. Consistently, the children exposed to CBZ did not
differ from the PHT exposed children on the non-verbal index
(CBZmean 99.6, 95%CI 95.0 to 104.2 versus PHTmean 102.0,
95% CI 96.9 to 107.2, P value not reported). Reassessment of
this cohort at six years of age also found no significant differences
between children exposed to CBZ and those exposed to PHT on
measures of verbal, (CBZ (n = 61) mean 104, 95% CI 102 to
107 versus PHT (n = 40) mean 106, 95% CI 102 to 109), non-
verbal (CBZ mean 104, 95% CI 102 to 107 versus PHT mean
106, 95% CI 103 to 109), memory (CBZmean 104, 95% CI 100
to 108 versus PHT mean 101, 95% CI 96 to 107) and executive
functioning skills (CBZ mean 105, 95% CI 103 to 108 versus
PHT 103, 95% CI 100 to 106) at six years of age.
In a linked paper to Rovet 1995, increased rates of expressive
language dysfunction in the children exposed to PHT (n = 26,
23%) were reported in comparison to CBZ exposed children (n =
28, 6.7%). Wide 2002 found no significant differences between
children exposed to CBZ (n = 35) and children exposed to PHT (n
= 15) on tasks of motor (CBZ mean 104, 95% CI unclear versus
PHT mean 98, 95% CI unclear, P > 0.05), social (CBZ mean
107, 95% CI unclear versus PHT mean 105, 95% CI unclear, P
> 0.05), language (CBZ mean 105, 95% CI unclear versus PHT
mean 111, 95%CI unclear, P > 0.05), hand and eye co-ordination
(CBZ mean 100 95% CI unclear versus PHT mean 101, 95%
CI unclear, P > 0.05) and practical reasoning ability (CBZ mean
101, 95% CI unclear versus PHT mean 110, 95% CI unclear, P
> 0.05).
CBZ versus PHT: prevalence of below average performance
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The prevalence of children exposed to CBZ falling below 1 SD
from the mean was not significantly increased compared to PHT
exposed infants (RR 0.78, 95% CI 0.52 to 1.15, P = 0.21, I2 =
0%) based on 149 CBZ and 149 PHT exposed children (NEAD
Study; Thomas 2008) (Analysis 13.3).
VPA versus LTG
Four studies were identified that made comparisons between chil-
dren exposed to VPA and LTG (NEAD Study; Bromley 2010;
Cummings 2011/2013; Rihtman 2013).
Developmental quotient (DQ)
The NEAD Study reported a significant difference between chil-
dren exposed to VPA (n = 28, mean 85, SD 19) and those exposed
to LTG (n = 57, mean 97, SD 17) when neurodevelopment was
assessed using the Bayley Scales of Infant and Toddler Develop-
ment.
Cummings 2011/2013, used both the Bayley and Griffiths Scales
and found differing levels of below average performance for those
exposed to VPA (39.6%) and those exposed to LTG (2.9%); how-
ever, the data were not in a format in which they could be utilised
in a meta-analysis.
Intellectual quotient (IQ)
At six years of age, the NEAD Study found that children exposed
to VPA (n = 49, mean 98, SD 10) had significantly poorer scores
compared to children exposed to LTG (n = 74, mean 108, SD
13). The pooled estimate from the NEAD Study and Bromley
2010, in six year old children, produced a significant MD of -
10.79 (95% CI -14.41 to -7.17, P < 0.00001, I2 = 0%) for 74
VPA exposed children in comparison to 84 LTG exposed children
(Analysis 14.2).
Rihtman 2013 also assessed the IQ of children exposed toVPA and
children exposed to LTG, however their study included women
taking these medications for indications other than epilepsy and
therefore this data was not included in the meta-analysis. In con-
trast to the data reported from the NEAD Study, Bromley 2010
and the meta-analysis, Rihtman 2013 failed to find a significant
difference between the IQ of children exposed to VPA (n = 29)
and those exposed to LTG (n = 41).
Autistic spectrum disorders
Two identified studies, one published (Bromley 2013) and one
with unpublished data (Cummings 2011/2013), reported rates of
community diagnoses of autistic spectrum disorders for children
exposed to VPA or LTG. In the study by Bromley 2013 no di-
agnoses of autistic spectrum disorder were reported for the LTG
exposed group (n = 30) whilst the prevalence in the VPA exposed
group was 8% (4/50). Consistently, there were no cases of autistic
spectrum disorder in the group exposed to LTG (n = 35) with the
VPA group prevalence at 13.7% (8/58) in the study of Cummings
2011/2013.
Specific cognitive abilities
The NEAD Study undertook a comprehensive assessment of spe-
cific cognitive abilities at both three and six years of age. A verbal
index was created by the authors which included a number of lan-
guage tasks. At three years of age the tasks included in this index
were a naming vocabulary task, a verbal comprehension task, an
expressive communication task, an auditory comprehension task
and a picture naming task. The children exposed to VPA (n = 43)
had significantly poorer scores on the verbal index (VPA mean
83.9, 95% CI 78.8 to 89.0 versus LTG mean 96.6, 95% CI 92.3
to 100.9, P < 0.0001) in comparison to the children exposed to
LTG (n = 70). The non-verbal index included a block building
task and a visuomotor integration task and the children exposed
to VPA again had poorer scores than the children exposed to LTG
(VPAmean 98.5, 95% CI 93.1 to 103.8 versus LTG mean 106.3,
95%CI 101.7 to 110.9, P value not reported). At this age themag-
nitude of the difference in verbal abilities (MD 12.7) of the VPA
exposed children was more than the non-verbal abilities (MD 7.8
points) when compared to the LTG group. In NEAD Study, the
verbal, non-verbal, memory and executive functioning abilities of
children exposed to VPA or LTG were analysed at six years of age.
Children exposed to VPA (n = 49) had significantly poorer scores
than children exposed to LTG (n = 74) on verbal (VPA mean 97,
95% CI 94 to 100 versus LTG mean 105, 95% CI 102 to 107, P
= 0.003), non-verbal (VPA mean 101, 95% CI 98 to 104 versus
LTG mean 108, 95% CI 105 to 110, P = 0.0015), memory (VPA
mean 92, 95% CI 87 to 98 versus LTG mean 106, 95% CI 102 to
110, P = 0.003) and executive functioning (VPA 101, 95% CI 98
to 104 versus LTG mean 107, 95% CI 104 to 109, P = 0.0078)
skills.
Nadebaum 2011 reported significantly poorer language abilities
in children exposed to VPA (n = 23) in comparison to LTG (n =
9) (VPA 30.4% versus LTG 0%, P = 0.025).
Rihtman 2013 failed to find a significant difference between the
children exposed to VPA (n = 29) and those exposed to LTG
(n = 42) on tasks of visuomotor integration (VPA mean 42.55,
SD 27.68 versus LTG mean 53.86, SD 25.54, P > 0.05), visual
perception (VPAmean 49.03, SD 31.42 versus LTG mean 42.76,
SD 31.85, P > 0.05), motor co-ordination (VPAmean 25.54, SD
26.54 versus LTG mean 31.18, SD 28.62, P > 0.05), fine motor
abilities (VPA mean 24.57, SD 18.74 versus LTG mean 30.57,
SD 22.90, P > 0.05) or gross motor ability (VPA mean 31.30, SD
24.18 versus LTG mean 34.78, SD 24.47, P > 0.05) but did not
assess language development.
VPA versus LTG: prevalence of below average performance
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The pooled estimate based on two studies (Bromley 2010; NEAD
Study) gave a significant RR of 4.87 (95% CI 1.50, 15.78, P =
0.008, I2 = 0%) for performance below 1 SD of themean based on
74 VPA exposed children and 83 LTG exposed children (Analysis
14.3). Children exposed to VPA were therefore found to be at a
higher risk of below average performance.
VPA versus LEV
Only a single study was identified comparing the neurodevelop-
ment of children exposed toVPA in comparison toLEV (Shallcross
2011). Comparisons were made at under two years of age and
again at between three and four years of age.However, only 32%of
the LEV exposed children and 11% of the VPA exposed children
were reassessed at the older age and the remaining proportion of
the cohort were newly recruited.
Developmental quotient (DQ)
Using the Griffiths Mental Development Scales, Shallcross 2011
found that children exposed to VPA (n = 44) (mean 87.9, 95%
CI 83 to 93, P < 0.001) had a significantly poorer level of global
cognitive development in comparison to those exposed to LEV (n
= 51) (mean 99.9, 95% CI 97 to 103).
Intellectual quotient (IQ)
No studies were identified.
Autistic spectrum disorders
No studies were identified.
Specific cognitive abilities
In the paper by Shallcross 2011 children exposed to VPA had
significantly poorer scores in comparison to LEV exposed children
under the age of two years on motor tasks (VPA (n = 44) mean
84.6, 95% CI 79 to 91 versus LEV (n = 51) mean 97.3, 95%
CI 94 to 98, P < 0.001), hand and eye co-ordination (VPA mean
88.2, 95% CI 82 to 94 versus LEV mean 101.8, 95% CI 97 to
106, P = 0.01), non-verbal skills (VPA mean 88.8, 95% CI 83
to 94 versus LEV mean 101.7, 95% CI 98 to 105, P < 0.001),
language (VPA mean 90.4, 95% CI 84 to 97 versus LEV mean
100.5, 95% CI 96 to 104, P = 0.01) and social skills (VPA mean
98.8, 95% CI 84 to 96 versus LEV 98, 95% CI 94 to 102, P =
0.03). Following assessment at between three and four years of
age the children exposed to LEV performed significantly better
than the children exposed to VPA on tasks of motor development
(LEV mean 110.4, SD 17.2 versus VPA mean 96.8, SD 22.1, P
= 0.002) and expressive language development (LEV mean 52.0,
SD 13.4 versus VPAmean 43.1, SD 15, P = 0.005). No significant
differenceswere foundbetween the LEV exposed andVPA exposed
children on social development (LEVmean 116.5, SD 19.1 versus
VPA mean 108.4, SD 21.4, P = 0.2), hand and eye co-ordination
skills (LEV mean 104.8, SD 13.9 versus VPA mean 102.1, SD
17.7, P = 0.8), non-verbal performance skills (LEV mean 109.9,
SD 15.4 versus VPA mean 11.4, SD 23.1, P = 0.6), practical
reasoning (LEV mean 113.4, SD 16.6 versus VPA mean 108.9,
SD 18.8, P = 0.2) and language comprehension ability (LEVmean
49.6, SD 10.3 versus VPA mean 44.0, SD 16.1, P = 0.2) at this
older age point.
PHT versus VPA
Four studies investigated the cognitive abilities of children exposed
to VPA and PHT (GERMAN Study; NEAD Study; Thomas
2007; Thomas 2008).
Developmental quotient (DQ)
Pooled estimates from the three studies using the Bayley Scales
of Infant and Toddler Development (GERMAN Study; NEAD
Study; Thomas 2008) found a significant MD of 7.04 (95% CI
0.44 to 13.65, P = 0.04, I2 = 0%), when 80 children exposed to
PHT were compared to 108 VPA exposed children. VPA exposed
childrenwere found tohave significantly poorer early development
(Analysis 16.1).
Intellectual quotient (IQ)
In school aged children, pooled estimates from two studies (NEAD
Study; Thomas 2007) measuring IQ demonstrated a significant
MD of 9.25 (95% CI 4.78 to 13.72, P < 0.0001, I2 = 70%),
with children exposed to PHT (n = 45) having significantly higher
scores than children exposed to VPA (n = 61) (Analysis 16.2). A
random-effectsmodel analysis was carried out for this comparison,
due to high heterogeneity, which gave an MD of 6.38 (95% CI
-4.84 to 17.58, P = 0.27) and the overall estimate became non-
significant.
Autistic spectrum disorders
No studies investigated this outcome.
Specific cognitive abilities
In children aged three years of age the NEAD Study reported
a significantly poorer verbal ability (as measured by a composite
index including a range of language based tasks) for the children
exposed to VPA (n = 43) in comparison to those exposed to PHT
(n = 39) (VPAmean 83.9, 95%CI 78.8 to 89.0 versus PHTmean
95.9, 95%CI 91.0 to 100.8, P value not reported). In comparison,
no significant difference was found between the children exposed
to VPA versus those exposed to PHT for their non-verbal ability
(as measured by a non-verbal index created by the authors) (VPA
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mean 98.5, 95% CI 93.1 to 103.8 versus PHT mean 102.0, 95%
CI 101.7 to 110.9, P value not reported). In the NEAD Study,
at six years of age the abilities of children exposed to PHT were
found to be superior to those of children exposed to VPA on verbal
(PHT (n = 40) mean 106, 95% CI 102 to 109 versus VPA (n =
49) mean 97, 95% CI 94 to 100, P = 0.0005) and memory ability
(PHTmean 101, 95%CI 96 to 107 versus VPAmean 92, 95%CI
87 to 98, P = 0.0260) at six years of age. There was no significant
difference however in non-verbal abilities (PHT mean 106, 95%
CI 103 to 109 versus VPA mean 101, 95% CI 98 to 104, P =
0.0514) and executive functioning skills (PHT mean 103, 95%
CI 100 to 106 versus VPA mean 101, 95% CI 98 to 104, P =
0.28) (NEAD Study).
VPA versus PHT: prevalence of below average performance
A non-significant RRwas demonstrated for VPA exposed children
(n = 120) in comparison to PHT exposed children (n = 71) (RR
1.40, 95% CI 0.91 to 2.15, P = 0.12, I2 = 78%) for the prevalence
of performance 1 SD below the mean (Analysis 16.3) (NEAD
Study;Thomas 2008).Caution is required however, as the findings
of these two studies were in the opposite direction, which led to
the high I2 statistic.
Sensitivity analysis
There were 44 meta-analyses that included two or more studies
for which heterogeneity could be assessed. There were 34 meta-
analyses containing continuous data measured as the MD. Of
these, the I2 was less than 25% in 23 analyses, and 0% in 19 of the
analyses. There were three meta-analyses with an I2 statistic in the
range 25% to 50%, seven between 50% and 75%, and one over
75%. Nine meta-analyses were undertaken on binary data using
the RR to investigate the prevalence of below average DQ or IQ.
Of these, eight had an I2 statistic less than 25%, all eight were
0%. The remaining I2 statistic was high at 78%. The percentage
of DQ and IQ meta-analyses with I2 statistics under 25% were
roughly comparable (63% for DQ and 69% for IQ). Due to the
limited data it was not possible to fully explore the heterogeneity.
However, the plots were visually inspected and random-effects
model analyses were undertaken, which provided similar results
and conclusions in all but three cases (see Table 4).
Studies which met inclusion criteria, results not
reported
A number of studies met the inclusion criteria for the review but
due to one or more issues with reporting they were not included
in the results section (D’Souza 1991; FINNISH Study; Hanson
1976;Hill 1974;Hirano 2004; Jones 1989; Regesta 1996; Sobczyz
1977). The failure to reportmean scores or percentages belowaver-
age scores occurred in two studies (D’Souza 1991; Sobczyz 1977)
with the others not reporting exposure types separately (FINNISH
Study; Hill 1974; Hirano 2004; Regesta 1996). Some studies did
not differentiate between exposure types even at the monother-
apy versus polytherapy level (Arulmozhi 2006; FINNISH Study;
Hanson 1976; Jones 1989; Regesta 1996; Sobczyz 1977).
D I S C U S S I O N
Summary of main results
Carbamazepine (CBZ)
Themost commonly investigated AEDwas CBZ, both in terms of
the frequency of investigations and the total number of children.
The pooled estimates from meta-analyses found that the DQ was
poorer for young children exposed to CBZ in comparison to both
control group types. However, there were high levels of hetero-
geneity for both comparisons and sensitivity analysis using a ran-
dom-effects model altered the effect estimates so that they became
non-significant, suggesting that the significant finding was linked
to the variability within study methodologies. Two relatively large
observational studies with better quality ratings also consistently
failed to find a significant difference between children exposed to
CBZ and control children when they were assessed using the Grif-
fiths Mental Development Scales (Bromley 2010; Wide 2002). In
contrast, the data from Cummings 2011/2013 were not included
in the meta-analysis but reported poorer early neurodevelopment
for children exposed to CBZ.
Data from school aged children that was collected with IQ mea-
sures failed to find a significant difference between children ex-
posed to CBZ and control children. Children exposed to CBZ
were not found to differ from control children in terms of either
their VIQ or PIQ. Limited evidence was available for specific cog-
nitive abilities, however two studies of pre-school children and
one with school aged children failed to find a significant associa-
tion between language development and exposure to CBZ. There
was little evidence from the studies reviewed here that children
exposed to CBZ may be at an increased risk for autistic spectrum
disorders; although there is not an adequate level of evidence to
refute this. However, the large record linkage study by Christensen
2013 failed to find an association between exposure to CBZ and
an increased rate of diagnoses of autistic spectrum disorder.
When compared to children exposed to other AEDs, younger
children exposed to CBZ did not perform significantly differently
from children exposed to VPA, LTG or PHT.When older children
were assessed with an IQ measure, children exposed to CBZ had
significantly higher IQ scores than children exposed to VPA and
comparable levels to children exposed to PHT and LTG.
Increased dose of CBZ is reportedly associated with an elevated
risk of major congential malformation (Tomson 2011). Six studies
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investigated the relationship between dose of CBZ and child cog-
nitive outcome and all failed to demonstrate a significant associa-
tion between increasing doses and reduced child global cognitive
ability.
It should be noted that the findings of this meta-analyses are in
contradiction to those reported in the review by Banach 2010, who
reported, based onmore heterogeneous data, that children exposed
to CBZ are at an increased risk of poorer PIQ. Our review differed
from that of Banach and colleagues due to the inclusion of only
prospectively ascertained cohorts and including data from cohorts
which uniformly were children born to women with epilepsy.
Valproate (VPA)
Since the early case reports pertaining to prenatal exposure to VPA
there have been frequent reports of neurodevelopmental deficits
(for example Adab 2004; Ardinger 1988; Chevallier 1989; Dean
2002; Moore 2000). Consistent with this, poorer cognitive abil-
ities for children exposed to VPA were reported by all included
studies with just three exceptions (Thomas 2007; Thomas 2008;
Rihtman 2013). The outcome of the meta-analyses reported here
are consistent with that of Banach 2010 and suggest an increasing
body of evidence reporting an association between VPA exposure
and poorer child neurodevelopment. Of note, in one of the meta-
analyses including VPA (VPA versus women without epilepsy on
IQ) the I2 statistic was above 75%. This was due to the inclusion
of the data (n = 12) from Thomas 2007, which was in contrast to
the other larger included studies. Removal of these data reduced
the I2 statistic to 2% and the significance remained unchanged,
therefore this comparison remains consistent with other evidence.
In our meta-analyses VPA exposure was associated with signifi-
cantly lower DQs and IQs in comparison with control children,
with the MD ranging from eight to nine DQ or IQ points lower.
The DQ and IQ are continuously measured skills with a normal
distribution and therefore a mean group reduction of eight to nine
points would cause a shift to the left in the normal distribution
curve. This would lead to a decrease in the number of children
falling within the above average range and an increase in the rate of
children falling below the average range. Interestingly, the preva-
lence of below average performance at 1 SD level was significantly
increased in comparison with children born to women with un-
treated epilepsy, with an RR of 10.33. Meta-analysis for the preva-
lence of below average performance compared with general pop-
ulation control children was not possible, however the studies of
Bromley 2010 and Cummings 2011/2013 demonstrated an in-
creased rate of below average performance for the VPA exposed
children in comparison to this control group population. Data on
the number of children falling 2 SD below the mean did not reach
significance, which may be accounted for by a lack of power to
detect such a rare outcome.
In comparisons with children exposed to other AEDs, children
exposed to VPA did not have significantly poorer scores for global
cognitive ability than those exposed to CBZ when the outcome
was measured in younger children as the DQ. However, a signif-
icant difference in IQ ability is reported by the individual stud-
ies included here with the pooled estimate from the meta-analysis
demonstrating an eight point lower mean for children exposed to
VPA, a figure which was comparable to the poorer outcome for
VPA exposed children compared to control children. In a compar-
ison with children exposed to LTG, more limited data suggest that
children exposed to VPA have a group mean 10 points lower than
for children exposed to LTG, and between seven and nine points
lower for DQ and IQ respectively in comparison to children ex-
posed to PHT. It is of note, however, that the pooled estimate for
VPA versus PHT was not significant in the random-effects model
analysis which was undertaken due to high levels of heterogeneity.
A consistent finding across comparisons with control groups and
other AED exposed groups is a poorer neurodevelopmental out-
come for children exposed to VPA. In context, a mean reduction
of 8 to 10 IQ points is a substantial decrease when it is consid-
ered that the standard deviation for the normative sample is 15
points. Research in typically developing children links IQ test per-
formance to educational outcome. A longitudinal study of 70,000
pupils in theUK demonstrated that 58% of children falling within
the average range for their IQ obtained five or more General Cer-
tificate of General Education subjects (GCSEs) at A* to C level in
comparison to just 16% of children whose IQ was within the be-
low average range (Deary 2007). The poorer levels of IQ observed
for groups of children exposed to VPA is therefore likely to con-
vey real life implications for educational attainment. Interestingly,
poorer educational abilities have been reported for children ex-
posed to VPA in retrospective cohorts (Adab 2001; Adab 2004b)
strengthening this conclusion regarding real life implications.
Investigations into the abilities of children in specific cognitive do-
mains was more limited. In younger children there was evidence of
poorer motor and language development (Bromley 2010; Thomas
2008). Previous research has suggested a particular vulnerability of
verbal skills in comparison to non-verbal skills (Nadebaum 2011),
but our meta-analysis demonstrated that VIQ and PIQ were sig-
nificantly lower than in both control groups, with comparable
MDs, and therefore does not support a specific vulnerability lim-
ited to the verbal domain.
An increased prevalence of autistic spectrum disorders has been re-
ported in three studies, with prevalence estimates ranging from8%
to 15% (Bromley 2013; Cummings 2011/2013; Eriksson 2005).
Cases were limited within the population, due to the relatively rar-
ity of this condition. However, a recent large study utilising elec-
tronic healthcare data has also found a significant risk of autistic
spectrum disorder associated with VPA (absolute risk of 4.42%,
95% CI, 2.59 to 7.46) based on 508 children exposed to VPA
(Christensen 2013). Retrospective data sets not included in this
review have also found increased prevalence rates for autistic spec-
trum diagnoses, ranging from 3% to 9% (Adab 2004b; Rasalam
2005). Finally, there is evidence from animal models that early
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exposure to VPA is associated with autistic type behavioural pre-
sentations (Ardnt 2005).
The majority of studies investigating the relevance of the dose of
VPA reported a significant correlation between dose and child IQ,
with the majority of studies reporting an increase in risk at doses
above 800 to1000mg,which is consistentwith earlier reports from
a large retrospective study (Adab 2004b). The study by Rihtman
2013 used a substantially lower mean daily dose (546.3 mg daily)
than the other included studies, which at least in part is likely to be
due to the inclusion of women taking VPA for indications other
than epilepsy. It is likely that this lower dose accounts for the patchy
level of association between the different cognitive outcomes and
VPA exposure thatwere seen in this paper. In addition to a reported
relationship between dose of VPA and IQ, Nadebaum 2011 and
the NEAD Study group reported a significant association between
the dose ofVPA and language abilities, with higher doses associated
with lower language functioning scores.
In meta-analysis the influence of other variables is not taken into
consideration. For the data included in the meta-analyses in this
review, the studies of Bromley 2010 and NEAD Study were rated
as having a low risk of bias because of their statistical control over
the a priori identified important confounding factors; the studies
by Gaily 2004 and GERMAN Study adjusted for certain but not
all identified key confounding variables. The studies by Eriksson
2005, Jackson 2013, Thomas 2007 and Thomas 2008 were given
high bias ratings due to their failure to measure and adjust for ma-
ternal andpaternal IQs. For the studies reviewed in relation toVPA
outcomes but not entered into the meta-analysis, four out of six
studies were rated as having a low risk of bias in relation to dealing
with potential confounding variables (Bromley 2013; Cummings
2011/2013; Nadebaum 2011; Shallcross 2011). Therefore, the
majority of evidence provided in this review in relation to VPA
made important adjustments to limit the impact of potential con-
founding variables. There is, however, a frequently raised con-
cern pertaining to confounding by indication in that VPA is most
frequently prescribed for idiopathic generalised epilepsies. There-
fore, a possible drug association is never looked for outside of the
potential influence of the presence of maternal idiopathic gener-
alised epilepsy. Whilst this is the case, certain studies have made
attempts to analyse the neurodevelopmental outcomes of children
born to women with idiopathic generalised epilepsy in isolation,
comparing VPA treated and non-VPA treated groups. The most
prominent example is the NEAD Study. This study demonstrates
that within the group of children born to mothers with idiopathic
generalised epilepsy, the mean IQ at six years was 12 points lower
than for those children exposed to other AEDs, a level compara-
ble to the discrepancies reported for the VPA group as a whole
in comparison to the other AEDs. A further consideration is the
wealth of data from animal models, which requires caution but
highlights that in the absence of any form of maternal epilepsy
VPA is associated with altered neuronal development and func-
tional outcomes (Bittigau 2003; Miyazaki 2005). Research into
the outcomes of children born to women taking VPA for other in-
dications will assist to definitively answer this point in the future.
Currently, however, the present evidence should be explained to
women and their families along with its strengths and limitations.
The risks associatedwithVPA treatment need to be communicated
to women and their families. Cognitive and behavioural function-
ing is complex and the risk to the individual woman and her child
will be dependent on the dose and genetic factors. Therefore, a
single risk figure to apply to all women would not be accurate.
The differences betweenVPA and other treatment groups reported
here range from eight to 10 points for DQ and IQ, with the poorer
developmental trajectory observed from infancy and present at
least into the school aged years and possibly beyond (Titze 2008).
However, such figures do not take account of the dose of VPA.
Data pertaining to dose would suggest that the risk for a women
on a lower dose of VPA would be less than the figures reported
here, whilst a higher dose would convey an even higher level of
risk. The included studies of Bromley 2010, Bromley 2013, Gaily
2004, Nadebaum 2011, NEAD Study and Jackson 2013 report
that an increased risk occurs from approximately 800 to 1000 mg
daily, but currently there are not enough data to determine risk
level at specific dose ranges. Future work needs to address this lack
of information.
Lamotrigine (LTG)
Despite its prevalent use in women of childbearing age (Ackers
2009; Meador 2009b), there is limited evidence pertaining to pre-
natal LTG exposure in terms of neurodevelopmental outcome.
Only four identified studies investigated the neurodevelopmental
abilities of children exposed to LTG in comparison to control chil-
dren, and meta-analysis was not possible. Despite methodological
differences, both Bromley 2010 and Cummings 2011/2013 failed
to find a significant difference in neurodevelopmental outcome for
younger children exposed to LTG compared to control children.
In the NEAD Study children exposed to LTG had significantly
higher IQs and other cognitive abilities than children exposed to
VPA, and these measures were similar to those in children exposed
to CBZ and PHT. The pooled estimates reported here incorpo-
rated the data from the NEAD Study, with a small number of
additional cases from the Liverpool and Manchester Neurodevel-
opment Group (Bromley 2010), to give a non-significant MD in
comparison to CBZ but a significantly higher mean IQ in com-
parison to VPA exposed children.
The study by Rihtman 2013 was not included in the meta-anal-
ysis due to the inclusion of women taking LTG for indications
other than epilepsy. This study found a significantly poorer level
of development on certain aspects of perceptual and motor devel-
opment for the LTG exposed children in comparison to control
children; however, confounding variables were not adjusted for
that have been noted to alter the significance levels in relation to
LTG exposure and the hand and eye co-ordination outcome in
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other studies (Bromley 2010).
No relationship with dose was found by the NEAD Study. Con-
sistent with other AEDs, increasing the dose of LTG has been as-
sociated with an increase in major congential malformation risk
(Tomson 2011) and further investigations regarding LTG dose
and neurodevelopmental outcome are required.
Phenytoin (PHT)
Despite its extensive historical use, few prospective studies have in-
vestigated PHT exposure and child neurodevelopmental outcome
in isolation from other AEDs. It is noted that a number of older
cohort studies did investigate the neurodevelopmental function-
ing of children exposed to PHT, however, due to their retrospective
nature they were not included here (for example.Adab 2004). A
meta-analysis of PHT children in comparison to control children
was limited by methodological heterogeneity, however the pooled
estimate from two studies found a non-significant difference for
PHT exposed children compared with general population con-
trols. This is consistent with other studies that have been reviewed
narratively (Leavitt 1992; Thomas 2008; Wide 2002). In terms of
specific abilities, two studies reported poorer motor development
(Arulmozhi 2006; Wide 2002) and one reported poorer language
abilities (Rovet 1995), but the quality of the study designs was
limited. Two studies investigated the dose of PHT and child neu-
rodevelopment (NEAD Study; Rovet 1995) and both failed to
demonstrate an association.
In comparison to other AEDs, children exposed to PHT have
been demonstrated as a group to have comparable mean DQ and
IQ scores when compared to CBZ and significantly higher DQ
and IQ levels compared to children exposed to VPA; with MDs
ranging from seven to nine DQ or IQ points.
Phenobarbital (PB)
Very few studies reported neurodevelopmental outcomes in chil-
dren prenatally exposed to PB. Both studies investigating the DQ
failed to find an association between exposure to PB and outcome
(Leavitt 1992; Thomas 2008). The numbers of exposed children
were not reported in one study (Leavitt 1992). Only the study by
Thomas 2007 assessed ability in school aged children, measured
by IQ, and reported no association between outcome and expo-
sure; however the number of exposed children was small (n = 14).
No identified studies investigated an association between dose of
PB and child neurodevelopmental outcome.
The evidence pertaining to PB is extremely limited. The absence of
evidence should not be regarded as evidence of safety, and women
should be counselled regarding the paucity of evidence for this
drug.
Levetiracetam (LEV)
There are limited data pertaining to the othermonotherapy AEDs.
A single study was identified which investigated the neurodevel-
opment of children exposed to LEV in utero (Shallcross 2011).
This study assessed children at two years of age, with reassessment
of part of the cohort at between three and four years of age. At
both time points this study failed to find a difference between
the neurodevelopment of children exposed to LEV and control
children, and found that the LEV exposed children were superior
in neurodevelopment in comparison to children exposed to VPA.
Replication is required. A significant dose dependent effect was
noted in the Shallcross 2011 study for LEV but the association
was weak.
LEV is in widespread use by women in their childbearing years
(Meador 2009b) due to the evidence pertaining to malforma-
tion risk, which, based on evidence to date, does not appear to
be increased from the background rate (Hernandez-Diaz 2012;
Mawhinney 2013). The use of LEV in women of childbearing age
and during pregnancy is not supported from a neurodevelopmen-
tal teratological safety point of view due to the lack of evidence.
Research is needed to address this lack of evidence and women
should be informed about the lack of evidence regarding neurode-
velopmental risk and safety.
Topiramate (TPM)
Only one identified study investigated the abilities of children
exposed to TPM in utero. Rihtman 2012 reported a significant
difference between the children exposed to TPM in comparison
to control children but extreme caution is required due to the
small number of TPM exposed children (n = 9) and because of
the heterogeneous indications for which the mothers were taking
TPM.
In the study by Meador 2009b, TPM was a relatively commonly
used medication in women of childbearing age. Therefore, more
research is needed to provide evidence on which counselling of
women and their families can be based. Currently, there is not
enough evidence to suggest neurodevelopmental safety or an in-
creased risk of harm.
Monotherapy and polytherapy
Historically there was a frequent analysis of monotherapy data as
a single unitary group. The variation between treatment types,
reported above, indicates that such practice should not be con-
tinued as it will lead to unreliable conclusions. As well as differ-
ences in risk levels across exposure types, groups of monotherapy
and polytherapy cases will vary from cohort to cohort due to the
documented differences in prescribing across countries (for exam-
ple Meador 2009b), meaning that the characteristics of the two
groups are unlikely to be the same. A number of older retrospective
papers reported that monotherapy outcomes were better than for
polytherapy, however data reviewed from the cohorts of Bromley
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2010 and Nadebaum 2011 highlight that the important driver in
this conclusion may be the presence of absence of VPA. More data
are required.
Due to the above noted variability in monotherapy and polyther-
apy groups across studies systematic review and meta-analysis was
not undertaken as were likely to contain large variation and high
bias.
Other antiepileptic drugs (AEDs)
No studies were identified which investigated the neurodevelop-
ment of children born to women with epilepsy and exposed to
any other AED in monotherapy. Whilst there is unavoidably a
latency between the onset of a medication use and adequate data,
a number of these drugs have been utilised for a decade or more
(for example TPM, zonisamide, ethosuximide and gabapentin),
suggesting that prescribing for women with epilepsy is not cur-
rently based on evidence of neurodevelopmental safety. Prescribers
are without the evidence on which to base their counselling of
women.
Overall completeness and applicability of
evidence
The complexity of this area has brought a number of challenges for
completing this review within the Cochrane framework. Hetero-
geneity across study methodologies and varied reporting methods
have greatly limited the number of studies included in the meta-
analyses. The dynamic nature of child neurodevelopment means
that different assessments are required to assess ability at different
ages and for different outcomes. Therefore, the results section and
meta-analyses needed to be divided to give consideration to the
type of assessment that was completed and the cognitive outcome
in question.
This systematic review is to our knowledge the most comprehen-
sive review completed to date in this area. The creation and ad-
vance publication of the review protocol, the clear inclusion crite-
ria, the extensive searches, the acquisition of unpublished data, and
the assessment of risk of bias and quality in the non-randomised
evidence are strengths of this review. Under the Cochrane guide-
lines this review will be updated every two years, or following the
publication of a significant amount of new data, to ensure it re-
mains up to date.
This review is limited by heterogeneity across study methods and
in terms of study quality, although more recent studies tended to
demonstrate higher quality methods. The largest limitation placed
on this review relates to the lack of evidence pertaining to the
newer AEDs. No evidence was found for AEDs such as tiagabine,
gabapentin, zonisamide, oxcarbazepine and ethosuximide. A fur-
ther limitation is that due to limited data and heterogeneity. The
potential impact of confounding variables could not be explored
and therefore the results need to be interpreted with a degree of
caution. However, the majority of included studies did investigate
the impact of confounding variables and several found a signif-
icant association with prenatal exposure to VPA even after con-
trolling for confounders (Bromley 2010; Gaily 2004; Nadebaum
2011; NEAD Study; Shallcross 2011) therefore producing results
consistent with the findings of this review. The dose of the AED
is likely to be a key variable in the level of risk. At this time, this
review is not able to analysis data stratified by dose.
It should be considered that in a few of the comparisons the num-
ber of children that were included was low (for example compar-
isons including LTG). Determining power is influenced by the
level of discrepancy present between the groups. For example, 45
children in each group would be required to detect a difference
of 1.5 SDs between two groups with 80% power at a 95% CI, ,
however larger levels of difference could be detected reliably with
smaller groups. Those comparisons with a low number of children
may be at risk of imprecision and therefore the results may be
subject to change in light of new data. It should also be consid-
ered that smaller levels of difference may not be detectable in the
group sizes included in this review, and that some non-significant
findings may change in light of new data.
This review is also limited by its failure to include study method-
ologies which utilise large national electronic data sets taken from
hospital and pharmacy records. Since the review protocol waswrit-
ten and published there has been a proliferation of studies using
this methodology (for example Christensen 2013) and future up-
dates of this review will include these data types.
Quality of the evidence
Randomised controlled trials are thought to be unethical in this
area due to the permanence of potential adverse effects for the
foetus. Gold standard evidence for this area would therefore com-
prise data coming from a prospective, blinded cohort study using
standardised measures to assess neurodevelopment and utilising
statistical methods to limit the influence of confounding variables.
The methodological quality for each study is displayed in Table
3. By their nature, all studies were rated as high risk on the ran-
domisation sequence and allocation concealment domains as they
were non-randomised trials. The included studies varied in their
approach to controlling confounding variables, a key issue in non-
randomised studies. The majority of studies scored well for blind-
ing of the outcome assessors; however blinding was unclear in five
studies and did not occur in six. By the nature of longitudinal fol-
low-up studies, participant attrition is likely; however themajority
of studies reported this clearly, providing reasons for the losses.
Selective reporting was difficult to rate for most studies due to the
absence of the study protocols. Other bias was a category created
to reflect bias in other domains such as the neuropsychological test
measure or principles, or failure to report specific AED treatments
separately; this led to high ratings of bias for 11 studies.
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More recent studies tend to be prospective, blinded, include
a reliable approach to control for confounders and have im-
proved reporting, indicating methodological improvement over
time. For recommendations on the conduct of future research see
Implications for research.
Potential biases in the review process
The review author RB was a study author on four of the included
data sets (Bromley 2010; Bromley 2013; NEAD Study; Shallcross
2011). This potential bias was reduced by delegating data extrac-
tion and risk of bias assessments to two other review authors.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is converging evidence that prenatal exposure to VPA is as-
sociated with an increased risk of a range of neurodevelopmental
deficits, including poorer early development, lower IQ in school
aged children, and an increased risk of autistic spectrum disor-
ders. In comparison to other treatments, VPA was associated with
reduced IQ compared to CBZ, LTG and PHT. It remains to be
seen, however, whether the levels of discrepancy between the chil-
dren exposed to VPA and controls or other AED exposed groups
increase or diminishe with time. Children exposed to CBZ were
not found to have reduced global cognitive development in com-
parison to control children, but less is known about any poten-
tial impact of exposure on specific cognitive skills. There is a lack
of evidence pertaining to the commonly prescribed treatments of
LTG, LEV and TPM, amongst others, and therefore current prac-
tices are not underpinned by evidence of foetal safety.
Women should be provided with information about the evidence
on the risks and safety of particular AED treatments. Preconcep-
tual counselling should be available and should cover both tera-
tological risk and considerations of the efficacy of treatments for
controlling seizures. A significant number of pregnancies are un-
planned and health professionals should ensure that women are
routinely informed about the risks and benefits of their medica-
tion, and prescribers should take the risk of unplanned pregnancy
into account when prescribing AEDs.
For those in paediatric services, poorer neurodevelopmental tra-
jectories are in evidence for children below the age of two years
that have been exposed to VPA. Routine monitoring should occur
for these children to ensure that, if required, early intervention
occurs to maximise child neurodevelopmental outcomes.
Implications for research
This area is complex and it is no wonder that knowledge about
the risks associated with AED teratogenicity is low amongst pre-
scribers (Roberts 2011) andwomenwith epilepsy (Metcalfe 2012).
Historical methods of surveillance are obviously not suitable to de-
tect neurodevelopmental impairment in a time-efficient manner
and therefore a different approach is required (Friedman 2012).
There has been a proliferation in the application of electronic
healthcare records in this area (for example Christensen 2013),
which may provide some progress. This methodology is unlikely
to offer a complete solution, however, as there is evidence that
the records may under-report malformation rates (Charlton 2011)
and in most cases they are unlikely to be suitable for IQ and other
cognitive data.
The neurodevelopmental risks reviewed here are likely to be life-
long and, as noted by Friedman 2012, signals of harm are impor-
tant in this area and should not be dismissed due to poor method-
ologies but investigated with urgency. The prominence of these
issues needs to be appraised and future work needs to ensure that
research occurs in a more timely and almost automatic manner to
ensure that the delays in establishing risk or safety data are reduced
to optimise the health of both the mother and the child. No clear
dominant method for investigation in this area has led to a va-
riety of methodologies, cohorts, control groups, child assessment
and reporting analysis methods being adopted. More coherence
across investigations will help to make the risk-benefit informa-
tion more clear. Below are some suggested guidelines for method-
ologies. Whilst there are always differences in opinion about how
to design a study these points aim to create more cohesion in this
area.
Design
Both truly prospective and registry based neurodevelopmental
studies have an important place. The dominance of pregnancy
registers for the collection of data pertaining to major congenital
malformations should not be ignored and their adaptation for the
collection of neurodevelopment data offers a timely and cost-ef-
fective method. However, the retrospective nature of recruitment
into the neurodevelopmental follow up means that estimates may
be seen as biased. Prospective studies where women enrol into the
study prior to knowing the child’s outcome offer less biased re-
cruitment, however losses to follow up over the childhood years
may mean that the biases for those who complete the final follow-
up assessment may not be that different from those who enrol
into a registry follow up. In this review no differences were found
between the outcomes of these methodologies and therefore both
these methods have a place.
Follow-up age
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Neurodevelopment is dynamic which presents a number of chal-
lenges. It has been argued that follow up to school age is required
to understand the neurodevelopment of an exposed child (Adab
2004b), and the present findings pertaining to CBZ emphasise
this point. This review demonstrates that whilst assessment at an
early age may detect stable levels of impairment (that is in the case
of VPA) it may also lead to premature conclusions about exposures
to other AEDs as by school age improvements may have occurred.
Follow up into the school age years is therefore required to ensure
reliable conclusions. However, the development of the brain does
not stop in the primary years and it could be argued that without
follow up into adulthood we run the risk of failing to document
reliable levels of risk to cognitive functioning.
Control groups
The offspring of women with epilepsy who were not taking AEDs,
or women without epilepsy whose children represent the general
population are two commoncontrol groups in the studies reviewed
here. The preference of one control group over the other has been
debated (for example Nicolai 2008). In this review no differences
were found between the pattern of results across control group
types, which is expected based on direct comparisons by other
authors (for example Bromley 2010; GERMAN Study; Holmes
2000). Decisions around control groups should also be based on
additional considerations including recruitment sources. The off-
spring of women with untreated epilepsy might convey benefits
in terms of reducing ascertainment bias as often pregnancy and
epilepsy registers do not recruit women without epilepsy.
Test selection
Over 15 different measurements were used to assess the different
aspects of neurodevelopment in the studies included in this review.
Whilst the manuals for these assessments will report correlations
between measures it would be inappropriate to pool outcomes
from all of these measures, and therefore direct comparisons across
cohorts were not always possible.
A measure of global cognitive ability (measured as IQ or DQ) was
the most commonly assessed domain. Whilst this is a useful way
to gauge cognitive development it may mask specific difficulties
in one or more cognitive domains. For example, the full scale IQ
score of a test comprises a number of subtests which measure a
variety of skills from processing speed to verbal knowledge. The
most common measure of neurodevelopment in younger children
was Bayley Scales of Infant and Toddler Development, with the
Wechsler IQ series being most commonly utilised for IQmeasure-
ment.Whilst the research question and author preferencemay dic-
tate test selection, authors are urged to consider selectingmeasures
which will allow direct comparisons across published cohorts.
Outcome reporting
Across the papers reviewed here there were varied reporting prac-
tices with regards to the outcomes across the studies. The major-
ity of studies report an overall mean and standard deviation or
confidence intervals for all the exposed children together, how-
ever, as noted above this is likely to mask differences in outcomes
across the groups. The reporting of outcomes of children exposed
to monotherapy and polytherapy is also common but again carries
a risk of masking effects which may be associated with an indi-
vidual drug. Differences in prescribing practices across countries
have been widely documented (Meador 2009b) and therefore one
monotherapy or polytherapy group is unlikely to be directly com-
parable to another. Outcomes by specific AEDs should always be
reported and studies should be powered to detect differences be-
tween different AED exposed groups.
In addition to reporting at a group level there was considerable
variation in how individual neurodevelopmental domains were
reported. The reporting, at least in table form, of global and all
individual domain standard (age adjusted) scores would assist with
comparisons across cohorts and will aid future meta-analysis.
The reporting of numbers of children who fall below the average
range may offer a more clinically meaningful representation of the
data.However, reduction of global cognitive ability from the above
average range to the average range should not be underestimated
in terms of its importance to the individual, family and society.
Dose
By their nature, dose is key to the effects of a teratogen (Brent
2004), yet this is not considered by all studies. Just like treating
all AEDs as a unified treatment group, treating all doses in the
same manner may lead to the masking of effects on cognitive de-
velopment. Doses should be investigated and reported. Dose ex-
ploration should at least undertake correlational analysis between
the dose of AED and child score (for example IQ, DQ or specific
language score).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arulmozhi 2006
Methods An open prospective cohort controlled study (India). Duration: 2 year period. Follow-
up: 1 year period
Participants Women with epilepsy taking AED monotherapy (n=33 enrolled, 30 babies examined);
women without epilepsy n=30)
Interventions Intervention group were taking either:
1) PHT
2) CBZ
3) VPA as monotherapy
Outcomes 1) Physical growth
2) Psychomotor development - assessed by Griffith Scale
Notes Women recruited when they became pregnant
Loss to follow-up: 3 babies were not examined (2 exposed to PHT, 1 exposed to CBZ)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as two important confounderswere
matched between groups
Blinding Unclear risk Rated unclear as no details present
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as only small amount of missing
data, unlikely to affect outcome
Selective reporting (reporting bias) Unclear risk Rated 3 as most data reported but some
missing from report due to non-significant
findings
Other bias Unclear risk Rated 3 as drug data was collected sepa-
rately but analysed together
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Bromley 2010
Methods A single blinded multi-centre prospective cohort controlled study (UK). Duration: 6
year period, with data reported at two time points: 2 years and 6 years of age
Participants 530 children enrolled in the study
2 years: 428 children completed the first assessment (81%)
1) Offspring of women with epilepsy (198 children completed assessment; 194 children
analysed)
• 167 children exposed to AED(s)
• 27 children not exposed to AED(s)
2) Offspring of women without epilepsy (287 enrolled, 230 examined)
6 years: 408 children completed the assessment
1) Offspring of women with epilepsy (198 children completed assessment; 187 analysed)
• 173 children exposed to AED(s)
• 25 children not exposed to AED(s)
2) Offspring of women without epilepsy (287 enrolled, 210 examined and analysed)
Interventions Intervention group were taking either:
1) VPA
2) CBZ
3) LTG
4) Other (including PHT, TPM, GBP, VGB, OXC)
5) Polytherapy
Outcomes 1) Neurodevelopment - assessed by Griffiths Mental Develiopment Scales at 2 years and
the Differential Ability Scales at 6 years
2) Physical growth (reported in separate paper)
3) Dysmorphic features (reported in separate paper)
Notes Loss to follow-up: 102 did not complete the first assessment therefore not included in
the analysis; 122 children did not complete the 6 year assessment
This study included 92 children who were also enrolled into the Meador 2009 series
where the primary outcome was measured against children exposed to other AEDs and
not control children. This data was not combined within this review or themeta-analysis.
Where possible the data which was independent from the Meador study was extracted
and utilised
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Low risk Rated 2 as important confounders were
considered and adjusted for appropriately
Blinding Low risk Rated 2 as outcome assessor blinded
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Bromley 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as only small amount of missing
data, unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 1 as protocol available and no evi-
dence of selective reporting bias
Other bias Low risk Rated 1 as no other bias identified
Bromley 2013
Methods A single blinded multi-centre prospective cohort controlled study (UK). Duration: 6
year period
Participants 501 women with 528 children were recruited between 2000 and 2004. 415 children
examined:
1) Offspring of women with epilepsy
• 209 children exposed to AED(s)
• 34 children not exposed to AED(s)
2) Women without epilepsy (214 children examined)
Interventions Intervention group were taking either:
1) VPA
2) CBZ
3) LTG
4) Other monotherapy
5) Polytherapy
Outcomes Diagnosis of an autism spectrum disorder (ASD)
Notes 113 children (42 children of womenwith epilepsy and 71 control childrenwere dropouts,
reasons given)
Diagnosis of autistic spectrum disorder was made independently of the study team
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Low risk Rated 1 as all important confounders inves-
tigated and appropriate analysis employed
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Bromley 2013 (Continued)
Blinding High risk Rated as 4 as clinician making diagnosis
probably not blinded, question of AED ex-
posure may not have been asked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated as 2 as small amount of missing data
unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 1 as protocol available and no evi-
dence of selective reporting bias
Other bias Low risk Rated as 2 as different clinicians made di-
agnosis of outcome
Cummings 2011/2013
Methods A single blinded prospective registry study (UK). Duration: 3 year period
Participants 150 women with epilepsy taking AED treatment, 12 women excluded as they did not
meet the inclusion criteria, 11 women withdrew
53 women without epilepsy consented to participate in the control group
Interventions Intervention group were taking either:
1) Sodium Valproate (n=58)
2) Carbamazepine (n=49)
3) Lamotrigine (n=35)
Control group (n=44)
Outcomes 1) Neurodevelopmental performance measured either by the Bayley Scales of Infant
Development (children aged 42 months and younger) or by the Griffiths Scale of Infant
Development (children older than 42 months)
Notes 127women in intervention group attended appointments, 19were excludedwith reasons
given (24 children excluded). Due to themethod of reporting in the paper this data could
not be utilised in meta-analysis. Additional information requested about prevalence of
autistic spectrum diagnosis and means by assessment type (i.e. Bayley or Griffiths)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Low risk Rated 2 as most important confounders
considered and adjusted for appropriately
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Cummings 2011/2013 (Continued)
Blinding Low risk Rated 2 as outcome assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data,
unlikely to affect outcome
Selective reporting (reporting bias) High risk Rated 4 as no details of mean scores which
would have been measured, no sub-scale or
overall continuous outcomes reported
Other bias Unclear risk Rated 3 as older versions of measures used
for year of recruitment
D’Souza 1991
Methods A single-centre (UK) prospective cohort controlled study.Duration: 2 year period. Follow
up: 3.5 years
Participants 61 women with epilepsy taking AED treatment and 62 control women without epilepsy
123 children assessed and 121 children included in the analysis
Interventions Intervention group were taking either:
1) Carbamazepine (n=3)
2) Phenobarbital (n=6)
3) Phenytoin (n=23)
4) Sodium valproate (n=2)
5) Clonazepam (n=1)
5) Polytherapy (n=18)
Control group:
1) No AED exposed group (n=8)
2) Women without epilepsy (n=62)
Outcomes 1) Developmental delay measured by Griffiths mental development scales
Notes Drug groups not analysed separately, median and range reported in paper so inclusion in
meta-analysis was not possible. Intervention group included women with epilepsy not
taking AED treatment during pregnancy (n=8)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
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D’Souza 1991 (Continued)
Confounding variables Unclear risk Rated 3 as some confounders considered
and adjusted for
Blinding Low risk Rated 2 as outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated as 2 due to small amount of missing
data, unlikely to affect outcome
Selective reporting (reporting bias) Unclear risk Rated 3 as domain specific sub-scales were
not reported though very likely to have
been measured
Other bias High risk Rated 4 as unclear description of recruit-
ment details and dose information
Eriksson 2005
Methods A single centre (Finland) registry study. Duration: 11 years
Participants 39 women with epilepsy initially recruited. 26 taking AED treatment and 13 taking no
AED treatment. 38 children completed assessments and analysed
Interventions Intervention group were taking either:
1) Sodium valproate (n=13)
2) Carbamazepine (n=13)
Control group:
1) No AED exposed (n=13)
Outcomes 1) Neurodevelopment measured by WISC-III and NEPSY
2) Rates of autistic spectrum diagnosis
Notes 1 child missing from analysis
Linked to Viinikainen 2006 paper
Protocol provided by authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 due to lack of consideration for
important confounders
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Eriksson 2005 (Continued)
Blinding Low risk Rated 2 as outcome assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data,
unlikely to affect outcome
Selective reporting (reporting bias) Unclear risk Rated 3 as certain sub-tests selected for re-
porting, no indication given as to why cer-
tain sub-scales chosen, possible implication
on outcome
Other bias High risk Rated 4 as FSIQ scoreswere estimated from
six sub-tests and VIQ and PIQ from two,
rather from core battery. Children’s ages
rangedwidely, usedmore than onemeasure
for maternal abilities
FINNISH Study
Methods A single-centre (Finland) prospective cohort controlled study. Follow-up: 5.5 years
Participants 253 children enrolled in the study
At 5.5 years 220 children completed assessments
• 104 children exposed to AED(s)
• 12 children not exposed
• 104 control children
Interventions Intervention group were taking either:
1) Sodium Valproate
2) Phenobarbital
3) Carbamazepine
4) Phenytoin
Numbers for individual monotherapies are not reported
Control group (n=104)
Non-exposed children (n=12)
Outcomes 1) IQ measured by WPPSI (3 subtests used)
2) Non-verbal IQ measured by LIPS
Notes 32 children lost to follow from time of enrolment
Protocol provided by authors. Study linked to Gaily 1990
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
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FINNISH Study (Continued)
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no confounding variables con-
sidered or adjusted for
Blinding Low risk Rated 2 as assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as only small amount of missing
data, unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 1 as protocol inspected and no selec-
tive outcome reporting identified
Other bias High risk Rated 5 as study analysedmonotherapy and
polytherapy together, estimated the intelli-
gence of 2 children, controls were not all
from the same source and the study did not
consider dose factors
Gaily 2004
Methods A single centre (Finland) registry study. Duration: 5 year period
Participants 149 women (189 children) with epilepsy were recruited and 121 women (141 children)
without epilepsy
Interventions Intervention group were taking either:
1) Sodium valproate (Mean 1200mg/day) (n=13)
2) Carbamazepine (Mean 600mg/day) (n=86)
3) Other monotherapy (n=8)
4) Polytherapy (n=30)
Control groups:
1) Women without epilepsy (n=141)
2) Women with epilepsy taking no AED (n=45)
Outcomes 1) Full scale IQ
2) Verbal IQ
3) Non-verbal IQ
Outcomes measured with WISC-R and WPPSI-R
Notes Linked to Kantola-Sorsa 2007
Risk of bias
Bias Authors’ judgement Support for judgement
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Gaily 2004 (Continued)
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders matched
at design stage however several important
confounders not considered and adjusted
for
Blinding Low risk Rated 2 as assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data
unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 1 as protocol inspected and no selec-
tive outcome reporting identified
Other bias Unclear risk Rated 3 as IQ scores were estimated from
Bayley Scales of Development for two chil-
dren
GERMAN Study
Methods A multi-centre (German) prospective cohort controlled study
Participants Women with epilepsy were recruited and women without epilepsy
Interventions For DQ assessment
Intervention group were taking either:
1) Monotherapy (n=44)
2) Polytherapy (n=15)
Control group (n=67)
*Numbers taken from Steinhausen 1994
For school age assessment
Intervention groups were taking either:
1) Monotherapy (n=52)
2) Polytherapy (n=26)
Control group (n=67)
*Numbers taken from Losche 1994
Outcomes 1) DQ measured by Bayley Scales
2) IQ measured by WPPSI
3) Motor performance measured by McCarthy Scales
4) Visual perception measured by FTVP
5) Psycholinguistic abilities
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GERMAN Study (Continued)
Notes Study linked to Steinhausen 1994, Koch 1996/1999, Hattig 1897/1987b, Titze 2008,
Rating 1982. Specific monotherapy data was only available for part of this cohort as
reported in Hattig and Steinhausen 1987
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as several factors considered i.e.
groups matched for SES, maternal age,
smoking during pregnancy and number of
abortions. Results analysed using multi-
variate analysis using polytherapy, SES and
gender. Then multiple correlation analy-
ses used for each psychological test explor-
ing the contribution of mono/polytherapy,
gender, SES, sibling rank, age of mother,
nicotine use, seizure frequency duringpreg-
nancy and obstetric score
Blinding Low risk Rated 2 as outcomes assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Rated 5 as large amount of missing data,
only graphs are shown. Numbers of par-
ticipants recruited were not stated in the
methods
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing, no protocol available
Other bias Unclear risk Rated 3 as age range of children is large,
monotherapy and polytherapy analysed to-
gether
Hanson 1976
Methods A single centre (US) prospective cohort controlled study. Study period: 7 years
Participants 104 women with epilepsy, 100 women without epilepsy enrolled
Interventions Intervention group were taking either:
1) Hydantoin monotherapy
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Hanson 1976 (Continued)
2) Hydantoin polytherapy
Combined intervention group (n=83) analysed
Contol group (n=83) analysed
Outcomes 1) Full scale IQ measured by WISC
Notes Monotherapy and polytherapy analysed together
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as controls matched for SES and
maternal age
Blinding Unclear risk Rated 3 as unclear whether any blinding
was employed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data,
unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing bias, no protocol available
Other bias High risk Rated as 5 did not analyse drugs separately,
did not examine dose and little informa-
tion about recruitment of women and rep-
resentativeness of the sample
Hill 1974
Methods A prospective multi-centre (USA) cohort study. Duration: 3 year period
Participants 23 women with epilepsy, 165 women formed the control group. 28 children examined
and analysed in intervention group and 165 in control group
Interventions Intervention group were taking either:
1) Ethosuximide
2) Phenobarbital
3) Primidone
4) Diphenylhydantoin
5) Polytherapy
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Hill 1974 (Continued)
Drug groups combined in analysis
Outcomes 1) Mental retardation measured by the Gesell developmental quotients
Notes Linked to Hill et al 1982. Study did not report monotherapy and polytherapy separately
and therefore could not be reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as no important confounding vari-
ables accounted for in analysis or at design
stage
Blinding Low risk Rated 2 as outcome assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Rated 3 as certain amount of missing data,
possible implication on outcome
Selective reporting (reporting bias) High risk Rated 4 as some outcome measures over
certain time-points are not reported
Other bias High risk Rated 5 as drug groups not analysed sep-
arately, dose not examined, lack of detail
regarding recruitment of mothers
Hirano 2004
Methods A single-centre (Japan) prospective cohort controlled study. Study period: 5 years
Participants 170 children enrolled in the study
Intervention Group:
71 children born to women with epilepsy (unknown number exposed to AEDs)
Control group:
99 children born to women without epilepsy
Interventions Intervention group were taking:
1) Polytherapy
Outcomes 1) DQ measured by Enjohi’s Test
2) Neurological status
52Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hirano 2004 (Continued)
Notes Study linked to Nomura 1984 and Fujioka 1984. Study did not report monotherapy
and polytherapy separately and therefore could not be reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders controlled for
Blinding Unclear risk Rated as unclear whether any blinding was
employed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 1 as no missing data
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing bias, no protocol available
Other bias High risk Rated 5 as analysed AEDs together
Jackson 2013
Methods A single-centre (UK) prospective cohort controlled study. Duration: 2 year follow up
Participants 288 women with epilepsy had completed questionnaires during pregnancy, 176 children
were assessed and 149 were included in the analysis
Interventions Intervention group were taking either:
1) Carbamazepine (n=62)
2) Sodium valproate (n=52)
3) Phenytoin (n=11)
4) Phenobarbital (n=1)
5) Polytherapy (n=24)
Control group:
1) Women with epilepsy not taking AED treatment (n=26)
Outcomes 1) Neurodevelopment measured by the Bayley’s Scales of Infant Development
Notes Large amount of missing data primarily due to excluding for age of children. Data from
this study is unpublished and was provided by the authors for the purpose of this review
Risk of bias
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Jackson 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as controlled for maternal ed-
ucation and maternal deprivation only.
Considered additional: maternal age, birth
weight etc
Blinding Low risk Rated 2 as outcome assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Rated 4 as larger amount of missing data,
likely to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing bias, no protocol available
Other bias Unclear risk Rated 3 as the control group is underpow-
ered
Jones 1989
Methods A single-centre registry study (USA). Duration: 5-6 year period. Follow up: yearly inter-
vals
Participants 72 women with epilepsy prospectively recruited via the California Teratogen Registry. 73
control women recruited. Number of children assessed for neurodevelopment is unclear
Interventions Intervention group were taking either:
1) Carbamazepine (n=50)
2) Carbamazepine polytherapy (n=22)
Control group consisted of women without epilepsy (n=73)
Outcomes 1) Neurodevelopment measured by the Bayley Scales or the Stanford-Binet Intelligence
Scale
Notes 18 children not included in the analysis due to terminations or loss to follow up. Study
did not report CBZ monotherapy and polytherapy separately and therefore could not
be reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Jones 1989 (Continued)
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as no adjustment employed for
confounders in the analysis
Blinding High risk Rated 5 as no blinding employed for neu-
rodevelopmental outcomes
Incomplete outcome data (attrition bias)
All outcomes
High risk Rated 4 as the control group were not as-
sessed, a large amount of missing data
Selective reporting (reporting bias) High risk Rated 4 as individual sub-scales were not
reported and developmental delay not as-
sessed or reported in control group
Other bias High risk Rated 5 as dose not examined, a number
of retrospectively recruited children were
combined with the prospectively recruited
children, age ranges of children were wide
Leavitt 1992
Methods A prospective single-centre (USA) cohort controlled study. Duration: 3 year period
Participants 107 women recruited in total
Interventions Intervention group (n=43) were taking either:
1) Carbamazepine
2) Phenobarbital
3) Phenytoin
Control group:
1) Women without epilepsy (n=41)
Outcomes 1) Neurodevelopment measured by the Bayleys Scales of Infant Development
Notes Unclear how many children were exposed to individual drugs therefore could not be
included in meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
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Leavitt 1992 (Continued)
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as no adjustment employed for im-
portant confounders
Blinding Low risk Rated 2 as outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as 90% of sample were assessed but
unclear in report if all were included in the
analysis
Selective reporting (reporting bias) High risk Rated 4 as Bayley scales of develop-
ment Performance indices not reported for
monotherapy group only MDI
Rated D using ORBIT tool as measure
analysed but not reported
Other bias High risk Rated 3 as limited data on specific
monotherapy drug and numbers exposed,
old test used, inflated means mean should
be 100 but mean 122 for CBZ groups,
shows inaccurate measure used out of date
Nadebaum 2011
Methods A multi-centre (Australia) registry study: Duration: 2 year period
Participants Paper one (2011a) 59 children of womenwith epilepsy were initially enrolled, 57 children
were assessed and included in the analysis
Paper two (2011b) 108 recruited and 102 children analysed
Interventions Nadebaum 2011a paper
Intervention group were taking either:
1) Sodium valproate (n=23)
2) Sodium valproate polytherapy (n=15)
3) Non-valproate polytherapy (n=19)
Nadebaum 2011b
Intervention group were taking either:
1) Sodium valproate (n=23)
2) Carbamazepine (n=34)
3) Lamotrigine (n=9)
4) Polytherapy (n=34)
Outcomes 1) IQ measured by the Weschler Intelligence Scale for Children
2) Language development as measured by the Clinical Evaluation of Language Funda-
mentals (reported in linked paper)
Notes Linked to Nadebaum 2011b
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Nadebaum 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Low risk Rated 2 as most important confounders
considered and adjusted for appropriately
Blinding Low risk Rated 2 as outcome assessor blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as only small amount of missing
data, unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing bias, no protocol available
Other bias Low risk Rated 2 as siblings were included within
the analysis
NEAD Study
Methods Single-blinded non-randomised prospective multi-centre study (USA/UK)
Participants Offspring of women with epilepsy (n=311). 224 children were assessed at age 6 year,
224 were analysed. Additional, intention-to-treat analysis contained 311 outcomes
Interventions Intervention group were taking either (6 year completers):
1) Carbamazepine (n=61)
2) Sodium valproate (n=49)
3) Phenytoin (n=40)
4) Lamotrigine (n=74)
Outcomes 1) Differential Ability Scales at 3, 4.5 and 6 years of age
2) Children’s Memory Scale at 6 years of age
3) NEPSY: Neurodevelopmental Assessment at 6 years of age
4) Expressive One Word Vocabulary Test at 6 years
5) Behaviour Rating Inventory of Executive Function at 6 years
6) Developmental Test of Visual-Motor Integration at 3years and 6 years
7) Bayley Scales of Infant and Child Development at 2 years and 3 years
8) Peadbody Picture Vocabulary Test at 3 years
9) Preschool Language Scale at 3 years
10) Bracken Basic Concept Scale at 4.5 years
11) Torrance Thinking and Creativity in Action and Movement at 3 years
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NEAD Study (Continued)
12) Adaptive Behaviour System 3, 4.5 and 6 years
13) Behavioural Assessment System for Children 3, 4.5 and 6 years
Notes Linked papers: Meador 2006 (abstract), 2009, 2011, 2011b, 2012, Cohen 2011,
McVearry 2009
This series utilised intention-to-treat analysis. This series contained 92 participants from
the UK who were also enrolled in the Bromley series
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Low risk Rated 1 as all important confounders con-
sidered and adjusted for appropriately
Blinding Low risk Rated 2 as assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as only small amount of missing
data and ITT used
Selective reporting (reporting bias) Low risk Rated 1 as protocol available and no evi-
dence of selective outcome reporting
Other bias Low risk Rated 1 as no other bias identified
Ornoy 1996
Methods A single-centre (Israel) prospective cohort controlled study. Duration: 6 year period
Participants 37womenwith epilepsy enrolled in the study and49 childrenwere examined. 57 children
completed assessments
Interventions Intervention group were taking:
1) Carbamazepine (n=41)
Control group:
1) Matched controls, women without epilepsy (n=47)
Outcomes 1) Neurodevelopment measured by the Bayley’s Scales of Infant Development or Mc-
Carthy’s Developmental Scales depending on age of child
Notes 2 children excluded from the analysis. Total number included in the analysis differs on
each measure used
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Ornoy 1996 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as groups were matched for birth
weight, gestational age and SES outcome.
Later explored age at assessment, birth-
weight, SES by showing mean results for
each group and dose effect and exposure
to convulsions by reporting the proportion
with low scores in stratified groups
Blinding Low risk Rated 2 as outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data,
unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing bias, no protocol available
Other bias Unclear risk Rated 3 as results were combined for Mc-
Carthy and Bayley as the main outcome,
smaller numbers for a given developmental
score. Not clear where the control group
from
Regesta 1996
Methods A single-centre (Italy) prospective cohort controlled study. Study period: 3 years
Participants 125 women with epilepsy and 113 control women enrolled
118 children analysed in intervention group, 107 analysed in control group
Interventions Intervention group were taking either:
1) Phenobarbital
2) Carbamazepine
3) Phenytoin
4) Sodium valproate
Outcomes 1) DQ measured by Egan Criteria
Notes All AEDs analysed as either monotherapy or polytherapy
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Regesta 1996 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as some confounders considered
and accounted for i.e. polytherapy, SES,
epilepsy type, age of child at assessment
Blinding Unclear risk Rated as unclear whether any blinding was
employed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data
unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing bias, no protocol available
Other bias Unclear risk Rated 3 as unclear if any other bias affecting
outcome
Rihtman 2012
Methods A single-centre (Israel) register cohort controlled study. Duration: 7 year period
Participants Nine children of women taking topiramate for epilepsy or other disorders
Interventions Intervention group:
Topiramate (n=9)
Outcomes 1) IQ measured by Stanford-Binet Intelligence Scales (5th Ed)
2) Motor coordination measured by Developmental Coordination Questionnaire
3) Visualmotor skillsmeasured by Beery-BuktenicaDevelopmental Test of Visual-Motor
Integration (5th Ed)
4) Motor skills measured by Miller Function and Participant Scales
5) Sensory processing abilities measured by Sensory Profile and Short Sensory Profile
6) Executive functioning measured by Behavior Rating Inventory of Executive Function
and Preschool Version
7) Problem behaviours and attention measured by Conners’ Ratign Scales-Revised
Notes 33% of the mothers were not taking topiramate for epilepsy. Excluded the children with
a full scale IQ less than 70
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Rihtman 2012 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated as 4 due to limited control for con-
founding variables
Blinding Unclear risk Rated as unclear whether any blinding was
employed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated as 1 no missing data reported
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing bias, no protocol available
Other bias High risk Rated as 4 due to the inclusion of women
taking topiramate for other indications,
multiple testing on small sample
Rihtman 2013
Methods A single-centre (Israel) registry cohort controlled study. Duration: 7 years
Participants 69 women with epilepsy and 51 control women enrolled
72 children analysed in intervention group, 52 analysed in control group
Interventions Intervention group were taking either:
1) Sodium valproate (n=30)
2) Lamotrigine (n=42)
Control group:
1) Children not exposed to AEDs (n=52)
Linked paper (2012)
1) Topirmate (n=9)
2) Children not exposed to AEDS (n=18)
Outcomes 1) IQ measured by Stanford-Binet Intelligence Scales (5th Ed)
2) Motor coordination measured by Developmental Coordination Questionnaire
3) Visualmotor skillsmeasured by Beery-BuktenicaDevelopmental Test of Visual-Motor
Integration (5th Ed)
4) Motor skills measured by Miller Function and Participant Scales
5) Sensory processing abilities measured by Sensory Profile and Short Sensory Profile
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Rihtman 2013 (Continued)
6) Executive functioning measured by Behavior Rating Inventory of Executive Function
and Preschool Version
7) Problem behaviours and attention measured by Conners’ Ratign Scales-Revised
Notes Linked to Rihtman 2012 (although investigating different AEDs) paper investigating
topiramate in which over 30% of women did not have a diagnosis of epilepsy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as some confounders were consid-
ered but not adjusted for
Blinding Low risk Rated 2 as outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 1 as no missing data
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing bias, no protocol available
Other bias High risk Rated 4 as due to the inclusion of women
taking AEDs for non-epilepsy indications,
due to exclusion of children with an IQ less
than 70
Rovet 1995
Methods A single-centre (Canada) prospective cohort controlled study. Duration: 5 year period
Participants 58 women with epilepsy were recruited, 58 children were assessed and included in the
analysis
Interventions Intervention group were taking either:
1) Carbamazepine (n=29)
2) Phenytoin (n=29)
Control group:
1) Matched controls of women without epilepsy (n=58)
Outcomes 1) Neurodevelopment measured by the Bayley Scales of Infant Development or Mc-
Carthy Scales depending on age of child
2) Language measured by the Reynell Development Language Scales
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Rovet 1995 (Continued)
Notes Linked to Scolnik 1994 paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as adjusted for maternal IQ, SES
and maternal age only
Blinding Low risk Rated 2 as outcomes assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data,
unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as separate developmental test re-
sults were not reported, although unlikely
to affect outcome
Other bias Low risk Rated 2 as different age ranges of children,
but unlikely to affect outcome due to ap-
propriate tests used
Shallcross 2011
Methods A single centre (UK) prospective cohort controlled study. Duration: 3 year period
Participants 197 children were assessed and included in the analysis. 22 women with epilepsy and 98
women without epilepsy were recruited from a previous cohort
Interventions Intervention group were taking either:
1) Levitiracetam (n=55)
2) Sodium valproate (n=44)
Control group:
1) Women without epilepsy (n=98)
Outcomes 1) Neurodevelopment measured by the Griffiths Mental Devlopment Scale
Notes Of 87 women who agreed, 10 were not included in the analysis, reasons given. The
control group from this paper is the same as Bromley 2010. Unpublished data from the
doctoral thesis of R Shallcross was provided for this review
Linked to Shallcross 2014 paper
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Shallcross 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Low risk Rated 2 as controlled for: seizures in preg-
nancy (not type of seizures), gestational age,
maternal full-scale IQ, maternal age, child
age at assessment, SES, exposure to nico-
tine, exposure to alcohol, and drug used in
pregnancy
Blinding High risk Rated 5 as no methods of blinding em-
ployed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data,
unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing bias, no protocol available
Other bias Low risk Rated 2 as some data were collected retro-
spectively
Sobczyz 1977
Methods A single-centre (Poland) prospective cohort controlled study. Duration: Unclear
Participants 27 mothers with epilepsy recruited. 59 pregnancies exposed to AEDs occurred, 40 chil-
dren were studied
Interventions Intervention group were taking either:
1) Phenytoin (n=4)
2) Phenobarbital (n=2)
3) Polytherapy (n=33)
Outcomes 1) Psychomotor and speech retardation
2) Developmental abnormalities
3) IQ measured by the Weschler Intelligence Scale for Children
Notes Not reported specific AED outcomes
Risk of bias
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Sobczyz 1977 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 5 as no confounding variables con-
sidered or controlled for appropriately
Blinding High risk Rated 5 as nomethodof blinding employed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Rated as unclear due to lack of information
regarding missing data
Selective reporting (reporting bias) Unclear risk Rated 2 as no evidence of selective report-
ing, no protocol available
Other bias High risk Rated 5 as data combined from three dif-
ferent measures and a large variation in age
of children assessed
Thomas 2007
Methods A single-centre (India) registry study
Participants 74 children born to mothers with epilepsy were enrolled in the study and completed
assessments, 71 were analysed
Interventions Intervention group were taking either:
1) Monotherapy (n=44)
2) Polytherapy (n=23)
Control group:
1) Women without epilepsy (n=201)
2) Women with epilepsy not taking AED treatment (n=4)
Outcomes 1) Development measured by the Development Assessment Scale in Indian Infants,
adaptation of the Bayley’s Scales of Infant Development
2) Intelligencemeasured by theMalin’s Intelligence Scale for IndianChildren, adaptation
of the Weschler Intelligence Scale
3) Language measured by the Malayalam Language Test, adaptation of the Language
Proficiency Test
Notes Women with epilepsy not taking AED treatment included in intervention group. It is
unclear whether data from this data are completely independent from the Thomas 2008
study
65Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Thomas 2007 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 as maternal IQ and SES were adjusted
for by age matched controls
Blinding High risk Rated 5 as no methods of blinding employed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Rated 3 as maternal IQ only measured for 23
mothers, and development assessment at one
year data was available for 62 of 71 children
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting, no
protocol available
Other bias Low risk Rated 1 as no other bias detected
Thomas 2008
Methods A single-centre (India) prospective study
Participants 395 children with epilepsy were assessed
Interventions Intervention group were taking either:
1) Carbamazepine (n=101)
2) Sodium valproate (n=71)
3) Phenobarbitone (n=41)
4) Phenytoin (n=29)
5) Clonazepam (n=2)
6) Lamotrigine (n=1)
7) Other (n=1)
7) Polytherapy (n=122 )
Control group:
1) Women with epilepsy not taking AED treatment (n=32)
Outcomes 1) Mental development
2) Motor development, both outcomes measured by the Assessment Scale for Indian
Infants, adaptation of the Bayley’s Scales of Infant Development
Notes It is unclear whether the data are completely independent from the Thomas 2007 study
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Thomas 2008 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables High risk Rated 4 as most important variables not ad-
justed for in the analysis (only looking at cu-
mulative drug scores and number of AEDs)
Blinding Low risk Rated 2 as outcomes assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Rated 2 as small amount of missing data,
unlikely to affect outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective reporting,
no protocol available
Other bias Low risk Rated 1 as no other bias detected
Veiby 2013
Methods Nested study within larger multi-centre study
Participants Women with epilepsy and their offspring (n= 333)
Interventions Intervention groups were taking either:
1) Lamotrigine (n=71)
2) Carbamazepine (n=48)
3) Sodium valproate (n=27)
4) Monotherapy (n=182)
5) Polytherapy (n=41)
Control group (n=276)
Outcomes 1) Ages and Stages Questionnaire
2) Social Communication Checklist
3) Modified Checklist for Autism in Toddlers
4) Early Screening of Autistic Traits Questionnaire
5) MoBa-specific questionniares
Notes Outcomes reported across main and linked papers
Risk of bias
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Veiby 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated as 3 as some but not all important
confounders were adjusted for
Blinding High risk Rated as 5 as the assessors (the parents)were
not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Rated as 5 due to large amount of miss-
ing data at the older assessment time points
(reasons not given)
Selective reporting (reporting bias) Unclear risk Rated 3 as evidence of selective reporting
or selection of items from outcomes, no
protocol available
Other bias Unclear risk Rated as 3 as bias identified due to parental
ratings, implication for the results unclear
Wide 2002
Methods A single-centre (Sweden) prospective cohort controlled study. Duration:
Participants 76 children to mothers with epilepsy were eligible and recruited into the study, 71
children were assessed at birth and 67 entered were examined at follow up and compared
to 66 children unexposed to AED treatment
Interventions Intervention group were taking either:
1) Carbamazepine (n=35)
2) Phenytoin (n=16)
3) Sodium valproate (n=3)
4) Phenobarbital/primidone (n=2)
5) Clonazepam (n=2)
6) Polytherapy (n=9)
Control group:
1) Women without epilepsy (n=66)
Outcomes 1) Psychomotor development measured the Griffiths test
Notes Smaller drug groups combined in analysis. Linked to Wide 2000
Risk of bias
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Wide 2002 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk High in bias due to non-randomised design
Allocation concealment (selection bias) High risk High in bias due to non-randomised design
Confounding variables Unclear risk Rated 3 asGriffiths’ test corrected for gesta-
tional age,andmaternal education and gen-
der were used as independent variable in
the regression model
Blinding Low risk Rated 2 as outcomes assessors blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Rated 3 as medium amount of missing
data, possible implication on the outcome
Selective reporting (reporting bias) Low risk Rated 2 as no evidence of selective report-
ing, no protocol available
Other bias Low risk Rated 2 as old measures were used how-
ever only developmental test standardised
for small children in Sweden was used
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Annegers 1974 Record linkage study, not prospective cohort control study
Antiga 2010 Non-prospective comparative study
Dean 2002 Retrospective design
Dessens 2000 Retrospective design
Forsberg 2011 Record linkage study, not prospective cohort control study
Holmes 2000 Retrospective design
Holmes 2005 Retrospective design
Jakubowska 1981 Retrospective case control study
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(Continued)
Kelly 1984 Extended case series
Kozhokaru 2010 Retrospective case control study
Latis 1982 Extended cases series
Lekwuwa 1995 No examination of cognitive outcomes
Majewski 1981 Retrospective recruitment
Meador 2010 No examination of cognitive outcomes
Moore 2000 Retrospective recruitment
Mortensen 1996 Epilespy cohort not examined, adults examined not children
Mortensen 2003 Record linkage study, not prospective cohort control study. Not solely women with epilepsy included
Oyen 2007 Record linkage study, not prospective cohort control study
Parisi 2003 Extended case series
Perinola 1992 No assessed control group
Rasalam 2005 Retrospective recruitment
Sereno-Colo 1984 Case series
Steinhausen 1982 Retrospective recruitment
Vanoverloop 1992 Retrospective design
Vert 1982 No comparator or control group
Yamatogi 1993 No examination of neurodevelopmental outcomes
Characteristics of studies awaiting assessment [ordered by study ID]
Adams 2000 Abstract
Methods No details
Participants No details
Interventions No details
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Adams 2000 Abstract (Continued)
Outcomes No details
Notes
Jovic 2011 Abstract
Methods Prospective study
Participants 28 offspring of women with juvenile myoclonic epilepsy
Interventions VPA (n=8)
LTG (n=12)
Polytherapy VPA and LTG (n=8)
Outcomes Childrenwere assessed using theWISC at 6 years of age. Children exposed to LTGwere reported to have a significantly
higher IQ than the children exposed to monotherapy VPA or polytherapy VPA and LTG
Daily doses of VPA above 1000mg was associated with lower IQ
Notes
Nadebaum 2011 Abstract
Methods Prospective study
Participants 106 children of women with epilepsy
Interventions VPA (n=26)
VPA polytherapy (n=15)
Others unknown
Outcomes Diagnosis of learning disorder 7/26 for VPA, 8/15 for VPA polytherapy
Notes
Wood 2011 Abstract
Methods Registry study
Participants 103 offspring of women with epilepsy
Interventions VPA (n=26)
CBZ (n=32)
VPA polytherapy (n=15)
Others unknown
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Wood 2011 Abstract (Continued)
Outcomes Children were assessed between 6 and 8 years on the Conners Autism Rating Scale
2/26 (7.7%) of children exposed to VPA monotherapy scored above the threshold on the Conners Autism Rating
Scale
2/32 (6.3%) of children exposed to CBZ monotherapy scored above the threshold on the Conners Autism Rating
Scale
7/15 (46.7%) of children exposed to polytherapy including VPA scored above the threshold on the Conners Autism
Rating Scale
A significant correlation between dose of VPA and Conners Autism Rating Scale is reported
Notes Contact from authors report that this is in preparation for publication
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D A T A A N D A N A L Y S E S
Comparison 1. CBZ versus controls (women without epilepsy)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development (Griffiths) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 278 Mean Difference (IV, Fixed, 95% CI) -2.0 [-6.44, 2.44]
2 Development (Bayley) 3 129 Mean Difference (IV, Fixed, 95% CI) -5.58 [-10.83, -0.34]
2.1 Prospective 3 129 Mean Difference (IV, Fixed, 95% CI) -5.58 [-10.83, -0.34]
3 IQ 3 702 Mean Difference (IV, Fixed, 95% CI) -0.03 [-3.08, 3.01]
3.1 Prospective 1 260 Mean Difference (IV, Fixed, 95% CI) -2.0 [-6.46, 2.46]
3.2 Registry 2 442 Mean Difference (IV, Fixed, 95% CI) 1.68 [-2.49, 5.85]
4 IQ <2SD 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5 VIQ 2 487 Mean Difference (IV, Fixed, 95% CI) -1.81 [-4.94, 1.33]
5.1 Prospective 2 487 Mean Difference (IV, Fixed, 95% CI) -1.81 [-4.94, 1.33]
6 PIQ 2 487 Mean Difference (IV, Fixed, 95% CI) 1.27 [-1.55, 4.09]
6.1 Prospective 2 487 Mean Difference (IV, Fixed, 95% CI) 1.27 [-1.55, 4.09]
Comparison 2. CBZ versus controls (women with epilepsy, no AED treatment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development (Griffiths) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 75 Mean Difference (IV, Fixed, 95% CI) -6.0 [-11.35, -0.65]
2 Development (Bayley) 2 221 Mean Difference (IV, Fixed, 95% CI) -7.22 [-12.76, -1.67]
2.1 Prospective 2 221 Mean Difference (IV, Fixed, 95% CI) -7.22 [-12.76, -1.67]
3 IQ 4 250 Mean Difference (IV, Fixed, 95% CI) 1.84 [-2.13, 5.80]
3.1 Prospective 2 93 Mean Difference (IV, Fixed, 95% CI) 1.27 [-5.08, 7.63]
3.2 Registry 2 157 Mean Difference (IV, Fixed, 95% CI) 2.20 [-2.87, 7.28]
4 VPA below vs CBZ below IQ >
1SD
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Registry 1 26 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.26, 95.02]
5 IQ > 2SD 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Registry 1 131 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.02, 2.81]
6 VIQ 3 232 Mean Difference (IV, Fixed, 95% CI) 0.13 [-3.98, 4.23]
6.1 Prospective 1 75 Mean Difference (IV, Fixed, 95% CI) -1.0 [-7.28, 5.28]
6.2 Registry 2 157 Mean Difference (IV, Fixed, 95% CI) 0.97 [-4.47, 6.40]
7 PIQ 3 232 Mean Difference (IV, Fixed, 95% CI) 3.65 [-0.60, 7.90]
7.1 Prospective 1 75 Mean Difference (IV, Fixed, 95% CI) 4.0 [-2.72, 10.72]
7.2 Registry 2 157 Mean Difference (IV, Fixed, 95% CI) 3.42 [-2.07, 8.91]
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Comparison 3. VPA versus controls (women without epilepsy)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development (Griffiths) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 272 Mean Difference (IV, Fixed, 95% CI) -8.0 [-12.79, -3.21]
2 Development (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Prospective 1 18 Mean Difference (IV, Fixed, 95% CI) -13.30 [-23.51, -3.
09]
3 IQ 3 628 Mean Difference (IV, Fixed, 95% CI) -8.94 [-11.96, -5.92]
3.1 Prospective 1 261 Mean Difference (IV, Fixed, 95% CI) -12.22 [-15.84, -8.
60]
3.2 Registry 2 367 Mean Difference (IV, Fixed, 95% CI) -1.48 [-6.94, 3.98]
4 IQ <2SD 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Registry 1 154 Risk Ratio (M-H, Fixed, 95% CI) 2.71 [0.33, 22.51]
5 IQ <1SD 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Prospective 1 236 Risk Ratio (M-H, Fixed, 95% CI) 16.88 [6.27, 45.44]
6 VIQ 2 415 Mean Difference (IV, Fixed, 95% CI) -11.39 [-14.68, -8.
10]
6.1 Prospective 1 261 Mean Difference (IV, Fixed, 95% CI) -11.39 [-15.02, -7.
76]
6.2 Registry 1 154 Mean Difference (IV, Fixed, 95% CI) -11.40 [-19.21, -3.
59]
7 PIQ 2 456 Mean Difference (IV, Fixed, 95% CI) -10.48 [-13.94, -7.
02]
7.1 Prospective 1 261 Mean Difference (IV, Fixed, 95% CI) -8.94 [-12.79, -5.09]
7.2 Registry 1 195 Mean Difference (IV, Fixed, 95% CI) -16.80 [-24.61, -8.
99]
Comparison 4. VPA versus controls (women with epilepsy, no AED treatment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development (Griffiths) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 69 Mean Difference (IV, Fixed, 95% CI) -12.0 [-17.73, -6.27]
2 Development (Bayley) 2 181 Mean Difference (IV, Fixed, 95% CI) -8.72 [-14.31, -3.14]
2.1 Prospective 2 181 Mean Difference (IV, Fixed, 95% CI) -8.72 [-14.31, -3.14]
3 IQ 4 176 Mean Difference (IV, Fixed, 95% CI) -8.17 [-12.80, -3.55]
3.1 Prospective 1 76 Mean Difference (IV, Fixed, 95% CI) -9.30 [-15.34, -3.26]
3.2 Registry 3 100 Mean Difference (IV, Fixed, 95% CI) -6.58 [-13.77, 0.62]
4 IQ < 1SD 2 76 Risk Ratio (M-H, Fixed, 95% CI) 10.33 [2.05, 52.01]
4.1 Prospective 1 50 Risk Ratio (M-H, Fixed, 95% CI) 10.0 [1.38, 72.39]
4.2 Registry 1 26 Risk Ratio (M-H, Fixed, 95% CI) 11.0 [0.67, 180.65]
5 IQ <2SD 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Registry 1 58 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [0.17, 17.61]
6 VIQ 3 160 Mean Difference (IV, Fixed, 95% CI) -8.81 [-13.32, -4.30]
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6.1 Prospective 1 76 Mean Difference (IV, Fixed, 95% CI) -7.45 [-13.02, -1.88]
6.2 Registry 2 84 Mean Difference (IV, Fixed, 95% CI) -11.42 [-19.13, -3.
72]
7 PIQ 3 160 Mean Difference (IV, Fixed, 95% CI) -7.20 [-12.44, -1.96]
7.1 Prospective 1 76 Mean Difference (IV, Fixed, 95% CI) -7.30 [-13.71, -0.89]
7.2 Registry 2 84 Mean Difference (IV, Fixed, 95% CI) -7.01 [-16.13, 2.11]
Comparison 5. PHT versus controls (women without epilepsy)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development (Bayley) 2 64 Mean Difference (IV, Fixed, 95% CI) -0.12 [-7.54, 7.30]
1.1 Prospective 2 64 Mean Difference (IV, Fixed, 95% CI) -0.12 [-7.54, 7.30]
2 IQ 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Registry 1 206 Mean Difference (IV, Fixed, 95% CI) 4.80 [-4.10, 13.70]
Comparison 6. PHT versus controls (women with epilepsy, no AED treatment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 61 Mean Difference (IV, Fixed, 95% CI) -2.0 [-18.26, 14.26]
2 IQ 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Registry 1 9 Mean Difference (IV, Fixed, 95% CI) 11.0 [-12.60, 34.60]
Comparison 7. PB versus controls (women without epilepsy)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IQ 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Registry 1 215 Mean Difference (IV, Fixed, 95% CI) -6.80 [-12.90, -0.70]
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Comparison 8. PB versus controls (women with epilepsy, no AED treatment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 73 Mean Difference (IV, Fixed, 95% CI) -2.0 [-14.33, 10.33]
2 IQ 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Registry 1 18 Mean Difference (IV, Fixed, 95% CI) -0.60 [-23.30, 22.
10]
Comparison 9. LTG versus controls (women without epilepsy)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Griffiths) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 264 Mean Difference (IV, Fixed, 95% CI) -1.0 [-5.75, 3.75]
2 IQ 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Prospective 1 239 Mean Difference (IV, Fixed, 95% CI) -4.0 [-8.32, 0.32]
Comparison 10. LTG versus controls (women with epilepsy, no AED treatment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Griffiths) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 61 Mean Difference (IV, Fixed, 95% CI) -5.0 [-10.70, 0.70]
2 IQ 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Prospective 1 54 Mean Difference (IV, Fixed, 95% CI) -1.0 [-7.48, 5.48]
Comparison 11. LEV versus control (women without epilepsy)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Griffiths) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Registry 1 148 Mean Difference (IV, Fixed, 95% CI) 1.09 [-2.81, 4.99]
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Comparison 12. CBZ versus LTG
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 100 Mean Difference (IV, Fixed, 95% CI) -3.0 [-9.29, 3.29]
2 IQ 2 162 Mean Difference (IV, Fixed, 95% CI) -1.62 [-5.44, 2.21]
2.1 Prospective 2 162 Mean Difference (IV, Fixed, 95% CI) -1.62 [-5.44, 2.21]
3 IQ>1SD 2 159 Risk Ratio (M-H, Fixed, 95% CI) 2.28 [0.63, 8.22]
3.1 Prospective 2 159 Risk Ratio (M-H, Fixed, 95% CI) 2.28 [0.63, 8.22]
Comparison 13. CBZ versus PHT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development (Bayley) 4 259 Mean Difference (IV, Fixed, 95% CI) 3.02 [-2.41, 8.46]
1.1 Prospective 4 259 Mean Difference (IV, Fixed, 95% CI) 3.02 [-2.41, 8.46]
2 IQ 2 120 Mean Difference (IV, Fixed, 95% CI) -3.30 [-7.91, 1.30]
2.1 Prospective 1 101 Mean Difference (IV, Fixed, 95% CI) -3.0 [-7.86, 1.86]
2.2 Registry 1 19 Mean Difference (IV, Fixed, 95% CI) -5.90 [-20.20, 8.40]
3 DQ>1SD 2 220 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.52, 1.15]
3.1 Prospective 2 220 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.52, 1.15]
Comparison 14. VPA versus LTG
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 85 Mean Difference (IV, Fixed, 95% CI) -12.0 [-20.31, -3.69]
2 IQ 2 158 Mean Difference (IV, Fixed, 95% CI) -10.80 [-14.42, -7.
17]
2.1 Prospective 2 158 Mean Difference (IV, Fixed, 95% CI) -10.80 [-14.42, -7.
17]
3 IQ>1SD 2 157 Risk Ratio (M-H, Fixed, 95% CI) 4.87 [1.50, 15.78]
3.1 Prospective 2 157 Risk Ratio (M-H, Fixed, 95% CI) 4.87 [1.50, 15.78]
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Comparison 15. LEV versus VPA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development (Griffiths) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Registry 1 95 Mean Difference (IV, Fixed, 95% CI) 12.03 [6.24, 17.82]
Comparison 16. PHT versus VPA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development (Bayley) 3 188 Mean Difference (IV, Fixed, 95% CI) 7.04 [0.44, 13.65]
1.1 Prospective 3 188 Mean Difference (IV, Fixed, 95% CI) 7.04 [0.44, 13.65]
2 IQ 2 106 Mean Difference (IV, Fixed, 95% CI) 9.25 [4.78, 13.72]
2.1 Prospective 1 89 Mean Difference (IV, Fixed, 95% CI) 11.0 [6.15, 15.85]
2.2 Registry 1 17 Mean Difference (IV, Fixed, 95% CI) -0.70 [-12.26, 10.
86]
3 DQ>1SD 2 191 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.91, 2.15]
3.1 Prospective 2 191 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.91, 2.15]
Comparison 17. CBZ versus VPA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development (Bayley) 4 370 Mean Difference (IV, Fixed, 95% CI) 4.16 [-0.21, 8.54]
1.1 Prospective 4 370 Mean Difference (IV, Fixed, 95% CI) 4.16 [-0.21, 8.54]
2 IQ 5 303 Mean Difference (IV, Fixed, 95% CI) 8.69 [5.51, 11.87]
2.1 Prospective 2 152 Mean Difference (IV, Fixed, 95% CI) 9.19 [5.49, 12.88]
2.2 Registry 3 151 Mean Difference (IV, Fixed, 95% CI) 7.29 [1.06, 13.53]
3 VIQ 3 226 Mean Difference (IV, Fixed, 95% CI) 8.44 [4.21, 12.66]
4 PIQ 3 226 Mean Difference (IV, Fixed, 95% CI) 10.48 [6.02, 14.94]
5 DQ>1SD 3 363 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.62, 1.12]
5.1 Prospective 3 363 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.62, 1.12]
6 DQ>2SD 2 191 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.38, 1.58]
6.1 Prospective 2 191 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.38, 1.58]
7 IQ>2SD 4 277 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.05, 1.19]
7.1 Prospective 2 152 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.04, 4.30]
7.2 Registry 2 125 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.02, 1.46]
8 IQ>1SD 3 178 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.19, 0.83]
8.1 Prospective 2 152 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.17, 0.93]
8.2 Registry 1 26 Risk Ratio (M-H, Fixed, 95% CI) 0.4 [0.09, 1.70]
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Comparison 18. PHT versus LTG
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 95 Mean Difference (IV, Fixed, 95% CI) -7.0 [-14.48, 0.48]
2 IQ 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Prospective 1 114 Mean Difference (IV, Fixed, 95% CI) 1.0 [-3.87, 5.87]
Comparison 19. CBZ versus PB
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 142 Mean Difference (IV, Fixed, 95% CI) 2.80 [-5.61, 11.21]
2 IQ 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Registry 1 28 Mean Difference (IV, Fixed, 95% CI) 5.70 [-7.04, 18.44]
3 DQ >1SD 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Prospective 1 142 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.62, 1.99]
Comparison 20. VPA versus PB
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 112 Mean Difference (IV, Fixed, 95% CI) -3.40 [-13.45, 6.65]
2 IQ 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Registry 1 26 Mean Difference (IV, Fixed, 95% CI) 12.30 [2.73, 21.87]
Comparison 21. PHT versus PB
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 70 Mean Difference (IV, Fixed, 95% CI) 0.0 [-14.03, 14.03]
2 IQ 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Prospective 1 19 Mean Difference (IV, Fixed, 95% CI) 11.60 [1.18, 22.02]
3 DQ >1SD 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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Comparison 22. Monotherapy versus controls (women without epilepsy)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Griffiths) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 368 Mean Difference (IV, Fixed, 95% CI) -4.0 [-6.86, -1.14]
2 Developmental (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Prospective 1 92 Mean Difference (IV, Fixed, 95% CI) -2.10 [-7.82, 3.62]
3 IQ 3 573 Mean Difference (IV, Fixed, 95% CI) -1.30 [-4.12, 1.51]
3.1 Prospective 1 80 Mean Difference (IV, Fixed, 95% CI) -5.70 [-11.53, 0.13]
3.2 Registry 2 493 Mean Difference (IV, Fixed, 95% CI) 0.04 [-3.18, 3.26]
Comparison 23. Monotherapy versus controls (women with epilepsy, no AED treatment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development (Griffiths) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 165 Mean Difference (IV, Fixed, 95% CI) -8.0 [-12.16, -3.84]
2 Developmental (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Prospective 1 278 Mean Difference (IV, Fixed, 95% CI) -1.70 [-12.80, 9.40]
3 IQ 2 196 Mean Difference (IV, Fixed, 95% CI) 1.30 [-4.19, 6.80]
3.1 Prospective 1 44 Mean Difference (IV, Fixed, 95% CI) -2.10 [-13.22, 9.02]
3.2 Registry 1 152 Mean Difference (IV, Fixed, 95% CI) 2.40 [-3.92, 8.72]
Comparison 24. Polytherapy versus controls (women without epilepsy)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Griffiths) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 260 Mean Difference (IV, Fixed, 95% CI) -6.0 [-13.27, 1.27]
2 Developmental (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Prospective 1 82 Mean Difference (IV, Fixed, 95% CI) -7.50 [-12.32, -2.68]
3 IQ 4 707 Mean Difference (IV, Fixed, 95% CI) -8.57 [-11.77, -5.38]
3.1 Prospective 2 312 Mean Difference (IV, Fixed, 95% CI) -8.24 [-12.39, -4.09]
3.2 Registry 2 395 Mean Difference (IV, Fixed, 95% CI) -9.06 [-14.07, -4.06]
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Comparison 25. Polytherapy versus controls (women with epilepsy, no AED treatment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Griffiths) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 57 Mean Difference (IV, Fixed, 95% CI) -10.0 [-17.92, -2.08]
2 Developmental (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Prospective 1 154 Mean Difference (IV, Fixed, 95% CI) -8.5 [-20.31, 3.31]
3 IQ 3 165 Mean Difference (IV, Fixed, 95% CI) -5.70 [-10.31, -1.08]
3.1 Prospective 2 90 Mean Difference (IV, Fixed, 95% CI) -5.42 [-11.42, 0.58]
3.2 Registry 1 75 Mean Difference (IV, Fixed, 95% CI) -6.10 [-13.33, 1.13]
Comparison 26. Monotherapy versus polytherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Griffiths) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 168 Mean Difference (IV, Fixed, 95% CI) 2.0 [-4.08, 8.08]
2 Developmental (Bayley) 2 433 Mean Difference (IV, Fixed, 95% CI) 8.80 [3.44, 14.17]
2.1 Prospective 2 433 Mean Difference (IV, Fixed, 95% CI) 8.80 [3.44, 14.17]
3 IQ 3 257 Mean Difference (IV, Fixed, 95% CI) 8.84 [4.35, 13.32]
3.1 Prospective 2 120 Mean Difference (IV, Fixed, 95% CI) 9.41 [2.04, 16.77]
3.2 Registry 1 137 Mean Difference (IV, Fixed, 95% CI) 8.5 [2.85, 14.15]
Comparison 27. VPA monotherapy versus VPA polytherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Developmental (Bayley) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Prospective 1 57 Mean Difference (IV, Fixed, 95% CI) 12.28 [-10.68, 35.
24]
2 IQ 3 138 Mean Difference (IV, Fixed, 95% CI) 1.96 [-2.68, 6.61]
2.1 Prospective 1 70 Mean Difference (IV, Fixed, 95% CI) -3.30 [-9.88, 3.28]
2.2 Registry 2 68 Mean Difference (IV, Fixed, 95% CI) 7.20 [0.64, 13.76]
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Comparison 28. VPA polytherapy versus non-VPA polytherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IQ 2 64 Mean Difference (IV, Fixed, 95% CI) -8.74 [-15.70, -1.78]
1.1 Prospective 1 30 Mean Difference (IV, Fixed, 95% CI) -5.0 [-14.65, 4.65]
1.2 Registry 1 34 Mean Difference (IV, Fixed, 95% CI) -12.80 [-22.86, -2.
74]
Analysis 1.1. Comparison 1 CBZ versus controls (women without epilepsy), Outcome 1 Development
(Griffiths).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 1 CBZ versus controls (women without epilepsy)
Outcome: 1 Development (Griffiths)
Study or subgroup CBZ
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 48 98 (14.6365) 230 100 (12.315) 100.0 % -2.00 [ -6.44, 2.44 ]
Subtotal (95% CI) 48 230 100.0 % -2.00 [ -6.44, 2.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Poorer outcome (CBZ) Poorer outcome (Controls)
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Analysis 1.2. Comparison 1 CBZ versus controls (women without epilepsy), Outcome 2 Development
(Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 1 CBZ versus controls (women without epilepsy)
Outcome: 2 Development (Bayley)
Study or subgroup CBZ
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
GERMAN Study 4 110.5 (19) 4 109 (16.1) 4.6 % 1.50 [ -22.91, 25.91 ]
Ornoy 1996 22 101.1 (14.8) 35 112 (10) 55.9 % -10.90 [ -17.92, -3.88 ]
Rovet 1995 24 114.2 (17.8) 40 113.1 (14) 39.5 % 1.10 [ -7.24, 9.44 ]
Total (95% CI) 50 79 100.0 % -5.58 [ -10.83, -0.34 ]
Heterogeneity: Chi2 = 5.00, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Poorer outcome (CBZ) Poorer outcome (Controls)
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Analysis 1.3. Comparison 1 CBZ versus controls (women without epilepsy), Outcome 3 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 1 CBZ versus controls (women without epilepsy)
Outcome: 3 IQ
Study or subgroup CBZ
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 50 105 (15) 210 107 (12) 46.6 % -2.00 [ -6.46, 2.46 ]
Subtotal (95% CI) 50 210 46.6 % -2.00 [ -6.46, 2.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
2 Registry
Gaily 2004 86 99.7 (16.6925) 141 97.6 (16.6241) 46.5 % 2.10 [ -2.37, 6.57 ]
Thomas 2007 14 91.9 (21.7) 201 93 (14.4) 7.0 % -1.10 [ -12.64, 10.44 ]
Subtotal (95% CI) 100 342 53.4 % 1.68 [ -2.49, 5.85 ]
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Total (95% CI) 150 552 100.0 % -0.03 [ -3.08, 3.01 ]
Heterogeneity: Chi2 = 1.65, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi2 = 1.40, df = 1 (P = 0.24), I2 =28%
-20 -10 0 10 20
Poorer outcome (CBZ) Poorer outcome (Controls)
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Analysis 1.4. Comparison 1 CBZ versus controls (women without epilepsy), Outcome 4 IQ <2SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 1 CBZ versus controls (women without epilepsy)
Outcome: 4 IQ <2SD
Study or subgroup CBZ
Women
without
epilepsy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gaily 2004 1/86 4/141 0.41 [ 0.05, 3.61 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (CBZ), 4 (Women without epilepsy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.05 0.2 1 5 20
Poorer outcome (CBZ) Poorer outcome (Controls)
Analysis 1.5. Comparison 1 CBZ versus controls (women without epilepsy), Outcome 5 VIQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 1 CBZ versus controls (women without epilepsy)
Outcome: 5 VIQ
Study or subgroup CBZ
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 50 98 (15) 210 103 (12) 49.3 % -5.00 [ -9.46, -0.54 ]
Gaily 2004 86 96.2 (17.6) 141 94.9 (14.2492) 50.7 % 1.30 [ -3.10, 5.70 ]
Total (95% CI) 136 351 100.0 % -1.81 [ -4.94, 1.33 ]
Heterogeneity: Chi2 = 3.88, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Poorer outcome (CBZ) Poorer outcome (Controls)
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Analysis 1.6. Comparison 1 CBZ versus controls (women without epilepsy), Outcome 6 PIQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 1 CBZ versus controls (women without epilepsy)
Outcome: 6 PIQ
Study or subgroup CBZ
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 50 108 (14) 210 106 (13) 43.9 % 2.00 [ -2.26, 6.26 ]
Gaily 2004 86 103.1 (13.9104) 141 102.4 (14.2492) 56.1 % 0.70 [ -3.06, 4.46 ]
Total (95% CI) 136 351 100.0 % 1.27 [ -1.55, 4.09 ]
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Poorer outcome (CBZ) Poorer outcome (Controls)
Analysis 2.1. Comparison 2 CBZ versus controls (women with epilepsy, no AED treatment), Outcome 1
Development (Griffiths).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 2 CBZ versus controls (women with epilepsy, no AED treatment)
Outcome: 1 Development (Griffiths)
Study or subgroup CBZ No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 48 98 (14.6365) 27 104 (8.974) 100.0 % -6.00 [ -11.35, -0.65 ]
Subtotal (95% CI) 48 27 100.0 % -6.00 [ -11.35, -0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Poorer outcome (CBZ) Poorer outcome (Controls)
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Analysis 2.2. Comparison 2 CBZ versus controls (women with epilepsy, no AED treatment), Outcome 2
Development (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 2 CBZ versus controls (women with epilepsy, no AED treatment)
Outcome: 2 Development (Bayley)
Study or subgroup CBZ No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Jackson 2013 62 95.45 (18.67) 26 104.96 (11.02) 77.8 % -9.51 [ -15.80, -3.22 ]
Thomas 2008 101 93.1 (27.3539) 32 92.3 (30.2326) 22.2 % 0.80 [ -10.96, 12.56 ]
Total (95% CI) 163 58 100.0 % -7.22 [ -12.76, -1.67 ]
Heterogeneity: Chi2 = 2.30, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 2.55 (P = 0.011)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Poorer outcome (CBZ) Poorer outcome (Controls)
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Analysis 2.3. Comparison 2 CBZ versus controls (women with epilepsy, no AED treatment), Outcome 3 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 2 CBZ versus controls (women with epilepsy, no AED treatment)
Outcome: 3 IQ
Study or subgroup CBZ No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 50 105 (15) 25 104 (13) 36.3 % 1.00 [ -5.58, 7.58 ]
Thomas 2007 14 91.9 (21.7) 4 86.8 (22.4) 2.6 % 5.10 [ -19.62, 29.82 ]
Subtotal (95% CI) 64 29 38.9 % 1.27 [ -5.08, 7.63 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
2 Registry
Eriksson 2005 13 98.9 (12.7421) 13 99.6 (7.6122) 24.1 % -0.70 [ -8.77, 7.37 ]
Gaily 2004 86 99.7 (16.6925) 45 95.6 (18.783) 36.9 % 4.10 [ -2.42, 10.62 ]
Subtotal (95% CI) 99 58 61.1 % 2.20 [ -2.87, 7.28 ]
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
Total (95% CI) 163 87 100.0 % 1.84 [ -2.13, 5.80 ]
Heterogeneity: Chi2 = 0.97, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
-20 -10 0 10 20
Poorer outcome (CBZ) Poorer outcome (Controls)
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Analysis 2.4. Comparison 2 CBZ versus controls (women with epilepsy, no AED treatment), Outcome 4
VPA below vs CBZ below IQ > 1SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 2 CBZ versus controls (women with epilepsy, no AED treatment)
Outcome: 4 VPA below vs CBZ below IQ > 1SD
Study or subgroup CBZ No AED treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Registry
Eriksson 2005 2/13 0/13 100.0 % 5.00 [ 0.26, 95.02 ]
Subtotal (95% CI) 13 13 100.0 % 5.00 [ 0.26, 95.02 ]
Total events: 2 (CBZ), 0 (No AED treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
0.01 0.1 1 10 100
Poorer outcome (CBZ) Poorer outcome (Controls)
Analysis 2.5. Comparison 2 CBZ versus controls (women with epilepsy, no AED treatment), Outcome 5 IQ
> 2SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 2 CBZ versus controls (women with epilepsy, no AED treatment)
Outcome: 5 IQ > 2SD
Study or subgroup CBZ No AED treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Registry
Gaily 2004 1/86 2/45 100.0 % 0.26 [ 0.02, 2.81 ]
Subtotal (95% CI) 86 45 100.0 % 0.26 [ 0.02, 2.81 ]
Total events: 1 (CBZ), 2 (No AED treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
0.05 0.2 1 5 20
Poorer outcome (CBZ) Poorer outcome (Controls)
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Analysis 2.6. Comparison 2 CBZ versus controls (women with epilepsy, no AED treatment), Outcome 6
VIQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 2 CBZ versus controls (women with epilepsy, no AED treatment)
Outcome: 6 VIQ
Study or subgroup CBZ No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 50 98 (15) 25 99 (12) 42.8 % -1.00 [ -7.28, 5.28 ]
Subtotal (95% CI) 50 25 42.8 % -1.00 [ -7.28, 5.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
2 Registry
Eriksson 2005 13 96.5 (15.8863) 13 98.2 (11.5838) 14.8 % -1.70 [ -12.39, 8.99 ]
Gaily 2004 86 96.2 (17.6199) 45 94.3 (17.4413) 42.4 % 1.90 [ -4.41, 8.21 ]
Subtotal (95% CI) 99 58 57.2 % 0.97 [ -4.47, 6.40 ]
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Total (95% CI) 149 83 100.0 % 0.13 [ -3.98, 4.23 ]
Heterogeneity: Chi2 = 0.54, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
-20 -10 0 10 20
Poorer outcome (CBZ) Poorer outcome (Controls)
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Analysis 2.7. Comparison 2 CBZ versus controls (women with epilepsy, no AED treatment), Outcome 7
PIQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 2 CBZ versus controls (women with epilepsy, no AED treatment)
Outcome: 7 PIQ
Study or subgroup CBZ No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 50 108 (14) 25 104 (14) 40.0 % 4.00 [ -2.72, 10.72 ]
Subtotal (95% CI) 50 25 40.0 % 4.00 [ -2.72, 10.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
2 Registry
Eriksson 2005 13 102.5 (14.5624) 13 102.1 (13.2386) 15.8 % 0.40 [ -10.30, 11.10 ]
Gaily 2004 86 103.1 (13.9104) 45 98.6 (19.4538) 44.2 % 4.50 [ -1.90, 10.90 ]
Subtotal (95% CI) 99 58 60.0 % 3.42 [ -2.07, 8.91 ]
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 149 83 100.0 % 3.65 [ -0.60, 7.90 ]
Heterogeneity: Chi2 = 0.43, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.092)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
-20 -10 0 10 20
Poorer outcome (CBZ) Poorer outcome (Controls)
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Analysis 3.1. Comparison 3 VPA versus controls (women without epilepsy), Outcome 1 Development
(Griffiths).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 3 VPA versus controls (women without epilepsy)
Outcome: 1 Development (Griffiths)
Study or subgroup VPA
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 42 92 (15.4033) 230 100 (8.4666) 100.0 % -8.00 [ -12.79, -3.21 ]
Subtotal (95% CI) 42 230 100.0 % -8.00 [ -12.79, -3.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.28 (P = 0.0011)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Poorer outcome (VPA) Poorer outcome (Controls)
Analysis 3.2. Comparison 3 VPA versus controls (women without epilepsy), Outcome 2 Development
(Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 3 VPA versus controls (women without epilepsy)
Outcome: 2 Development (Bayley)
Study or subgroup VPA
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
GERMAN Study 9 103.5 (10.9) 9 116.8 (11.2) 100.0 % -13.30 [ -23.51, -3.09 ]
Subtotal (95% CI) 9 9 100.0 % -13.30 [ -23.51, -3.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.55 (P = 0.011)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 VPA versus controls (women without epilepsy), Outcome 3 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 3 VPA versus controls (women without epilepsy)
Outcome: 3 IQ
Study or subgroup VPA
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 51 94.78 (11.8) 210 107 (12) 69.5 % -12.22 [ -15.84, -8.60 ]
Subtotal (95% CI) 51 210 69.5 % -12.22 [ -15.84, -8.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.61 (P < 0.00001)
2 Registry
Gaily 2004 13 89.7 (12.98) 141 97.6 (16.6241) 15.9 % -7.90 [ -15.47, -0.33 ]
Thomas 2007 12 98.5 (13.5) 201 93 (14.4) 14.6 % 5.50 [ -2.39, 13.39 ]
Subtotal (95% CI) 25 342 30.5 % -1.48 [ -6.94, 3.98 ]
Heterogeneity: Chi2 = 5.77, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 0.53 (P = 0.60)
Total (95% CI) 76 552 100.0 % -8.94 [ -11.96, -5.92 ]
Heterogeneity: Chi2 = 16.08, df = 2 (P = 0.00032); I2 =88%
Test for overall effect: Z = 5.80 (P < 0.00001)
Test for subgroup differences: Chi2 = 10.31, df = 1 (P = 0.00), I2 =90%
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Analysis 3.4. Comparison 3 VPA versus controls (women without epilepsy), Outcome 4 IQ <2SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 3 VPA versus controls (women without epilepsy)
Outcome: 4 IQ <2SD
Study or subgroup VPA
Women
without
epilepsy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Registry
Gaily 2004 1/13 4/141 100.0 % 2.71 [ 0.33, 22.51 ]
Subtotal (95% CI) 13 141 100.0 % 2.71 [ 0.33, 22.51 ]
Total events: 1 (VPA), 4 (Women without epilepsy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Poorer outcome (VPA) Poorer outcome (Controls)
Analysis 3.5. Comparison 3 VPA versus controls (women without epilepsy), Outcome 5 IQ <1SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 3 VPA versus controls (women without epilepsy)
Outcome: 5 IQ <1SD
Study or subgroup VPA
Women
without
epilepsy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prospective
Bromley 2010 10/25 5/211 100.0 % 16.88 [ 6.27, 45.44 ]
Subtotal (95% CI) 25 211 100.0 % 16.88 [ 6.27, 45.44 ]
Total events: 10 (VPA), 5 (Women without epilepsy)
Heterogeneity: not applicable
Test for overall effect: Z = 5.59 (P < 0.00001)
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Analysis 3.6. Comparison 3 VPA versus controls (women without epilepsy), Outcome 6 VIQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 3 VPA versus controls (women without epilepsy)
Outcome: 6 VIQ
Study or subgroup VPA
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 51 91.55 (11.9) 210 102.94 (11.7) 82.2 % -11.39 [ -15.02, -7.76 ]
Subtotal (95% CI) 51 210 82.2 % -11.39 [ -15.02, -7.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.15 (P < 0.00001)
2 Registry
Gaily 2004 13 83.5 (13.7011) 141 94.9 (14.2492) 17.8 % -11.40 [ -19.21, -3.59 ]
Subtotal (95% CI) 13 141 17.8 % -11.40 [ -19.21, -3.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0042)
Total (95% CI) 64 351 100.0 % -11.39 [ -14.68, -8.10 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 6.78 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 3.7. Comparison 3 VPA versus controls (women without epilepsy), Outcome 7 PIQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 3 VPA versus controls (women without epilepsy)
Outcome: 7 PIQ
Study or subgroup VPA
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 51 97.06 (12.5) 210 106 (13) 80.4 % -8.94 [ -12.79, -5.09 ]
Subtotal (95% CI) 51 210 80.4 % -8.94 [ -12.79, -5.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.55 (P < 0.00001)
2 Registry
Gaily 2004 13 83.5 (13.7011) 182 100.3 (16.1889) 19.6 % -16.80 [ -24.61, -8.99 ]
Subtotal (95% CI) 13 182 19.6 % -16.80 [ -24.61, -8.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.22 (P = 0.000025)
Total (95% CI) 64 392 100.0 % -10.48 [ -13.94, -7.02 ]
Heterogeneity: Chi2 = 3.13, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 5.94 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.13, df = 1 (P = 0.08), I2 =68%
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Analysis 4.1. Comparison 4 VPA versus controls (women with epilepsy, no AED treatment), Outcome 1
Development (Griffiths).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 4 VPA versus controls (women with epilepsy, no AED treatment)
Outcome: 1 Development (Griffiths)
Study or subgroup VPA No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 42 92 (15.4033) 27 104 (8.8476) 100.0 % -12.00 [ -17.73, -6.27 ]
Subtotal (95% CI) 42 27 100.0 % -12.00 [ -17.73, -6.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.10 (P = 0.000041)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Poorer outcome (VPA) Poorer outcome (Controls)
Analysis 4.2. Comparison 4 VPA versus controls (women with epilepsy, no AED treatment), Outcome 2
Development (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 4 VPA versus controls (women with epilepsy, no AED treatment)
Outcome: 2 Development (Bayley)
Study or subgroup VPA No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Jackson 2013 52 95.48 (16.59) 26 104.96 (11.02) 81.5 % -9.48 [ -15.67, -3.29 ]
Thomas 2008 71 86.9 (32.9536) 32 92.3 (30.2326) 18.5 % -5.40 [ -18.38, 7.58 ]
Total (95% CI) 123 58 100.0 % -8.72 [ -14.31, -3.14 ]
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 VPA versus controls (women with epilepsy, no AED treatment), Outcome 3 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 4 VPA versus controls (women with epilepsy, no AED treatment)
Outcome: 3 IQ
Study or subgroup VPA No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 51 94.7 (11.8) 25 104 (13) 58.7 % -9.30 [ -15.34, -3.26 ]
Subtotal (95% CI) 51 25 58.7 % -9.30 [ -15.34, -3.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
2 Registry
Eriksson 2005 13 84.5 (24.9878) 13 99.6 (7.6122) 10.6 % -15.10 [ -29.30, -0.90 ]
Gaily 2004 13 89.7 (12.98) 45 95.6 (18.783) 26.8 % -5.90 [ -14.84, 3.04 ]
Thomas 2007 12 98.5 (13.5) 4 86.8 (22.4) 4.0 % 11.70 [ -11.54, 34.94 ]
Subtotal (95% CI) 38 62 41.3 % -6.58 [ -13.77, 0.62 ]
Heterogeneity: Chi2 = 3.78, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 1.79 (P = 0.073)
Total (95% CI) 89 87 100.0 % -8.17 [ -12.80, -3.55 ]
Heterogeneity: Chi2 = 4.10, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 3.46 (P = 0.00053)
Test for subgroup differences: Chi2 = 0.32, df = 1 (P = 0.57), I2 =0.0%
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Analysis 4.4. Comparison 4 VPA versus controls (women with epilepsy, no AED treatment), Outcome 4 IQ
< 1SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 4 VPA versus controls (women with epilepsy, no AED treatment)
Outcome: 4 IQ < 1SD
Study or subgroup VPA No AED treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prospective
Bromley 2010 10/25 1/25 66.7 % 10.00 [ 1.38, 72.39 ]
Subtotal (95% CI) 25 25 66.7 % 10.00 [ 1.38, 72.39 ]
Total events: 10 (VPA), 1 (No AED treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.28 (P = 0.023)
2 Registry
Eriksson 2005 5/13 0/13 33.3 % 11.00 [ 0.67, 180.65 ]
Subtotal (95% CI) 13 13 33.3 % 11.00 [ 0.67, 180.65 ]
Total events: 5 (VPA), 0 (No AED treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.093)
Total (95% CI) 38 38 100.0 % 10.33 [ 2.05, 52.01 ]
Total events: 15 (VPA), 1 (No AED treatment)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 2.83 (P = 0.0046)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
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Analysis 4.5. Comparison 4 VPA versus controls (women with epilepsy, no AED treatment), Outcome 5 IQ
<2SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 4 VPA versus controls (women with epilepsy, no AED treatment)
Outcome: 5 IQ <2SD
Study or subgroup VPA No AED treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Registry
Gaily 2004 1/13 2/45 100.0 % 1.73 [ 0.17, 17.61 ]
Subtotal (95% CI) 13 45 100.0 % 1.73 [ 0.17, 17.61 ]
Total events: 1 (VPA), 2 (No AED treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
0.01 0.1 1 10 100
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Analysis 4.6. Comparison 4 VPA versus controls (women with epilepsy, no AED treatment), Outcome 6
VIQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 4 VPA versus controls (women with epilepsy, no AED treatment)
Outcome: 6 VIQ
Study or subgroup VPA No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 51 91.55 (11.9) 25 99 (11.5) 65.7 % -7.45 [ -13.02, -1.88 ]
Subtotal (95% CI) 51 25 65.7 % -7.45 [ -13.02, -1.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0087)
2 Registry
Eriksson 2005 13 85.1 (24.6569) 13 98.2 (11.5838) 9.3 % -13.10 [ -27.91, 1.71 ]
Gaily 2004 13 83.5 (13.7011) 45 94.3 (17.4413) 25.0 % -10.80 [ -19.82, -1.78 ]
Subtotal (95% CI) 26 58 34.3 % -11.42 [ -19.13, -3.72 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0037)
Total (95% CI) 77 83 100.0 % -8.81 [ -13.32, -4.30 ]
Heterogeneity: Chi2 = 0.74, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 3.83 (P = 0.00013)
Test for subgroup differences: Chi2 = 0.67, df = 1 (P = 0.41), I2 =0.0%
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Analysis 4.7. Comparison 4 VPA versus controls (women with epilepsy, no AED treatment), Outcome 7
PIQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 4 VPA versus controls (women with epilepsy, no AED treatment)
Outcome: 7 PIQ
Study or subgroup VPA No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 51 97.06 (12.5) 25 104.36 (13.8) 67.0 % -7.30 [ -13.71, -0.89 ]
Subtotal (95% CI) 51 25 67.0 % -7.30 [ -13.71, -0.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.026)
2 Registry
Eriksson 2005 13 84.7 (26.9736) 13 102.1 (13.2386) 10.3 % -17.40 [ -33.73, -1.07 ]
Gaily 2004 13 96.3 (17.3066) 45 98.6 (19.4538) 22.7 % -2.30 [ -13.29, 8.69 ]
Subtotal (95% CI) 26 58 33.0 % -7.01 [ -16.13, 2.11 ]
Heterogeneity: Chi2 = 2.26, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI) 77 83 100.0 % -7.20 [ -12.44, -1.96 ]
Heterogeneity: Chi2 = 2.26, df = 2 (P = 0.32); I2 =12%
Test for overall effect: Z = 2.69 (P = 0.0071)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
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Analysis 5.1. Comparison 5 PHT versus controls (women without epilepsy), Outcome 1 Development
(Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 5 PHT versus controls (women without epilepsy)
Outcome: 1 Development (Bayley)
Study or subgroup PHT
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
GERMAN Study 4 121.5 (3) 4 115 (11.3) 42.0 % 6.50 [ -4.96, 17.96 ]
Rovet 1995 16 108.2 (17.8) 40 113.1 (14) 58.0 % -4.90 [ -14.64, 4.84 ]
Total (95% CI) 20 44 100.0 % -0.12 [ -7.54, 7.30 ]
Heterogeneity: Chi2 = 2.21, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 PHT versus controls (women without epilepsy), Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 5 PHT versus controls (women without epilepsy)
Outcome: 2 IQ
Study or subgroup PHT
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Registry
Thomas 2007 5 97.8 (9.9) 201 93 (14.4) 100.0 % 4.80 [ -4.10, 13.70 ]
Subtotal (95% CI) 5 201 100.0 % 4.80 [ -4.10, 13.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 PHT versus controls (women with epilepsy, no AED treatment), Outcome 1
Developmental (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 6 PHT versus controls (women with epilepsy, no AED treatment)
Outcome: 1 Developmental (Bayley)
Study or subgroup PHT No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Thomas 2008 29 90.3 (34.1764) 32 92.3 (30.2326) 100.0 % -2.00 [ -18.26, 14.26 ]
Subtotal (95% CI) 29 32 100.0 % -2.00 [ -18.26, 14.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 PHT versus controls (women with epilepsy, no AED treatment), Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 6 PHT versus controls (women with epilepsy, no AED treatment)
Outcome: 2 IQ
Study or subgroup PHT No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Registry
Thomas 2007 5 97.8 (9.9) 4 86.8 (22.4) 100.0 % 11.00 [ -12.60, 34.60 ]
Subtotal (95% CI) 5 4 100.0 % 11.00 [ -12.60, 34.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Poorer outcome (PHT) Poorer outcome (Controls)
Analysis 7.1. Comparison 7 PB versus controls (women without epilepsy), Outcome 1 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 7 PB versus controls (women without epilepsy)
Outcome: 1 IQ
Study or subgroup PB
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Registry
Thomas 2007 14 86.2 (11) 201 93 (14.4) 100.0 % -6.80 [ -12.90, -0.70 ]
Subtotal (95% CI) 14 201 100.0 % -6.80 [ -12.90, -0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 PB versus controls (women with epilepsy, no AED treatment), Outcome 1
Developmental (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 8 PB versus controls (women with epilepsy, no AED treatment)
Outcome: 1 Developmental (Bayley)
Study or subgroup PB No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Thomas 2008 41 90.3 (21.2268) 32 92.3 (30.2326) 100.0 % -2.00 [ -14.33, 10.33 ]
Subtotal (95% CI) 41 32 100.0 % -2.00 [ -14.33, 10.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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Poorer outcome (PB) Poorer outcome (Controls)
Analysis 8.2. Comparison 8 PB versus controls (women with epilepsy, no AED treatment), Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 8 PB versus controls (women with epilepsy, no AED treatment)
Outcome: 2 IQ
Study or subgroup PB No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Registry
Thomas 2007 14 86.2 (11) 4 86.8 (22.4) 100.0 % -0.60 [ -23.30, 22.10 ]
Subtotal (95% CI) 14 4 100.0 % -0.60 [ -23.30, 22.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 LTG versus controls (women without epilepsy), Outcome 1 Developmental
(Griffiths).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 9 LTG versus controls (women without epilepsy)
Outcome: 1 Developmental (Griffiths)
Study or subgroup LTG
Women
with
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 34 99 (13.7569) 230 100 (8.4666) 100.0 % -1.00 [ -5.75, 3.75 ]
Subtotal (95% CI) 34 230 100.0 % -1.00 [ -5.75, 3.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Poorer outcome (LTG) Poorer outcome (Controls)
Analysis 9.2. Comparison 9 LTG versus controls (women without epilepsy), Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 9 LTG versus controls (women without epilepsy)
Outcome: 2 IQ
Study or subgroup LTG
Women
with
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 29 103 (11) 210 107 (12) 100.0 % -4.00 [ -8.32, 0.32 ]
Subtotal (95% CI) 29 210 100.0 % -4.00 [ -8.32, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 LTG versus controls (women with epilepsy, no AED treatment), Outcome 1
Developmental (Griffiths).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 10 LTG versus controls (women with epilepsy, no AED treatment)
Outcome: 1 Developmental (Griffiths)
Study or subgroup LTG No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 34 99 (13.7569) 27 104 (8.8476) 100.0 % -5.00 [ -10.70, 0.70 ]
Subtotal (95% CI) 34 27 100.0 % -5.00 [ -10.70, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 LTG versus controls (women with epilepsy, no AED treatment), Outcome 2
IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 10 LTG versus controls (women with epilepsy, no AED treatment)
Outcome: 2 IQ
Study or subgroup LTG No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 29 103 (11) 25 104 (13) 100.0 % -1.00 [ -7.48, 5.48 ]
Subtotal (95% CI) 29 25 100.0 % -1.00 [ -7.48, 5.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 LEV versus control (women without epilepsy), Outcome 1 Developmental
(Griffiths).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 11 LEV versus control (women without epilepsy)
Outcome: 1 Developmental (Griffiths)
Study or subgroup LEV
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Registry
Shallcross 2011 51 99.96 (9.9554) 97 98.87 (13.9919) 100.0 % 1.09 [ -2.81, 4.99 ]
Subtotal (95% CI) 51 97 100.0 % 1.09 [ -2.81, 4.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 CBZ versus LTG, Outcome 1 Development (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 12 CBZ versus LTG
Outcome: 1 Development (Bayley)
Study or subgroup CBZ LTG
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
NEAD Study 43 94 (15) 57 97 (17) 100.0 % -3.00 [ -9.29, 3.29 ]
Subtotal (95% CI) 43 57 100.0 % -3.00 [ -9.29, 3.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 12.2. Comparison 12 CBZ versus LTG, Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 12 CBZ versus LTG
Outcome: 2 IQ
Study or subgroup CBZ LTG
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 17 102.3 (15.4) 10 101.8 (10.5) 15.2 % 0.50 [ -9.30, 10.30 ]
NEAD Study 61 106 (11.7) 74 108 (12.9) 84.8 % -2.00 [ -6.15, 2.15 ]
Total (95% CI) 78 84 100.0 % -1.62 [ -5.44, 2.21 ]
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 12.3. Comparison 12 CBZ versus LTG, Outcome 3 IQ>1SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 12 CBZ versus LTG
Outcome: 3 IQ>1SD
Study or subgroup CBZ LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prospective
Bromley 2013 2/15 1/9 40.9 % 1.20 [ 0.13, 11.43 ]
NEAD Study 5/61 2/74 59.1 % 3.03 [ 0.61, 15.09 ]
Total (95% CI) 76 83 100.0 % 2.28 [ 0.63, 8.22 ]
Total events: 7 (CBZ), 3 (LTG)
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 13.1. Comparison 13 CBZ versus PHT, Outcome 1 Development (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 13 CBZ versus PHT
Outcome: 1 Development (Bayley)
Study or subgroup CBZ PHT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
GERMAN Study 4 110.5 (19) 4 121.5 (3) 8.3 % -11.00 [ -29.85, 7.85 ]
NEAD Study 43 94 (15) 38 90 (19) 52.2 % 4.00 [ -3.52, 11.52 ]
Rovet 1995 24 114.2 (17.8) 16 108.2 (17.8) 23.3 % 6.00 [ -5.26, 17.26 ]
Thomas 2008 101 93.1 (27.3539) 29 90.3 (34.1764) 16.1 % 2.80 [ -10.73, 16.33 ]
Total (95% CI) 172 87 100.0 % 3.02 [ -2.41, 8.46 ]
Heterogeneity: Chi2 = 2.46, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 13.2. Comparison 13 CBZ versus PHT, Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 13 CBZ versus PHT
Outcome: 2 IQ
Study or subgroup CBZ PHT
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
NEAD Study 61 106 (11.71) 40 109 (12.51) 89.6 % -3.00 [ -7.86, 1.86 ]
Subtotal (95% CI) 61 40 89.6 % -3.00 [ -7.86, 1.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
2 Registry
Thomas 2007 14 91.9 (21.7) 5 97.8 (9.9) 10.4 % -5.90 [ -20.20, 8.40 ]
Subtotal (95% CI) 14 5 10.4 % -5.90 [ -20.20, 8.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Total (95% CI) 75 45 100.0 % -3.30 [ -7.91, 1.30 ]
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 13.3. Comparison 13 CBZ versus PHT, Outcome 3 DQ>1SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 13 CBZ versus PHT
Outcome: 3 DQ>1SD
Study or subgroup CBZ PHT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prospective
NEAD Study 15/48 17/42 51.5 % 0.77 [ 0.44, 1.35 ]
Thomas 2008 30/101 11/29 48.5 % 0.78 [ 0.45, 1.36 ]
Total (95% CI) 149 71 100.0 % 0.78 [ 0.52, 1.15 ]
Total events: 45 (CBZ), 28 (PHT)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 14.1. Comparison 14 VPA versus LTG, Outcome 1 Development (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 14 VPA versus LTG
Outcome: 1 Development (Bayley)
Study or subgroup VPA LTG
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
NEAD Study 28 85 (19) 57 97 (17) 100.0 % -12.00 [ -20.31, -3.69 ]
Subtotal (95% CI) 28 57 100.0 % -12.00 [ -20.31, -3.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P = 0.0046)
Test for subgroup differences: Not applicable
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Analysis 14.2. Comparison 14 VPA versus LTG, Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 14 VPA versus LTG
Outcome: 2 IQ
Study or subgroup VPA LTG
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 25 88.36 (9.7) 10 101.8 (10.5) 23.2 % -13.44 [ -20.98, -5.90 ]
NEAD Study 49 98 (10.4) 74 108 (12.9) 76.8 % -10.00 [ -14.14, -5.86 ]
Total (95% CI) 74 84 100.0 % -10.80 [ -14.42, -7.17 ]
Heterogeneity: Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 5.83 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 14.3. Comparison 14 VPA versus LTG, Outcome 3 IQ>1SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 14 VPA versus LTG
Outcome: 3 IQ>1SD
Study or subgroup VPA LTG Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prospective
Bromley 2010 10/25 1/9 48.0 % 3.60 [ 0.53, 24.29 ]
NEAD Study 8/49 2/74 52.0 % 6.04 [ 1.34, 27.26 ]
Total (95% CI) 74 83 100.0 % 4.87 [ 1.50, 15.78 ]
Total events: 18 (VPA), 3 (LTG)
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 2.64 (P = 0.0083)
Test for subgroup differences: Not applicable
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Analysis 15.1. Comparison 15 LEV versus VPA, Outcome 1 Development (Griffiths).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 15 LEV versus VPA
Outcome: 1 Development (Griffiths)
Study or subgroup LEV VPA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Registry
Shallcross 2011 51 99.96 (9.9554) 44 87.93 (17.2682) 100.0 % 12.03 [ 6.24, 17.82 ]
Subtotal (95% CI) 51 44 100.0 % 12.03 [ 6.24, 17.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.07 (P = 0.000046)
Test for subgroup differences: Not applicable
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Analysis 16.1. Comparison 16 PHT versus VPA, Outcome 1 Development (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 16 PHT versus VPA
Outcome: 1 Development (Bayley)
Study or subgroup PHT VPA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
GERMAN Study 13 116.7 (18.4) 9 103.5 (10.9) 28.9 % 13.20 [ 0.92, 25.48 ]
NEAD Study 38 90 (19) 28 85 (19) 50.7 % 5.00 [ -4.27, 14.27 ]
Thomas 2008 29 90.3 (34.1764) 71 86.9 (32.9536) 20.4 % 3.40 [ -11.21, 18.01 ]
Total (95% CI) 80 108 100.0 % 7.04 [ 0.44, 13.65 ]
Heterogeneity: Chi2 = 1.39, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 16.2. Comparison 16 PHT versus VPA, Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 16 PHT versus VPA
Outcome: 2 IQ
Study or subgroup PHT VPA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
NEAD Study 40 109 (12.51) 49 98 (10.4) 85.0 % 11.00 [ 6.15, 15.85 ]
Subtotal (95% CI) 40 49 85.0 % 11.00 [ 6.15, 15.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.45 (P < 0.00001)
2 Registry
Thomas 2007 5 97.8 (9.9) 12 98.5 (13.5) 15.0 % -0.70 [ -12.26, 10.86 ]
Subtotal (95% CI) 5 12 15.0 % -0.70 [ -12.26, 10.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
Total (95% CI) 45 61 100.0 % 9.25 [ 4.78, 13.72 ]
Heterogeneity: Chi2 = 3.35, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 4.05 (P = 0.000050)
Test for subgroup differences: Chi2 = 3.35, df = 1 (P = 0.07), I2 =70%
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Analysis 16.3. Comparison 16 PHT versus VPA, Outcome 3 DQ>1SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 16 PHT versus VPA
Outcome: 3 DQ>1SD
Study or subgroup PHT VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prospective
NEAD Study 17/42 8/49 30.5 % 2.48 [ 1.19, 5.16 ]
Thomas 2008 11/29 29/71 69.5 % 0.93 [ 0.54, 1.60 ]
Total (95% CI) 71 120 100.0 % 1.40 [ 0.91, 2.15 ]
Total events: 28 (PHT), 37 (VPA)
Heterogeneity: Chi2 = 4.54, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 17.1. Comparison 17 CBZ versus VPA, Outcome 1 Development (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 17 CBZ versus VPA
Outcome: 1 Development (Bayley)
Study or subgroup CBZ VPA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
GERMAN Study 4 110.5 (19) 9 103.5 (10.9) 4.8 % 7.00 [ -12.93, 26.93 ]
Jackson 2013 62 95.45 (18.67) 52 95.48 (16.59) 45.7 % -0.03 [ -6.51, 6.45 ]
NEAD Study 43 94 (15) 28 85 (19) 27.5 % 9.00 [ 0.66, 17.34 ]
Thomas 2008 101 93.1 (27.3539) 71 86.9 (32.9536) 22.0 % 6.20 [ -3.14, 15.54 ]
Total (95% CI) 210 160 100.0 % 4.16 [ -0.21, 8.54 ]
Heterogeneity: Chi2 = 3.16, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 1.86 (P = 0.062)
Test for subgroup differences: Not applicable
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Analysis 17.2. Comparison 17 CBZ versus VPA, Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 17 CBZ versus VPA
Outcome: 2 IQ
Study or subgroup CBZ VPA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 17 102.3 (15.4) 25 88.4 (9.7) 14.9 % 13.90 [ 5.65, 22.15 ]
NEAD Study 61 106 (11.71) 49 98 (10.4) 59.1 % 8.00 [ 3.86, 12.14 ]
Subtotal (95% CI) 78 74 74.0 % 9.19 [ 5.49, 12.88 ]
Heterogeneity: Chi2 = 1.57, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 4.87 (P < 0.00001)
2 Registry
Eriksson 2005 13 98.9 (12.7421) 13 84.5 (24.9878) 4.4 % 14.40 [ -0.85, 29.65 ]
Gaily 2004 86 99.7 (16.6925) 13 89.7 (12.98) 16.3 % 10.00 [ 2.11, 17.89 ]
Thomas 2007 14 91.9 (21.7) 12 98.5 (13.5) 5.4 % -6.60 [ -20.29, 7.09 ]
Subtotal (95% CI) 113 38 26.0 % 7.29 [ 1.06, 13.53 ]
Heterogeneity: Chi2 = 5.24, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 2.29 (P = 0.022)
Total (95% CI) 191 112 100.0 % 8.69 [ 5.51, 11.87 ]
Heterogeneity: Chi2 = 7.07, df = 4 (P = 0.13); I2 =43%
Test for overall effect: Z = 5.36 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.26, df = 1 (P = 0.61), I2 =0.0%
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Analysis 17.3. Comparison 17 CBZ versus VPA, Outcome 3 VIQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 17 CBZ versus VPA
Outcome: 3 VIQ
Study or subgroup CBZ VPA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bromley 2010 50 98.04 (14.4) 51 91.55 (11.9) 67.2 % 6.49 [ 1.33, 11.65 ]
Eriksson 2005 13 96.5 (15.8863) 13 85.1 (24.6569) 7.0 % 11.40 [ -4.54, 27.34 ]
Gaily 2004 86 96.2 (17.6199) 13 83.5 (13.7011) 25.8 % 12.70 [ 4.37, 21.03 ]
Total (95% CI) 149 77 100.0 % 8.44 [ 4.21, 12.66 ]
Heterogeneity: Chi2 = 1.69, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.91 (P = 0.000092)
Test for subgroup differences: Not applicable
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Analysis 17.4. Comparison 17 CBZ versus VPA, Outcome 4 PIQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 17 CBZ versus VPA
Outcome: 4 PIQ
Study or subgroup CBZ VPA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bromley 2010 50 107.86 (14.3) 51 97.06 (12.5) 72.4 % 10.80 [ 5.56, 16.04 ]
Eriksson 2005 13 102.5 (14.5624) 13 84.7 (26.9736) 7.2 % 17.80 [ 1.14, 34.46 ]
Gaily 2004 86 103.1 (13.9104) 13 96.3 (17.3066) 20.5 % 6.80 [ -3.06, 16.66 ]
Total (95% CI) 149 77 100.0 % 10.48 [ 6.02, 14.94 ]
Heterogeneity: Chi2 = 1.29, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 4.61 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 17.5. Comparison 17 CBZ versus VPA, Outcome 5 DQ>1SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 17 CBZ versus VPA
Outcome: 5 DQ>1SD
Study or subgroup CBZ VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prospective
Jackson 2013 17/62 12/52 21.0 % 1.19 [ 0.63, 2.25 ]
NEAD Study 15/48 12/29 24.1 % 0.76 [ 0.41, 1.38 ]
Thomas 2008 30/101 29/71 54.9 % 0.73 [ 0.48, 1.10 ]
Total (95% CI) 211 152 100.0 % 0.83 [ 0.62, 1.12 ]
Total events: 62 (CBZ), 53 (VPA)
Heterogeneity: Chi2 = 1.70, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 17.6. Comparison 17 CBZ versus VPA, Outcome 6 DQ>2SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 17 CBZ versus VPA
Outcome: 6 DQ>2SD
Study or subgroup CBZ VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prospective
Jackson 2013 7/62 5/52 38.4 % 1.17 [ 0.40, 3.48 ]
NEAD Study 6/48 7/29 61.6 % 0.52 [ 0.19, 1.39 ]
Total (95% CI) 110 81 100.0 % 0.77 [ 0.38, 1.58 ]
Total events: 13 (CBZ), 12 (VPA)
Heterogeneity: Chi2 = 1.20, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 0.71 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 17.7. Comparison 17 CBZ versus VPA, Outcome 7 IQ>2SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 17 CBZ versus VPA
Outcome: 7 IQ>2SD
Study or subgroup CBZ VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prospective
Bromley 2010 0/17 0/25 Not estimable
NEAD Study 1/61 2/49 34.4 % 0.40 [ 0.04, 4.30 ]
Subtotal (95% CI) 78 74 34.4 % 0.40 [ 0.04, 4.30 ]
Total events: 1 (CBZ), 2 (VPA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
2 Registry
Eriksson 2005 0/13 2/13 38.7 % 0.20 [ 0.01, 3.80 ]
Gaily 2004 1/86 1/13 26.9 % 0.15 [ 0.01, 2.27 ]
Subtotal (95% CI) 99 26 65.6 % 0.18 [ 0.02, 1.46 ]
Total events: 1 (CBZ), 3 (VPA)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
Total (95% CI) 177 100 100.0 % 0.26 [ 0.05, 1.19 ]
Total events: 2 (CBZ), 5 (VPA)
Heterogeneity: Chi2 = 0.31, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 =0.0%
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Analysis 17.8. Comparison 17 CBZ versus VPA, Outcome 8 IQ>1SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 17 CBZ versus VPA
Outcome: 8 IQ>1SD
Study or subgroup CBZ VPA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prospective
Bromley 2010 2/17 10/25 36.9 % 0.29 [ 0.07, 1.18 ]
NEAD Study 5/61 8/49 40.4 % 0.50 [ 0.18, 1.44 ]
Subtotal (95% CI) 78 74 77.2 % 0.40 [ 0.17, 0.93 ]
Total events: 7 (CBZ), 18 (VPA)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
2 Registry
Eriksson 2005 2/13 5/13 22.8 % 0.40 [ 0.09, 1.70 ]
Subtotal (95% CI) 13 13 22.8 % 0.40 [ 0.09, 1.70 ]
Total events: 2 (CBZ), 5 (VPA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
Total (95% CI) 91 87 100.0 % 0.40 [ 0.19, 0.83 ]
Total events: 9 (CBZ), 23 (VPA)
Heterogeneity: Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 18.1. Comparison 18 PHT versus LTG, Outcome 1 Developmental (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 18 PHT versus LTG
Outcome: 1 Developmental (Bayley)
Study or subgroup PHT LTG
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
NEAD Study 38 90 (19) 57 97 (17) 100.0 % -7.00 [ -14.48, 0.48 ]
Subtotal (95% CI) 38 57 100.0 % -7.00 [ -14.48, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Not applicable
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Analysis 18.2. Comparison 18 PHT versus LTG, Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 18 PHT versus LTG
Outcome: 2 IQ
Study or subgroup PHT LTG
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
NEAD Study 40 109 (12.51) 74 108 (12.9) 100.0 % 1.00 [ -3.87, 5.87 ]
Subtotal (95% CI) 40 74 100.0 % 1.00 [ -3.87, 5.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 19.1. Comparison 19 CBZ versus PB, Outcome 1 Developmental (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 19 CBZ versus PB
Outcome: 1 Developmental (Bayley)
Study or subgroup CBZ PB
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Thomas 2008 101 93.1 (27.3539) 41 90.3 (21.2268) 100.0 % 2.80 [ -5.61, 11.21 ]
Subtotal (95% CI) 101 41 100.0 % 2.80 [ -5.61, 11.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 19.2. Comparison 19 CBZ versus PB, Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 19 CBZ versus PB
Outcome: 2 IQ
Study or subgroup CBZ PB
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Registry
Thomas 2007 14 91.9 (21.7) 14 86.2 (11) 100.0 % 5.70 [ -7.04, 18.44 ]
Subtotal (95% CI) 14 14 100.0 % 5.70 [ -7.04, 18.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
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Analysis 19.3. Comparison 19 CBZ versus PB, Outcome 3 DQ >1SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 19 CBZ versus PB
Outcome: 3 DQ >1SD
Study or subgroup CBZ PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Prospective
Thomas 2008 30/101 11/41 100.0 % 1.11 [ 0.62, 1.99 ]
Subtotal (95% CI) 101 41 100.0 % 1.11 [ 0.62, 1.99 ]
Total events: 30 (CBZ), 11 (PB)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 20.1. Comparison 20 VPA versus PB, Outcome 1 Developmental (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 20 VPA versus PB
Outcome: 1 Developmental (Bayley)
Study or subgroup VPA PB
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Thomas 2008 71 86.9 (32.9536) 41 90.3 (21.2268) 100.0 % -3.40 [ -13.45, 6.65 ]
Subtotal (95% CI) 71 41 100.0 % -3.40 [ -13.45, 6.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 20.2. Comparison 20 VPA versus PB, Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 20 VPA versus PB
Outcome: 2 IQ
Study or subgroup VPA PB
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Registry
Thomas 2007 12 98.5 (13.5) 14 86.2 (11) 100.0 % 12.30 [ 2.73, 21.87 ]
Subtotal (95% CI) 12 14 100.0 % 12.30 [ 2.73, 21.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 21.1. Comparison 21 PHT versus PB, Outcome 1 Developmental (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 21 PHT versus PB
Outcome: 1 Developmental (Bayley)
Study or subgroup PHT PB
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Thomas 2008 29 90.3 (34.1764) 41 90.3 (21.2268) 100.0 % 0.0 [ -14.03, 14.03 ]
Subtotal (95% CI) 29 41 100.0 % 0.0 [ -14.03, 14.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 21.2. Comparison 21 PHT versus PB, Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 21 PHT versus PB
Outcome: 2 IQ
Study or subgroup PHT PB
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Thomas 2007 5 97.8 (9.9) 14 86.2 (11) 100.0 % 11.60 [ 1.18, 22.02 ]
Subtotal (95% CI) 5 14 100.0 % 11.60 [ 1.18, 22.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Not applicable
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Analysis 21.3. Comparison 21 PHT versus PB, Outcome 3 DQ >1SD.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 21 PHT versus PB
Outcome: 3 DQ >1SD
Study or subgroup PHT PB Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thomas 2008 11/29 11/41 1.41 [ 0.71, 2.81 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 11 (PHT), 11 (PB)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 22.1. Comparison 22 Monotherapy versus controls (women without epilepsy), Outcome 1
Developmental (Griffiths).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 22 Monotherapy versus controls (women without epilepsy)
Outcome: 1 Developmental (Griffiths)
Study or subgroup Monotherapy
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 138 96 (14.4) 230 100 (12) 100.0 % -4.00 [ -6.86, -1.14 ]
Subtotal (95% CI) 138 230 100.0 % -4.00 [ -6.86, -1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.0061)
Test for subgroup differences: Not applicable
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Analysis 22.2. Comparison 22 Monotherapy versus controls (women without epilepsy), Outcome 2
Developmental (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 22 Monotherapy versus controls (women without epilepsy)
Outcome: 2 Developmental (Bayley)
Study or subgroup Monotherapy
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
GERMAN Study 46 110 (15.2) 46 112.1 (12.7) 100.0 % -2.10 [ -7.82, 3.62 ]
Subtotal (95% CI) 46 46 100.0 % -2.10 [ -7.82, 3.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 22.3. Comparison 22 Monotherapy versus controls (women without epilepsy), Outcome 3 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 22 Monotherapy versus controls (women without epilepsy)
Outcome: 3 IQ
Study or subgroup Monotherapy
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
GERMAN Study 31 99.7 (13.8) 49 105.4 (11.5) 23.4 % -5.70 [ -11.53, 0.13 ]
Subtotal (95% CI) 31 49 23.4 % -5.70 [ -11.53, 0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
2 Registry
Gaily 2004 107 98 (16.5505) 141 97.6 (16.6241) 45.8 % 0.40 [ -3.77, 4.57 ]
Thomas 2007 44 92.5 (15.8) 201 93 (14.4) 30.8 % -0.50 [ -5.58, 4.58 ]
Subtotal (95% CI) 151 342 76.6 % 0.04 [ -3.18, 3.26 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 182 391 100.0 % -1.30 [ -4.12, 1.51 ]
Heterogeneity: Chi2 = 2.92, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 2.85, df = 1 (P = 0.09), I2 =65%
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Analysis 23.1. Comparison 23 Monotherapy versus controls (women with epilepsy, no AED treatment),
Outcome 1 Development (Griffiths).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 23 Monotherapy versus controls (women with epilepsy, no AED treatment)
Outcome: 1 Development (Griffiths)
Study or subgroup Monotherapy No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 138 96 (14.4) 27 104 (9) 100.0 % -8.00 [ -12.16, -3.84 ]
Subtotal (95% CI) 138 27 100.0 % -8.00 [ -12.16, -3.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.77 (P = 0.00016)
Test for subgroup differences: Not applicable
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Analysis 23.2. Comparison 23 Monotherapy versus controls (women with epilepsy, no AED treatment),
Outcome 2 Developmental (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 23 Monotherapy versus controls (women with epilepsy, no AED treatment)
Outcome: 2 Developmental (Bayley)
Study or subgroup Monotherapy No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Thomas 2008 246 90.6 (29.4626) 32 92.3 (30.2326) 100.0 % -1.70 [ -12.80, 9.40 ]
Subtotal (95% CI) 246 32 100.0 % -1.70 [ -12.80, 9.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 23.3. Comparison 23 Monotherapy versus controls (women with epilepsy, no AED treatment),
Outcome 3 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 23 Monotherapy versus controls (women with epilepsy, no AED treatment)
Outcome: 3 IQ
Study or subgroup Monotherapy No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
GERMAN Study 31 99.7 (13.8) 13 101.8 (18.4) 24.4 % -2.10 [ -13.22, 9.02 ]
Subtotal (95% CI) 31 13 24.4 % -2.10 [ -13.22, 9.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
2 Registry
Gaily 2004 107 98 (16.5505) 45 95.6 (18.783) 75.6 % 2.40 [ -3.92, 8.72 ]
Subtotal (95% CI) 107 45 75.6 % 2.40 [ -3.92, 8.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 138 58 100.0 % 1.30 [ -4.19, 6.80 ]
Heterogeneity: Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Chi2 = 0.48, df = 1 (P = 0.49), I2 =0.0%
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Analysis 24.1. Comparison 24 Polytherapy versus controls (women without epilepsy), Outcome 1
Developmental (Griffiths).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 24 Polytherapy versus controls (women without epilepsy)
Outcome: 1 Developmental (Griffiths)
Study or subgroup Polytherapy
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 30 94 (20.0854) 230 100 (8.4666) 100.0 % -6.00 [ -13.27, 1.27 ]
Subtotal (95% CI) 30 230 100.0 % -6.00 [ -13.27, 1.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 24.2. Comparison 24 Polytherapy versus controls (women without epilepsy), Outcome 2
Developmental (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 24 Polytherapy versus controls (women without epilepsy)
Outcome: 2 Developmental (Bayley)
Study or subgroup Polytherapy
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
GERMAN Study 15 121.7 (7.3) 67 129.2 (12.9) 100.0 % -7.50 [ -12.32, -2.68 ]
Subtotal (95% CI) 15 67 100.0 % -7.50 [ -12.32, -2.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Not applicable
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Analysis 24.3. Comparison 24 Polytherapy versus controls (women without epilepsy), Outcome 3 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 24 Polytherapy versus controls (women without epilepsy)
Outcome: 3 IQ
Study or subgroup Polytherapy
Women
without
epilepsy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 30 99.57 (12.8) 211 106 (11.7) 43.5 % -6.43 [ -11.27, -1.59 ]
GERMAN Study 22 92.2 (17.6) 49 105.4 (11.5) 15.8 % -13.20 [ -21.23, -5.17 ]
Subtotal (95% CI) 52 260 59.3 % -8.24 [ -12.39, -4.09 ]
Heterogeneity: Chi2 = 2.00, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 3.89 (P = 0.000099)
2 Registry
Gaily 2004 30 89.5 (13.1453) 141 97.6 (16.6241) 34.4 % -8.10 [ -13.55, -2.65 ]
Thomas 2007 23 78.7 (30.7) 201 93 (14.4) 6.3 % -14.30 [ -27.00, -1.60 ]
Subtotal (95% CI) 53 342 40.7 % -9.06 [ -14.07, -4.06 ]
Heterogeneity: Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 3.55 (P = 0.00039)
Total (95% CI) 105 602 100.0 % -8.57 [ -11.77, -5.38 ]
Heterogeneity: Chi2 = 2.84, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 5.26 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
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Analysis 25.1. Comparison 25 Polytherapy versus controls (women with epilepsy, no AED treatment),
Outcome 1 Developmental (Griffiths).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 25 Polytherapy versus controls (women with epilepsy, no AED treatment)
Outcome: 1 Developmental (Griffiths)
Study or subgroup Polytherapy No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 30 94 (20.0854) 27 104 (8.8476) 100.0 % -10.00 [ -17.92, -2.08 ]
Subtotal (95% CI) 30 27 100.0 % -10.00 [ -17.92, -2.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.47 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 25.2. Comparison 25 Polytherapy versus controls (women with epilepsy, no AED treatment),
Outcome 2 Developmental (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 25 Polytherapy versus controls (women with epilepsy, no AED treatment)
Outcome: 2 Developmental (Bayley)
Study or subgroup Polytherapy No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Thomas 2008 122 83.8 (30.6852) 32 92.3 (30.2326) 100.0 % -8.50 [ -20.31, 3.31 ]
Subtotal (95% CI) 122 32 100.0 % -8.50 [ -20.31, 3.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 25.3. Comparison 25 Polytherapy versus controls (women with epilepsy, no AED treatment),
Outcome 3 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 25 Polytherapy versus controls (women with epilepsy, no AED treatment)
Outcome: 3 IQ
Study or subgroup Polytherapy No AED treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 30 99.57 (12.8) 25 103.72 (13) 45.4 % -4.15 [ -11.00, 2.70 ]
GERMAN Study 22 92.2 (17.6) 13 101.8 (18.4) 13.8 % -9.60 [ -22.01, 2.81 ]
Subtotal (95% CI) 52 38 59.2 % -5.42 [ -11.42, 0.58 ]
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.076)
2 Registry
Gaily 2004 30 89.5 (13.1453) 45 95.6 (18.783) 40.8 % -6.10 [ -13.33, 1.13 ]
Subtotal (95% CI) 30 45 40.8 % -6.10 [ -13.33, 1.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.098)
Total (95% CI) 82 83 100.0 % -5.70 [ -10.31, -1.08 ]
Heterogeneity: Chi2 = 0.59, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.42 (P = 0.016)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 26.1. Comparison 26 Monotherapy versus polytherapy, Outcome 1 Developmental (Griffiths).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 26 Monotherapy versus polytherapy
Outcome: 1 Developmental (Griffiths)
Study or subgroup Monotherapy Polytherapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 138 96 (14.4) 30 94 (15.6) 100.0 % 2.00 [ -4.08, 8.08 ]
Subtotal (95% CI) 138 30 100.0 % 2.00 [ -4.08, 8.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 26.2. Comparison 26 Monotherapy versus polytherapy, Outcome 2 Developmental (Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 26 Monotherapy versus polytherapy
Outcome: 2 Developmental (Bayley)
Study or subgroup Monotherapy Polytherapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
GERMAN Study 46 110 (15.2) 19 97.2 (18.2) 33.4 % 12.80 [ 3.51, 22.09 ]
Thomas 2008 246 90.6 (29.4626) 122 83.8 (30.6852) 66.6 % 6.80 [ 0.23, 13.37 ]
Total (95% CI) 292 141 100.0 % 8.80 [ 3.44, 14.17 ]
Heterogeneity: Chi2 = 1.07, df = 1 (P = 0.30); I2 =6%
Test for overall effect: Z = 3.22 (P = 0.0013)
Test for subgroup differences: Not applicable
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Analysis 26.3. Comparison 26 Monotherapy versus polytherapy, Outcome 3 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 26 Monotherapy versus polytherapy
Outcome: 3 IQ
Study or subgroup Monotherapy Polytherapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
GERMAN Study 31 99.7 (13.8) 22 92.2 (17.6) 25.9 % 7.50 [ -1.31, 16.31 ]
Thomas 2007 44 92.5 (15.8) 23 78.7 (30.7) 11.2 % 13.80 [ 0.41, 27.19 ]
Subtotal (95% CI) 75 45 37.1 % 9.41 [ 2.04, 16.77 ]
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.012)
2 Registry
Gaily 2004 107 98 (16.5505) 30 89.5 (13.1453) 62.9 % 8.50 [ 2.85, 14.15 ]
Subtotal (95% CI) 107 30 62.9 % 8.50 [ 2.85, 14.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.95 (P = 0.0032)
Total (95% CI) 182 75 100.0 % 8.84 [ 4.35, 13.32 ]
Heterogeneity: Chi2 = 0.63, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 3.86 (P = 0.00011)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Analysis 27.1. Comparison 27 VPA monotherapy versus VPA polytherapy, Outcome 1 Developmental
(Bayley).
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 27 VPA monotherapy versus VPA polytherapy
Outcome: 1 Developmental (Bayley)
Study or subgroup VPA Monotherapy VPA Polytherapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Jackson 2013 52 95.48 (16.59) 5 83.2 (25.68) 100.0 % 12.28 [ -10.68, 35.24 ]
Subtotal (95% CI) 52 5 100.0 % 12.28 [ -10.68, 35.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Poorer outcome (VPA Mono) Poorer outcome (VPA Poly)
143Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 27.2. Comparison 27 VPA monotherapy versus VPA polytherapy, Outcome 2 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 27 VPA monotherapy versus VPA polytherapy
Outcome: 2 IQ
Study or subgroup VPA Monotherapy VPA Polytherapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 51 94.7 (11) 19 98 (13) 49.8 % -3.30 [ -9.88, 3.28 ]
Subtotal (95% CI) 51 19 49.8 % -3.30 [ -9.88, 3.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
2 Registry
Gaily 2004 13 89.7 (12.98) 17 86.6 (9.8955) 30.0 % 3.10 [ -5.38, 11.58 ]
Nadebaum 2011 23 94.3 (13.1) 15 81 (17.5) 20.1 % 13.30 [ 2.95, 23.65 ]
Subtotal (95% CI) 36 32 50.2 % 7.20 [ 0.64, 13.76 ]
Heterogeneity: Chi2 = 2.23, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 2.15 (P = 0.031)
Total (95% CI) 87 51 100.0 % 1.96 [ -2.68, 6.61 ]
Heterogeneity: Chi2 = 7.14, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 4.91, df = 1 (P = 0.03), I2 =80%
-20 -10 0 10 20
Poorer outcome (VPA Mono) Poorer outcome (VPA Poly)
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Analysis 28.1. Comparison 28 VPA polytherapy versus non-VPA polytherapy, Outcome 1 IQ.
Review: Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Comparison: 28 VPA polytherapy versus non-VPA polytherapy
Outcome: 1 IQ
Study or subgroup VPA Polytherapy
Non-VPA
Polyther-
apy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Prospective
Bromley 2010 19 98 (13) 11 103 (13) 52.0 % -5.00 [ -14.65, 4.65 ]
Subtotal (95% CI) 19 11 52.0 % -5.00 [ -14.65, 4.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
2 Registry
Nadebaum 2011 15 81 (17.5) 19 93.8 (10.6) 48.0 % -12.80 [ -22.86, -2.74 ]
Subtotal (95% CI) 15 19 48.0 % -12.80 [ -22.86, -2.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.49 (P = 0.013)
Total (95% CI) 34 30 100.0 % -8.74 [ -15.70, -1.78 ]
Heterogeneity: Chi2 = 1.20, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Chi2 = 1.20, df = 1 (P = 0.27), I2 =17%
-20 -10 0 10 20
Poorer outcome (VPA Poly) Poorer outcome (non-VPA)
A D D I T I O N A L T A B L E S
Table 1. Risk of bias scale parameters
1
Low risk
2 3 4 5
High risk
Confounding All important1 con-
founders considered
2
and suitablemethod
of adjustment3 em-
ployed. Out-
come unlikely to be
affected
Most important
4 confounders con-
sidered and suit-
able method of ad-
justment employed.
Outcome unlikely
to be affected
Some confounders
5 considered and
full or partial ad-
justment employed
6. Possible implica-
tion on outcome
Some con-
founders considered
and no adjustment
employed. Likely to
affect outcome
No important con-
founders considered
and no adjustment
employed. Likely to
affect outcome
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Table 1. Risk of bias scale parameters (Continued)
Blinding Assessors blinded to
participant’s drug
regime and partic-
ipants blinded to
drug regime. Out-
come unlikely to be
affected
Assessors blinded to
participants
drug regime. Out-
come unlikely to be
affected
Partial blinding7 in-
volved in study. Pos-
sible implication on
outcome
Partial or no blind-
ing involved
in study. Outcome
likely to be affected
No blinding
involved in study.
Outcome likely to
be affected
Incomplete
outcome data
No missing data
and/or
appropriate analysis
8 used to deal with
missing data. Un-
likely to affect out-
come
Smaller
amount (<25%) of
missing data with
reasons given, bal-
anced across groups.
Unlikely to affect
outcome
Larger amount of
miss-
ing data (>25%)
with or without rea-
sons given, balanced
across groups. Pos-
sible implication on
outcome
Larger
amount (>25%) of
missing data, imbal-
ance across groups.
Outcome likely to
be affected
No information
provided regarding
missing data. Likely
to affect outcome
Selective outcome
reporting
A pri-
ori outcomes mea-
sured, analysed and
reported in main re-
port. Protocol avail-
able. Unlikely to af-
fect outcome
A priori outcomes
measured, anal-
ysed and reported in
main report9. Pro-
tocol not available.
Unlikely to affect
outcomes
Limited in-
formation regarding
a priori outcomes
and measures. Pos-
sible implication on
outcome
Outcomes mea-
sured but not anal-
ysed or reported
Outcomes mea-
sured but not anal-
ysed or reported and
clinical judgement
infers the presence
of an unreported
measured outcome
10
Other bias No bias identified Bias identified. Un-
likely to affect out-
come
Bias identified. Pos-
sible implication on
outcome
Bias
identified. Likely to
affect outcome
Bias identified. Ex-
tremely likely to af-
fect outcome
1 Important confounders include maternal IQ, socio-economic status, epilepsy type, seizure exposure, child age at assessment, child
gender, child gestational age at birth or birth weight, polytherapy.
2 Reported demographic information and other confounders.
3 Matching scores, multiple regression, analysis of co-variance, stratification.
4 At least five out of eight important confounders including maternal IQ and socio-economic status, gestational age at birth.
5 At least two out of eight important confounders.
6 Full adjustment of confounding variables e.g. see footnote 2 or partial adjustment such as researchers select limited number of variables
to adjust for.
7 Assessors of outcome are only blinded to certain groups e.g. blinded to intervention group but not controls.
8 Intention-to-treat analysis.
9 An a priori statement is made in methods section of main report regarding measurement and analysis of outcome.
10 For example, failure to report full scale IQ when all other indices are reported.
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Table 2. Sensitivity analysis results for below average performance outcome
Analysis AED Control/Another
AED
Main result: risk ra-
tio
Sensitivity (i): risk
difference (MH)
Sensitivity (ii): OR
(M-H)
Sensitivity (iii): OR
(Peto)
IQ<1SD VPA Con-
trols (women with
epilepsy, no AED
treatment)
10.33 (2.05, 52.01)
P=0.0046
0.37 (0.20, 0.54)
P<0.0001
16.49 (2.86, 95.27)
P=0.002
8.68 (2.92, 25.80)
P=0.001
IQ>1SD CBZ LTG 2.28 (0.63, 8.22) 0.05 (-0.03, 0.13) 2.43 (0.60, 9.77) 2.35 (0.64, 8.56)
IQ>1SD VPA LTG 4.87 (1.50, 15.78) 0.16 (0.06, 0.27) 6.35 (1.73, 23.36) 4.94 (1.79, 13.66)
IQ>2SD CBZ VPA 0.26 (0.05, 1.19)
P=0.083
-0.04 (-0.10, 0.01)
P=0.12
0.24 (0.05, 1.21)
P=0.08
0.19 (0.04, 0.96)
P=0.04
Table 3. Matrix of study quality characteristics
Study Repre-
senta-
tive
Popula-
tion
Con-
trols
From
Same
Com-
munity
Prospec-
tive/
Reg-
istry
Expo-
sure As-
certain-
ment
Reli-
able Di-
agnosis
Re-
cruit-
ment
Ade-
quate
Differ-
ent In-
terven-
tions
Com-
pared
Out-
comes
Investi-
gated
Over
TIme
Stan-
dard-
ised
Mea-
sure
Used
Data on
Specific
Monother-
apy
Dose
Investi-
gated
Siblings
Ac-
counted
For
Arul-
mozhi
2006
Yes Unclear
Prospec-
tive
Yes Yes Unclear Unclear Yes Yes No No Unclear
Brom-
ley
2008
Yes Yes
Prospec-
tive
Yes Yes Yes Yes No Yes Yes No No
Brom-
ley
2010
Yes Yes
Prospec-
tive
Yes Yes Yes Yes No Yes Yes Yes Yes
Cum-
mings
2011
Yes No Reg-
istry
Yes Yes Yes Yes No Yes Yes No Yes
D’Souza
1991
Unclear Yes
Prospec-
tive
Yes Yes Unclear No No Yes No No Unclear
Eriks-
son
2005
Yes Yes Reg-
istry
Yes Yes Yes Yes No Yes Yes No Yes
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Table 3. Matrix of study quality characteristics (Continued)
FINNISH
Study
Yes Yes
Prospec-
tive
Yes Yes Yes Yes Yes Yes Unclear Yes Yes
Hirano
2004
Yes Yes
Prospec-
tive
Unclear Unclear Unclear No No Yes No Yes Unclear
Gaily
2004
Yes Yes
Prospec-
tive
Yes Yes Yes Yes No Yes Yes Yes No
GER-
MAN
Study
Yes Unclear
Prospec-
tive
Unclear Unclear Unclear Yes Unclear Yes No Unclear Yes
Glad-
stone
1992
No Yes
Prospec-
tive
No Unclear Unclear Yes No No Yes No Unclear
Hanson
1974
Unclear Yes
Prospec-
tive
Unclear Yes Unclear Yes No Yes No No Unclear
Jackson
2013
Yes Yes
Prospectve
Yes Yes Yes Yes No Yes Yes Yes Unclear
Jones
1989
No Yes
Prospec-
tive
No Unclear Yes Yes No Yes Yes No No
Leavitt
1992
No Unclear
Prospec-
tive
Yes Unclear Unclear Yes No Yes Yes Unclear Unclear
Nade-
baum
2011
Unclear Yes
Prospec-
tive
Yes Yes Unclear Yes No Yes Yes Yes No
NEAD
Study
Yes Yes
Prospec-
tive
Yes Yes Yes Yes Yes Yes Yes Yes Yes
Ornoy
1996
No Unclear
Prospec-
tive
Unclear No Unclear Yes No Yes Yes Unclear Unclear
Regesta
1996
Unclear Yes
Prospec-
Unclear Unclear Unclear Yes Yes Unclear No No Unclear
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Table 3. Matrix of study quality characteristics (Continued)
tive
Riht-
man
2012
No No Reg-
istry
Unclear Unclear Unclear No No Yes Yes No Unclear
Riht-
man
2013
No No Reg-
istry
Unclear Unclear Unclear Yes No Yes Yes No Unclear
Scolnik
1994
Unclear Yes
Prospec-
tive
Yes Yes Yes Yes No Yes Yes yes No
Shall-
cross
2011
Yes Yes
Prospec-
tive
Yes Yes Yes Yes No Yes Yes Yes No
Sobczyk
1977
Yes Yes
Prospec-
tive
Unclear Yes Yes Yes No Yes Yes Unclear Unclear
Thomas
2007
Yes Yes Reg-
istry
Yes Yes Yes Yes Yes Yes Yes Yes No
Thomas
2008
Yes Yes
Prospec-
tive
Yes Yes Yes Yes No Yes Yes Yes No
Veiby
2013
Yes Yes
Prospec-
tive
Yes Unclear Unclear Yes Yes Yes Yes No Unclear
Wide
2002
Yes Yes
Prospec-
tive
Yes Yes Yes Yes Yes Yes Yes Yes No
Table 4. Fixed and random effects analysis
Comparison Measure No. stud-
ies
Effect
measure
Fixed-ef-
fect result
Heterogeneity Random-
effects re-
sult
Conclu-
sion
change?
AED Control/
Another
AED
I2 Chi2∗
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Table 4. Fixed and random effects analysis (Continued)
CBZ Women
without
epilepsy
Bayley 3 MD -5.58 (-10.
83 to -
0.34), P=0.
04
60% P=0.08 -4.35 (-14.
04 to 5.34)
, P=0.38
Changed
to non-sig-
nificant
CBZ Women
without
epilepsy
VIQ 2 MD 1.81 (-4.94
to 1.33) P=
0.026
74% P=0.05 -1.84 (-8.
01 to 4.34)
, P=0.56
No change
CBZ Women
with
epilepsy,
no AED
treatment
Bayley 2 MD -7.22 (-12.
76 to -
1.67), P=0.
01
56% P=0.13 -5.60 (-15.
40 to 4.20)
, P=0.26
Changed
to non-sig-
nificant
VPA Women
without
epilepsy
IQ 3
2
MD
MD
-8.94 (-11.
96 to -
5.92), P<0.
00001
-11.42
(-14.68 to -
8.15), P<0.
00001
88%
2%
P=0.003
P=0.31
-5.28 (-15.
54 to 4.97)
, P=0.31
Changed
to non-sig-
nificant
Changed
to signifi-
cant
with the re-
moval
of Thomas
2007
VPA Women
without
epilepsy
PIQ 2 MD -10.48
(-13.94 to -
7.02), P<0.
00001
68% P=0.08 -12.11
(-19.66 to -
4.55), P=0.
002
No change
PHT VPA IQ 2 MD 9.25 (4.78
to 13.72),
P<0.0001
70% P=0.07 6.38 (-4.84
to 17.58),
P=0.27
Changed
to non-sig-
nificant
VPAmono VPA poly-
therapy
IQ 3 MD 1.96 (-2.
68 to 6.61)
, P=0.41
72% P=0.03 3.67 (-5.46
to 12.80),
P=0.43
No change
*Chi2 is significant at 0.1
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Pregnancy explode all trees
#2 MeSH descriptor Pregnancy Complications explode all trees
#3 MeSH descriptor Prenatal Exposure Delayed Effects explode all trees
#4 (fetal OR foetal OR fetus OR foetus OR prenatal)
#5 (newborn OR infant)
#6 MeSH descriptor Teratogens explode all trees
#7 (teratogen*)
#8 (in NEXT utero)
#9 (intra uterine) or (intrauterine)
#10 MeSH descriptor Fetal Development explode all trees
#11 MeSH descriptor Infant, Newborn explode all trees
#12 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)
#13 MeSH descriptor Fetal Diseases explode all trees
#14 MeSH descriptor Fetal Death explode all trees
#15 MeSH descriptor Infant Mortality explode all trees
#16 MeSH descriptor Birth Weight explode all trees
#17 MeSH descriptor Abnormalities, Drug-Induced explode all trees
#18 MeSH descriptor Congenital Abnormalities explode all trees
#19 (congenital NEXT defec*)
#20 (congenital NEXT malformation*)
#21 (congenital NEXT anomal*)
#22 (birth NEXT defec*)
#23 (minor NEXT anomal*)
#24 (dysmorph*)
#25 (maternal NEXT mortality)
#26 MeSH descriptor Intellectual Disability explode all trees
#27 (intellectual* NEXT impair*)
#28 (IQ)
#29 (intellectual NEXT ability)
#30 neurodevelopment
#31 (mental* NEXT retard*)
#32 “educational needs”
#33 “longer term outcome”
#34 MeSH descriptor Child Development explode all trees
#35 “child development”
#36 MeSH descriptor Autistic Disorder explode all trees
#37 (autism OR autistic)
#38 MeSH descriptor Attention Deficit Disorder with Hyperactivity explode all trees
#39 “attention deficit”
#40 MeSH descriptor Apraxias explode all trees
#41 dyspraxia
#42 MeSH descriptor Memory explode all trees
#43 (memory)
#44 MeSH descriptor Language Disorders explode all trees
#45 language
#46 MeSH descriptor Executive Function explode all trees
#47 (executive NEXT function*)
#48 cognitive
#49 MeSH descriptor Neuropsychology explode all trees
151Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#50 neuropsycholog*
#51 (#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR
#27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR
#42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50)
#52 MeSH descriptor Phenytoin explode all trees
#53 MeSH descriptor Carbamazepine explode all trees
#54 MeSH descriptor Valproic Acid explode all trees
#55 MeSH descriptor Phenobarbital explode all trees
#56 MeSH descriptor Ethosuximide explode all trees
#57 MeSH descriptor Clonazepam explode all trees
#58 MeSH descriptor Anticonvulsants explode all trees
#59 (phenytoin) or (carbamazepine) or (valproate) or (valproic) or (phenobarb*)
#60 (lamotrigine) or (gabapentin) or (vigabatrin) or (levetiracetam) or (topiramate)
#61 (tiagabine) or (zonisamide) or (pregabalin) or (lacosamide) or (rufinamide)
#62 (retigabine) or (ezogabine) or (oxcarbazepine) or (ethosuximide) or (sulthiame)
#63 (clonazepam) or (clobazam) or (anti-epilep*) or (antiepilep*)
#64 MeSH descriptor Epilepsy explode all trees
#65 MeSH descriptor Seizures explode all trees
#66 (seizure*) or (epilep*) or (convuls*)
#67 (#52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR
#66)
#68 (#12 AND #51 AND #67)
Appendix 2. MEDLINE search strategy
1. exp Pregnancy/
2. exp Pregnancy Complications/
3. exp Prenatal Exposure Delayed Effects/
4. (fetal or foetal or fetus or foetus or prenatal).tw.
5. (newborn or infant).tw.
6. exp Teratogens/
7. teratogen$.tw.
8. (in adj utero).tw.
9. (intra uterine or intrauterine).tw.
10. exp Fetal Development/
11. exp Infant, Newborn/
12. or/1-11
13. exp Fetal Diseases/
14. exp Fetal Death/
15. exp Infant Mortality/
16. exp Birth Weight/
17. exp Abnormalities, Drug-Induced/ or exp Congenital Abnormalities/
18. (congenital adj defec$).tw.
19. (congenital adj malformation$).tw.
20. (congenital adj anomal$).tw.
21. (birth adj defec$).tw.
22. (minor adj anomal$).tw.
23. dysmorph$.tw.
24. (maternal adj mortality).tw.
25. exp Intellectual Disability/
26. (intellectual$ adj impair$).tw.
27. IQ.tw.
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28. (intellectual adj ability).tw.
29. neurodevelopment.tw.
30. (mental$ adj retard$).tw.
31. educational needs.tw.
32. longer term outcome.tw.
33. exp Child Development/
34. child development.tw.
35. exp Autistic Disorder/
36. (autism or autistic).tw.
37. exp Attention Deficit Disorder with Hyperactivity/
38. attention deficit.tw.
39. exp Apraxias/
40. dyspraxia.tw.
41. exp Memory/
42. memory.tw.
43. exp Language Disorders/
44. language.tw.
45. exp Executive Function/
46. executive function$.tw.
47. cognitive.tw.
48. exp Neuropsychology/
49. neuropsycholog$.tw.
50. or/13-49
51. phenytoin.tw.
52. exp Carbamazepine/
53. carbamazepine.tw.
54. exp Valproic Acid/
55. (valproic or valproate).tw.
56. exp Phenobarbital/
57. phenobarb$.tw.
58. lamotrigine.tw.
59. gabapentin.tw.
60. vigabatrin.tw.
61. levetiracetam.tw.
62. topiramate.tw.
63. tiagabine.tw.
64. zonisamide.tw.
65. pregabalin.tw.
66. lacosamide.tw.
67. (retigabine or ezogabine).tw.
68. rufinamide.tw.
69. oxcarbazepine.tw.
70. exp Ethosuximide/
71. ethosuximide.tw.
72. sulthiame.tw.
73. exp Clonazepam/
74. clonazepam.tw.
75. clobazam.tw.
76. antiepilep$.tw.
77. anti-epilep$.tw.
78. exp Anticonvulsants/
79. exp Epilepsy/
80. exp Seizures/
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81. (seizure$ or epilep$ or convuls$).tw.
82. or/51-81
83. 12 and 50 and 82
84. exp animals/ not humans.sh.
85. 83 not 84
Appendix 3. EMBASE search strategy
EMBASE search strategy
1. exp pregnancy/
2. exp pregnancy disorder/
3. exp prenatal exposure/
4. prenatal development/
5. prenatal drug exposure/
6. exp teratogenic agent/
7. exp teratogenicity/
8. exp drug toxicity/
9. exp embryotoxicity/
10. reproductive toxicity/
11. exp fetotoxicity/
12. exp congenital malformation/
13. exp infant mortality/
14. exp maternal mortality/
15. exp “parameters concerning the fetus, newborn and pregnancy”/
16. exp infant disease/
17. teratogen:.tw.
18. congenital defec:.tw.
19. congenital anomal:.tw.
20. congenital malformation:.tw.
21. birth defec:.tw.
22. minor anomal:.tw.
23. dysmorph:.tw.
24. exp Intellectual Disability/
25. (intellectual$ adj impair$).tw.
26. IQ.tw.
27. (intellectual adj ability).tw.
28. neurodevelopment.tw.
29. (mental$ adj retard$).tw.
30. education.tw.
31. longer term outcome.tw.
32. exp Child Development/
33. child development.tw.
34. exp Autistic Disorder/
35. (autism or autistic).tw.
36. exp Attention Deficit Disorder with Hyperactivity/
37. attention deficit.tw.
38. exp Apraxias/
39. dyspraxia.tw.
40. exp Memory/
41. memory.tw.
42. exp Language Disorders/
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43. language.tw.
44. exp Executive Function/
45. executive function$.tw.
46. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
or 24 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46
47. epilepsy
48. seizures
49. antiepileptic
50. exp hydantoin/
51. hydantoin:.tw.
52. exp phenobarbital/
53. phenobarbit:.tw.
54. exp carbamazepine/
55. carbamazepine:.tw.
56. exp valproic acid/
57. valpr:.tw.
58. exp lamotrigine/
59. lamotrigine:.tw.
60. exp gabapentin/
61. gabapentin:.tw.
62. exp topiramate/
63. topiramat:.tw.
64. exp vigabatrin/
65. vigabatrin:.tw.
66. exp tiagabin/
67. tiagabin:.tw.
68. exp zonisamide/
69. zonisamid:.tw.
70. exp ethosuximide/
71. ethosuximide:.tw.
72. exp lacosamide/
73. lacosamide:.tw.
74. exp rufinamide/
75. rufinamide:.tw
76. 46 and 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67
or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75
Appendix 4. Data extraction form
Cochrane Epilepsy Review Group Reviewer Initials...............
Study Selection, Quality Assessment & Data Extraction Form
Study ID Authors Journal/Conference Year
Linked Studies
(Check Endnote Library for any other studies linked to this study and list below)
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Study ID Authors Journal/Conference Year
References to Other Trials
(Check article for any other studies mentioned within the paper or in reference list which may potentially be included within the
review)
Authors Journal Year
Participant and Study Characteristics
StudyDesign (prospective cohort, retrospective cohort, RCT, reg-
istry)
Study Setting (community, hospital, etc.)
Single/Multicentre
City, Country/Countries
Source of Funding
Ascertainment of Exposure Info (hospital records/interview etc.
)
Where was intervention group recruited from?
Where was control group recruited from?
Which AEDs under study? (list all)
Were AEDs analysed separately?
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(Continued)
Number of mothers initially recruited? Intervention Control
Any dose information reported? (list doses for each AED if avail-
able)
How was participant eligibility defined?
Maternal Type of Epilepsy (epilepsy type and seizure types re-
ported)
Control Group Details (who formed control group)
Duration of follow-up
Assessment Intervals (time assessed and age of participants when
assessed)
Assessments (list all cognitive, developmental tests used)
Blinding (participants, assessors, other study personnel)
Missing Data (is loss to follow-up reported, are reasons reported)
Details of Children
Age (mean, median, range) Intervention Controls
Gender (numbers, %) Intervention Controls
Number of Children Initially Recruited
(for each AED if available)
Intervention Controls
Number of Children Completed Assessments? (for each AED
if available)
Intervention Controls
Number of Children analysed? (for each AED if available) Intervention Controls
Abbreviations of AEDs
Carbamazepine CBZ Sulthiame SUL
Clobazam COZ Tiagabine TGB
Clonazepam CZP Topiramate TPM
Diazepam DZP Vigabatrin VGB
Ethosuximide ESM Zonisamide ZNS
Gabapentin GBP
Lacosamide LCM
Lamotrigine LTG
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Levetiracetam LEV
Lorazepam LZP
Oxcarbazepine OXC
Phenytoin PHT
Phenobaritone/tal PB
Primidone PRM
Retigabine RTB
Rufinamide RFM
Sodium Valproate SVP
Outcomes
Measurements Reported
Mean Scores (all groups) Yes/No
Standard Deviations (all groups) Yes/No
Percentage of children below average Yes/No
Percentage of children receiving clinical intervention (educa-
tional support, psychologist, physiotherapy, etc.)
Yes/No
Cases of neurodevelopmental disorder (autism, ADHD, dys-
praxia etc.)
Yes/No
Others Reported in Paper (list below)
Data (Continuous) Total or global scores and scores on each domain
Neuro Assess-
ment (name)
Total
or Global (list
all domains re-
ported in pa-
per)
AED (name
both
AEDs if com-
paring two)
AED Group Control Group (or other AED De-
tails of find-
ings if only
described in
text
No. of ps Mean (SD or
95% CI)
No. of ps Mean (SD or
95% CI)
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(Continued)
Data (Dichotomous) Percentage of children below average
AED Group Control Group (or other AED)
Name of Drug
(name both if
comparing two)
Number of
events
Number of chil-
dren in group
% of children
<84 by AED
Number of
events
Number of chil-
dren in group
% of children
<84 by AED
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(Continued)
Confounding Variables
Assuming a pre-specified list of potential confounders defined in the review protocol
Is the method for identifying relevant confounders or imbalance between study groups described? Yes or No
If yes, describe the method used.
Is confounding controlled for at the design stage of the study by matching characteristics of subjects? Yes or No
If yes, list the variables on which subjects were matched.
Is one of the following statistical methods* used to control or adjust for confounding at the analysis stage?
Univariate regression
Multivariate regression
Stratification
Propensity scores (regression)
Propensity scores (matching / strata)
Other method (specify)
Please describe the method used (e.g. strata selected, regression model used etc.)
Pre-specified confounders for the pregnancy review
For each individual factor tick ‘Considered’ if the researchers identify the factor as a confounder and tick ‘Adjusted’ if the factor has
been controlled for in a careful and appropriate manner (based on the above questions)
General factors
Population (regional, national/international, single/multicentre) Considered Adjusted
Proportion of subjects lost to follow up Considered Adjusted
Maternal Factors
Age Considered Adjusted
Duration of AED treatment Considered Adjusted
IQ Considered Adjusted
Lifestyle factors Considered Adjusted
Monotherapy or polytherapy Considered Adjusted
Socioeconomic status Considered Adjusted
Type of epilepsy Considered Adjusted
Use of other medications Considered Adjusted
Years of education Considered Adjusted
Child factors
Age of assessment Considered Adjusted
Gestational age at birth Considered Adjusted
Gender Considered Adjusted
Seizure exposure Considered Adjusted
Time of follow-up Considered Adjusted
Outcome measurement Considered Adjusted
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Appendix 5. Extended risk of bias tool for non-randomised studies
Item Judgement1 Description (quote from paper, or describe key information)
1. Sequence generation
2. Allocation concealment
3a. Confounding2 Outcome 1
3b. Confounding2 Outcome 2
4a. Blinding? Outcome 1
4b. Blinding? Outcome 2
5a. Incomplete outcome data
addressed?
Outcome 1
5b. Incomplete outcome data
addressed?
Outcome 2
6a. Free of selective reporting? Outcome 1
6b. Free of selective reporting? Outcome 2
7. Free of other bias?
8. A priori protocol?3
161Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
9. A priori analysis plan?4
Footnotes
1 Some items on low/high risk/unclear scale (double-line border), some on 5 point scale/unclear (single line border), some on yes/no/
unclear scale (dashed border). For all items, record “unclear” if inadequate reporting prevents a judgement being made.
2 Based on list of confounders considered important at the outset and defined in the protocol for the review (and assessment against
worksheet)
3 Did the researchers write a protocol defining the study population, intervention and comparator, primary and other outcomes, data
collection methods, etc. in advance of starting the study? N.B. May be outcome specific.
4 Did the researchers have an analysis plan defining the primary and other outcomes, statistical methods, subgroup analyses, etc. in
advance of starting the study?
Studies for which the risk of bias tool is intended
Only suitable for ‘cohort-like’ studies, individually or cluster-allocated. This can include secondary analyses of clinical databases
providing the analysis is clearly structured as a comparison of control and intervention participants (XXXXX):
Individually allocated study designs
• Randomised controlled trial
• Quasi randomised controlled trial
• Non-randomised controlled trial
• Controlled before and after study (not common use of this label, see controlled cohort before and after study below)
• Prospective cohort study
• Retrospective cohort study
Cluster allocated study designs
• Cluster randomised controlled trial
• Cluster quasi randomised controlled trial
• Cluster non-randomised controlled trial
• Controlled interrupted time series
• Controlled cohort before and after study
Assessment of risk of bias
Issues when using the modified risk of bias tool to assess cohort-like non-randomised studies:
• follow principle for existing Cochrane Collaboration’s tool for risk of bias: score judgement and provide information (preferably
direct quote) to support judgement
• modified risk of bias tool include an additional item on confounding.
• five-point scale for some items (distinguish “unclear” from intermediate risk of bias).
• keep in mind the general philosophy - assessment is not about whether researchers could have done better but about risk of bias;
the assessment tool must be used in a standard way whatever the difficulty/circumstances of investigating the research question of
interest and whatever study design features were used.
• use of a five-point scale is uncharted territory; very interested to know whether this makes things easier or more difficult for
reviewers.
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• anchors for five-point scale: “1/No/low risk” of bias should correspond to a high quality RCT. “5/high risk” of bias should
correspond to a risk of bias that means the findings should not be considered (too risky, too much bias, more likely to mislead than
inform).
Sequence generation
• Low/high/unclear risk of bias item
• Always high risk of bias (not random) for a non-randomised study
• Might argue that this item is redundant for non-randomised studies since they are always of high risk of bias - but important to
include in risk of bias table (’level playing field’ argument)
Allocation concealment
• Low/high/unclear risk of bias item
• Potentially low risk of bias for a non-randomised study, e.g. quasi-randomised (high risk of bias due to sequence generation) but
concealed (author judges that the people making decisions about including participants didn’t know how allocation was being done,
e.g. odd/even date of birth/hospital number)
Risk of bias from confounding (additional item for non-randomised studies; assess for each outcome)
• Assumes a prespecified list of potential confounders defined in the protocol for the systematic review
• Low(1) / 2 / 3 / 4 / high(5) / unclear risk of bias item
• Judgement needs to factor in (see ’worksheet’):
◦ proportion of confounders (from pr-especified list) that were considered
◦ whether most important confounders (from pre-specified list) were considered
◦ resolution/precision with which confounders were measured
◦ extent of imbalance between groups at baseline
◦ care with which adjustment was done (typically a judgement about the statistical modelling carried out by authors)
• Low risk of bias requires that all important confounders are balanced at baseline, i.e.:
◦ not primarily / not only a statistical judgement; or
◦ measured ’well’ and ’carefully’ controlled for in the analysis.
We have provided an optional ’worksheet’ to help reviewers to focus on the task (rows = confounders and columns = factors to consider).
Authors should make a risk of bias judgement about each factor first and then combine these (by eyeballing rather than quantitatively)
to make the judgement in the main risk of bias table.
Risk of bias from lack of blinding (assess for each outcome, as per the existing risk of bias tool)
• Low(1) / 2 / 3 / 4 / high(5) / unclear risk of bias item
• Judgement needs to factor in:
◦ nature of outcome (subjective / objective; source of information);
◦ who was/was not blinded and the risk that those who were not blinded could introduce performance or detection bias.
Risk of bias from incomplete outcome data (assess for each outcome, as per the existing risk of bias tool)
• Low(1) / 2 / 3 / 4 / high(5) / unclear risk of bias item
• Judgement needs to factor in:
◦ reasons for missing data;
◦ whether amount of missing data balanced across groups, with similar reasons;
◦ whether group comparison appropriate (e.g. ’analysed in allocated group’ issue).
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Risk of bias from selective reporting (assess for each outcome)
• More wide ranging than existing assessment recommendation. Key issue is whether outcomes were clearly defined, and methods
of analysis, were pre-specified and adhered to
• Low(1) / 2 / 3 / 4 / high(5) /unclear risk of bias item
• Judgement needs to factor in:
◦ existing risk of bias guidance on selective outcome reporting;
◦ also, extent to which analyses (and potentially other choices) could have been manipulated to bias the findings reported,
e.g. choice of method of model fitting, potential confounders considered/included;
◦ look for evidence that there was a protocol in advance of doing any analysis/obtaining the data (difficult unless explicitly
reported); non-randomised studies are very different from RCTs. RCTs must have a protocol in advance of starting to recruit (for
research ethics committee/institutional review board/other regulatory approval); non-randomised studies need not (especially older
studies);
◦ Hence, separate yes/no items asking reviewers whether they think the researchers had a prespecified protocol and analysis
plan?
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Appendix 6. Assessment of confounding variables
Assessment of how researchers dealt with confounding
Method for identifying relevant confounders described by researchers: yes
no
If yes, describe the method used:
Relevant confounders described: yes
no
List confounders described below
Method used for controlling for confounding
At design stage: matching by characteristics of subjects (see below for matching
by propensity score)
Variables on which subjects matched: …………………………………
…………………………………
…………………………………
…………………………………
At analysis stage: stratification
multivariable regression
propensity scores (matching)
propensity scores (multivariable regression)
Describe confounders controlled for below
Confounders described by researchers
Enter / preprint prespecified list of confounders (rank order in importance? Important in bold?)
Tick (yes/no judgement) if confounder considered by the researchers [Cons’d?]
Score (1 to 5) precision with which confounder measured
Score (1 to 5) imbalance between groups
Score (1 to 5) care with which adjustment for confounder was carried out
Confounder Considered Precision Imbalance Adjustment
o o o o
o o o o
o o o o
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol it was stated that we would report standardised mean differences. Due to careful selection of the measures that we
combined in meta-analysis and across study type and control groups, mean difference was instead utilised due to the ease with which it
can convey levels of difference to the reader. Further, in the protocol it stated that, where possible, we would conduct meta-analysis at
themonotherapy and polytherapy group level.However, given the bias likely to be included in such an analysis and on recommendation
of one of the peer reviewers we have not included these comparisons.
Within the protocol it was stated that, if appropriate, summary of findings tables using the GRADE approach would be presented.
However, due to the inclusion of more than one AED across a number of outcomes, the creating and presenting of all data would be
difficult to produce in a manner that could be understood and used appropriately.
In the protocol it was also stated that both fixed-effect and random-effects model analyses would be implemented, however the authors
did not state exactly how these would be utilised and therefore we have elaborated on the methods here to clarify the situation. It was
always the intention that fixed-effect models would be carried out primarily, with random-effects model analysis to explore potential
heterogeneity. In addition, due to data being sparse in some comparisons, and with some studies reporting zero events in one or both
groups, the risk difference (RD) was calculated and this was not stipulated within the protocol as we were not expecting to find such
sparse data.
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